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This thesis documents the synthesis of the antibiotic anisomycin 10, whose 
use as a tool for the activation of the mitogen-activated protein (MAP) JNK and p38 
stress kinase pathways is well documented. The synthesis makes use of a highly 
efficient asymmetric boron mediated syn glycolate aldol reaction employing the 
tyrosine derived aldehyde 31 and acylated Evans' auxiliary 32 
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The synthesis of the more lipophilic C(4) analogues 82 and 84 is also 
described and a SAR study of these and their synthetic precursors on the p38 and 










An investigation into the asymmetric boron mediated glycolate aldol reaction 
employed in the synthesis of anisomycin is also reported. Finally studies into 
extending our methodology to incorporate six membered piperidine rings is 
discussed in our approach to the synthesis of the glycosidase inhibitor 
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Chapter 1: Introduction 
1.1 Anisomycin 
Anisomycin was originally isolated from the fermentation broths of 
Streptomyces griseolus and Sreptomyces roseochromo genes by Stobin and Tanner in 
1954.' Since its discovery it has also been isolated from Streptomyces sp. SA3097 2 
and No 638 3 by two other groups in Japan. The gross structure of anisomycin was 
elucidated by Beereboom in 1965,   and its relative stereochemistry was established 
by NMR3 and X-Ray analysis. 6 Wong7 finally confirmed the absolute 
stereochemistry to be (2R,3S,4S) in 1968 by chemical correlation with L-tyrosine 
(Figure 1). 
MeO 	 51 
AcO 
Figure 1: Anisomycin 
Anisomycin's activity as an antibiotic was first tested in vitro by Lynch. 8 It was 
found that E. histolytica, T vaginalis, T foetus, and Candida albicans were all 
inhibited by anisomycin, requiring concentrations of only 1 tg per ml of cell culture. 
Consequently, anisornycin was used in clinical trials for the treatment of both 
amoebic dysentery  and vaginitis caused by Trichomonas vaginalis.'° However in the 
latter, the trials were prevented from progressing due to the uncertainty of success 
and the inconvenient method of application. Anisomycin was found to be inactive 
towards bacteria at realistic concentrations, with Staphalococus aureus, Streptomyces 
faecalis, mycobacteria and Gram-negative organisms all requiring more than 100 tg 
per ml of cell culture for inhibition. 
Anisomycin's ability to effectively inhibit peptide bond formation on eukaryotic 
ribosomes, as well as its relatively low toxicity, has made it an invaluable tool in 
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molecular biology." Anisomycin has been used to show that various processes 
occurring within the body are the result of protein synthesis. For example, the 
acquired tolerance to alcohol of laboratory rats was suppressed when an initial dose 
of alcohol was preceded by an injection of anisomycin, indicating the presence of a 
protein that provides tolerance to, and is stimulated by alcohol. 12 
In a similar study anisomycin was used to show that consolidated 'fear 
memories', when reactivated during retrieval, return to a labile state that requires c/c 
novo protein synthesis for reconsolidation. 13 It was found that when laboratory rats 
were treated with anisomycin shortly after 'fear memory' reactivation, they showed 
amnesia towards later tests. The same treatment with anisomycin 6 hours after the 
fear memory reactivation, as well as in the absence of any 'fear memory' 
reactivation, left the rats 'fear memory' intact. 
Recently, anisomycin has been shown to display cytotoxicity towards human 
tumour cell lines in vitro 2,14  and to activate the mitogen-activated protein (MAP) 
INK and p38 stress kinase pathways.' 5 
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1.2 Anisomycin as an Antibiotic 
In contrast to many antibacterial antibiotics, anisomycin acts by inhibiting 
protein biosynthesis in eukaryotic cells. Protein synthesis involves complex 
processes many of which are beyond the scope of this study. As an aid to 
understanding anisomycin's mode of action as an antibiotic, a brief description of the 
main concepts involved is presented, with an emphasis placed on the processes 
which anisomycin has a direct effect on. 
1.2.1 Protein Synthesis in Eukaryotic Cells 
Protein synthesis begins in the nucleus of a cell where transcription takes 
place. Transcription is the process by which RNA is formed from DNA, and occurs 
when an enzyme, RNA polymerase,' 6 creates a transcription 'bubble' in which DNA 
is transiently unravelled. 17 RNA polymerase then controls the replication of one of 
the two unravelled strands of DNA by the complimentary base pairing of 
ribonucleotides with deoxyribonucleotides. 18 As the RNA polymerase travels down 
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Figure 2 : Nuclear Transcription 
The coding sequence on the RNA produced is interrupted at various points by 
noncoding tracts known as introns. These introns are 'edited out' by a process known 
as splicing 19 to produce a substance known as messenger RNA 21  (mRNA) that is 
responsible for the coding of a specific polypeptide at the ribosome of the cell. 
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mRNA is comprised of a series of codons. A codon is a sequence of three 
ribonucleotides that code for a specific amino acid 2 ' and base pair with anticodons in 
tRNA during the translation stage of protein synthesis. From Table 1 it is noticeable 
that three of the codons (UAA, UAG, UGA) code for the termination of a peptide 
chain , 22 and one codon (AUG) codes for the initiation of a peptide chain. The table 
also shows that a single amino acid may have multiple codons, and when this occurs, 
the difference between codons is usually in the third base. The reason behind this lies 
in the anticodon. If the anticodon contains either a U, G, or I base, this base may 
weakly bond to two or more different nucleotides. The result of this is that multiple 
codons can code for a single amino acid. 23 
U C A G 
UUU = Phe UCU = Ser UAU = Tyr UGU = Cys U 
UUC = Phe UCC = Ser UAC = Tyr UGC = Cys C 
UUA = Leu UCA = Ser UAA = Stop UGA = Stop A 
UUG = Leu UCG = Ser UAG = Stop UGG = Trp G 
CUU = Leu CCU = Pro CAU = His CGU = Arg U 
C 
cuc = Leu CCC = Pro CAC = His CGC = Arg C 
CUA = Leu CCA = Pro CAA = Gin CGA = Arg A 
CUG = Leu CCG = Pro CAG = Gin CGG = Arg G 
AUU 	= lie ACU = Thr AAU = Asn AGU = Ser U 
A AUC = lie ACC = Thr AAC = Asn AGC = Ser C AUA = lie ACA = Thr AAA = Lys AGA = Arg A 
= Met ACG = Thr AAG = Lys AGG = Arg G 
GUU = Val GCU = Ala GAU = Asp GGU = Giy U 
CUC = Val GCC = Ala GAC = Asp GCG = Gly C 
GUA = Val GCA = Ala GAA = Glu GGA = Gly A 
GUG = Val GCG = Ala GAG = Glu GGG = Gly G 
Table 1 : The Universal Genetic Code 24 
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When the mRNA reaches the ribosome the next phase of protein synthesis 
begins. Transfer RNA (tRNA), 25 (Figure 3), has a specific amino acid attached at its 
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Figure 3: The Structure of tRNA 
The mRNA described earlier contains a short nucleotide sequence called a 
ribosome binding site and this binds to the 40S ribosomal subunit. The subunit 
begins reading the mRNA and when it encounters the AUG codon an initiation 
complex is formed comprising of the aminoacyl-tRNA and a group of proteins called 
initiation factors .27  The aminoacyl-tRNA base pairs with the AUG codon and the 
initiation factors leave. A 60S ribosomal subunit 28 then attaches to the initiation 
complex to form an 80S ribosome. 
The 80S ribosome consists of an acceptor site (A site) which is occupied by 
aminoacyl-tRNA, and a peptide site (P site) 29 occupied by tRNA to which is attached 
the peptide chain (peptidyl-tRNA). During peptide bond formation, the a-amino 
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group of the amino acid at the A site acts as a nucleophile, displacing the tRNA in 
the P site to form a peptide bond (Figure 4)3031  This reaction was initially thought 
to be catalysed by a protein called peptidyl transferase, however, recently it was 
found to be the ribosome that catalyses this reaction. The tRNA left at the P site 
leaves the ribosome through the exit site (E site) to be recycled '32  and the peptidyl-
tRNA, now at the A site, moves to the vacant P site 33  as the 80S ribosome 
translocates to the next codon on the mRNA. This process is repeated 34  until a stop 
codon on the mRNA is reached. At this point a group of proteins called release 
factors are produced which free the polypeptide from the peptidyl-tRNA, and the 
remaining 80S ribosome breaks down to be recycled. 35 
The discussion above describes protein synthesis in eukaryotic cells. Protein 
synthesis in bacterial cells is quite similar, with the only major difference being that 
the ribosome is comprised of 50S and 30S subunits, as opposed to the 60S and 40S 
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coc 	GGA 	UCC 	CCC 
codori *2 - codon #3 	codon#4 	codon *2 
jArg 	 (Gly) (SUer) 
mRNA 
Figure 4 : Translation 
1.2.2 Other Inhibitors of Protein Synthesis 
Antibiotics may inhibit protein synthesis in a number of different ways. For 
example antimicrobials, such as the fluoroquinolones, inhibit normal nucleic acid 
replication. Similarly rifampin blocks transcription by inhibiting bacterial RNA 
polymerase. In the following section only the antibiotics that act on ribosomes, and 
therefore function in a similar manner to anisomycin, will be discussed. 
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Puromycin 1 is an antibiotic isolated from Streptomyces alhoniger.' 6 Its 
structure clearly resembles the 3' end of a charged aminoacyl-tRNA, but instead of 
containing an activated ester it contains an unreactive amide bond (Figure 5)•37 
Puromycin acts by mimicking aminoacyl-tRNA 238  and participates in all the usual 
chain elongation steps to produce peptidyl puromycin. However, peptidyl puromycin 
does not bind to the P site, or participate in translocation, 33 and instead dissociates 
from the ribosome prematurely, terminating protein synthesis. 
Chioramphenicol 3 acts by binding to the 50S ribosomal subunit in bacteria 39 
and preventing peptidyl transfer. This halts protein synthesis and stops the growth of 
the bacterial organism (Figure 6). 
Tetracycline 4 and its group of antibiotics, inhibit protein synthesis in 
bacterial cells by attaching themselves to the 30S ribosomal subunit. This prevents 
aminoacyl-tRNA binding to the acceptor site, and stops protein synthesis. 40 
Linezolid 5 and other oxazolidinones function by binding to the 50S 
ribosomal subunit at a site close to that of chloramphenicol. 4 ' They act by stopping 
the 50S and 30S subunit coming together to form the 70S initiation complex ,42 and 
result in the inhibition of protein synthesis in bacteria. 
The streptogramins 6 are comprised of two different components which work 
in a synergistic fashion. The first component (type A) binds to the 50S ribosomal 
subunit, and prevents the binding of aminoacyl-tRNA to the acceptor site in the 
ribosome. The conformational changes brought about by type A binding to the 
ribosome increase type B's binding affinity for the 50S ribosome, 43 and it too binds 
to the 50S ribosomal subunit. Type B then acts by blocking peptide bond formation, 
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Figure 6 : Antibiotics Which Act on Ribosomes 
1.2.3 Mode of Action of Anisomycin 
During the 1960s research was carried out into discovering how anisomycin 
behaved as an antifungal antibiotic. It was found that when anisomycin was used at 
concentrations that caused 95% inhibition of protein synthesis, RNA synthesis was 
unaffected. 45 DNA synthesis however, was reduced but it was thought that this 
occurred as a direct consequence of the inhibition of protein synthesis. 46  It is clear 




Anisomycin has been found to inhibit the synthesis of haemoglobin from 
aminoacyl-tRNA in reticulocyte cell free extracts, and polyphenylalanine from 
phenylalanyl-tRNA in yeast extracts. 47  Therefore anisomycin must block some step 
after the formation of aminoacyl-tRNA. Since anisomycin has been shown to inhibit 
the puromycin- induced release of peptides from reticulocyte polysomes 4548 and to 
block the formation of N-acetyl-( 3H)Leu-puromycin in both the fragment 4 ' 
reaction 49,47(a)  and the purornycin reaction, 50  anisomycin may specifically block 
peptide bond formation on eukaryotic ribosomes. 
Vazquez showed that anisomycin partially inhibits the interaction of the 
fragment CACCA-Leu-Ac with the donor site and the fragment CACCA-Leu with 
the acceptor site of the 60S ribosomal subunit. 47(a)  A year later he showed that 
anisomycin also inhibits the binding of phenylalanyl-tRNA and N-Ac-phenylalanyl-
tRNA to the ribosomal A and P sites, 50 suggesting that anisomycin might inhibit 
peptide bond formation by affecting the correct positioning of the 3' termini of 
aminoacyl-tRNA and/or peptidyl-tRNA on the peptidyl transferase centre. 46 
In the fragment reaction both substrates involved in peptidyl transfer are replaced with simplified 
molecules. This is in contrast to the puromycin reaction where only the peptidyl acceptor is replaced. 
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1.3 Anisomycin As A Glycosidase Inhibitor 
Glycosidases are a group of enzymes typically found in biological systems. 51 
They function by catalysing the hydrolysis of glycoside bonds in carbohydrates. Not 
surprisingly, compounds such as iminosugars which inhibit glycosidases, display a 
number of biological properties. Castanospermine 752  for example, has been shown 
to be effective against HIV, the agent responsible for AIDS. 53 Similarly swainsonine 
8 54  has been found to affect tumour growth by inhibiting the breakdown of 
oligosaccharides on cell surfaces, thereby effectively starving the tumour of sugar 
(Figure 7)•53 
HO ::x Et OH  OH OH IIIIIIII!IIII 111111110H 
8 
Figure 7 : Castanospermine and Swainsonine 
1.3.1 The Role of Glycosidase Enzymes 
Disaccharides are produced when a hydroxyl group on one sugar unit reacts 
at the anomeric carbon centre on another, to form a glycoside bond that covalently 
joins the two monosaccharides (Scheme 1). Further reaction of this disaccharide with 
additional sugar units would allow the formation of oligo- and polysaccharides. 
12 
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Polysaccharides can be readily broken down to monosaccharides by treatment 
with dilute aqueous acids (Scheme 2). Under acidic conditions the glycoside bond is 
activated, allowing water to attack at the anorneric center forcing the glycoside bond 
to break. 
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In biological systems glycoside bonds are also cleaved by glycosidases. 
Glycosidases are a class of enzyme which act in a more controlled manner, by either 
hydrolysing glycoside bonds within the polysaccharide (endo), or at the ends of the 
sugar chain (exo) 56 using general acid/base catalysis.  57  Glycosidases show high 
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specificity towards the monosaccharides present in the substrate, and also towards 
the stereochemistry at the anomeric position. The hydrolysis occurs by one of two 
mechanisms giving rise to either inversion, or retention of the anomenc 
configuration. 
In retaining glycosidases, the acid/base catalysis is brought about by the 
presence of amino acid residues on the wall of the enzyme's active site (Scheme 3). 
One of these acids acts as a general acid/base, whilst another behaves as a 
nucleophile/leaving group. The reaction is brought about by the activation of the 
glycoside bond, which then allows a second carboxylate group to attack the anomenc 
carbon centre. The reaction produces a covalent intermediate 9 and allows the release 
of the remaining polysaccharide chain (aglycone). In the next phase of the reaction, 
water present in the active site is activated towards the attack of the anomeric carbon. 
Its subsequent reaction displaces the carboxylate group, allowing the stereochemistry 
at the anomeric centre to be conserved in the resulting monosaccharide. 5859 
14 
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With inverting glycosidases, the reaction again proceeds with the activation 
of the glycoside bond. However, rather than a carboxylate group in the active site 
acting as a nucleophile, it instead behaves as a base by activating trapped water. The 
attack by water leads to the direct displacement of the aglycone leaving the 
monosaccharide (glycone), with its stereochemistry at the anomenc position inverted 
























1.3.2 The Mode of Action of Glycosidase Inhibitors 
For the inhibition of a glycosidase to occur, an inhibitor must bind to the 
active site of the enzyme in preference to a polysaccharide. It is clear therefore, that 
to produce an effective glycosidase inhibitor, it must be able to mimic the transition 
state produced in a glycosidase enzyme. 
A closer study of the mechanism for both inverting and retaining glycosidases 
shows that a common transition state is formed, in which the anomeric carbon is sp 2 
hybridized (Figure 8) .60  This change in hybridization gives rise to a half chair 
conformation. Therefore to produce an effective glycosidase inhibitor, it too must 
have this half chair conformation. 
The inhibitory behavior of iminosugars has been attributed to the fact that 
they can fit into the active site of the enzyme by adopting an envelope or twisted half 
chair conformation . 5) Among other factors, the ability of a protonated iminosugar to 
form an ion pair with the carboxylate group of the catalytic site ensures that it binds 
in preference to other polysaccharides. 61 
Figure 8 : A Protonated Iminosugar Mimicking a Polysaccharide in the 
Catalytic Site of a Glycosidase Enzyme 
17 
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1.3.3 Pyrrolidine Iminosugars as Glycosidase Inhibitors 
DAB-i (11)62  and DMDP (12)63  are both examples of iminosugars which 
have successfully been used to inhibit glycosidases (Figure 9). DAB-I has been 
shown to inhibit yeast a-glucosidase (IC50 1.8 x 10 7 M)64 , where as DMDP has been 
shown to inhibit rat intestine lactase and bovine liver cytosolic fl-glucosidase 
(IC50 3 x 10 6 M).65 
Ar 	 OH 
AcO 	OH 	HO 	OH 
10 	 11 12 
Figure 9: A Comparison of Anisomycin with Two Iminosugars that 
Inhibit Glycosidase Enzymes 
It has been shown that for the formation of glycoside bonds using E. coli 13-
galactosidase, the presence of a benzyl group at the anomeric position of 
xyiopyranosides such as 13 increases the enzyme-acceptor binding, but also results 
in its partial inhibition (Figure 10).66  It is anticipated therefore, that anisomycin with 
its p-methoxybenzyl group at the 2-position, and its potential to form an ion pair 
within the active site, will bind preferentially to glycosidase enzymes and function as 














1.4 Anisomycin as a JNKIp38 Kinase Activator 
MAP kinases (mitogen-activated protein kinase) are a group of protein 
serine/threonine kinases that are activated in response to a variety of extracellular 
stimuli. They function by mediating signal transduction from the cell surface to the 
nucleus. 67,68  The controlled regulation of MAP kinase cascades results in cell 
proliferation, differentiation, and cell repair/apoptosi s •69  However, unregulated 
activation can lead to oncogenesis. 70 '71 '72 
Anisomycin has been shown to strongly activate the JNKISAPK (c-Jun 
NH2-terminal kinase/stress activated protein kinases) and p38 MAP kinases in 
mammalian cells, 15 and results in the switching of cells from a resting state (GO) to 
an active state (GI). There are three major types of MAP kinase pathway in 
mammalian cells that have been reported. A brief discussion of these cascades is 
presented below. 
1.4.1 Mitogen-Activated Protein Kinase (MAPK) Cascades 
Cells membranes contain many different types of receptors to which growth 
factors and cytokines can bind. These receptors are comprised of two components. 
The first component is a ligand binding component, and is situated on the outside of 
the cell and ensures ligand specificity. The second component lies inside the cell and 
generates biological responses upon ligand binding. The biological response is 
determined by the type of receptor. 
In the ERK1/ERK2 pathway the receptor is a protein tyrosine kinase (Figure 
11). On ligand binding, tyrosine residues on the receptor are phosphorylated thereby 
providing a binding site for Grb. Grb is an adapter protein which binds to the 
receptor after it has bound to Sos (a guanine nucleotide releasing factor). These 
interactions bring Sos into close proximity with Ras (a membrane bound 
phospholipase), allowing Ras to become activated by the exchange of GTP for GDP. 
19 
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The activated Ras protein phosphorylates the first signalling protein in the 
MAP kinase pathway called Raf. The active Ras protein then becomes deactivated 
through the hydrolysis of its GTP with the help of Ras-specific GAPs. The active Raf 
kinase then moves into the cytosol and phosphorylates a dual specificity kinase, 
MEK on serine (218) and serine (222). The activated MEK, (the second signalling 
protein in the map kinase pathway) then phosphorylates MAP-K (ERK) on threonine 
(183) and tyrosine (185) and a fraction of this enzyme translocates to the nucleus to 
phosphorylate the transcription factor Elk-l. The proteins Raf, MEK and MAP-K are 
all deactivated after they have phosphorylated the next signalling protein in the MAP 
kinase pathway by specific phosphatases. 
Once inside the nucleus Elk-I begins to mediate changes in the expression 
of early response genes including c-jun and c-fos. Activated c-jun and c-fos then 
form a dimer which is an ideal DNA-binding protein that recognises specific DNA 
elements within promoter regions of genes. When the dirner binds to the promoter 
region of a gene, general transcription factors and RNA polymerases are produced 
allowing the transcription of downstream genes to occur. (cf. Section 1.2) The 
mRNA produced is transcribed into protein at the ribosome. This leads to an overall 
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Figure!!: The ERK1IERK2 Pathway 
The JNKJSAPK cascade is activated following exposure to UV radiation, 
heat shock, or inflammatory cytokines. 68 ' 74 One mechanism of activation is via a 
receptor on the cell membrane. Once this receptor has been activated it transmits its 
message through G-proteins (GTP-binding proteins) to a membrane bound 
phospholipase, Rac. 67'74 Once this membrane bound phospholipase has been 
activated it binds to the PAK65 protein kinase phosphorylating it, 75 initiating a 
similar MAP kinases cascade to Elk-l. Thus PAK65 activates MEKK which in turn 
phosphorylates and activates MKK 4/7 at serine (219) and serine (223).68  MKK 4/7 
then activates JNKJSAPKI allowing it to translocate to the nucleus. Once inside the 
nucleus it binds to the N-terminal region of c-Jun and phosphorylates it at serine (63) 
and serine (73)76 The result is again the transcription of genes and eventually the 
formation of protein. 
21 
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The p38 kinase is the newest member of the MAP kinase family. 68 
Consequently much is still not known about the upstream steps in its activation. The 
kinase cascade is activated in response to inflammatory cytokines, endotoxins and 
osmotic stress. 72 ' 77 ' 78 The first known kinase to be activated is MMK3/6, a dual 
specificity kinase. This kinase activates the p38 kinase causing it to translocate to the 
nucleus and phosphorylate the transcription factor ATF-2. 79 The p38 kinase has also 
been found to activate MAPKAPK2, a kinase involved in the phosphorylation and 
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Figure 12: Stress—Activated Kinase Pathways 
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Although much has been discovered about the MAP kinase pathways a lot 
still remains unclear. Even though it has been shown that the MAP kinase family can 
be separated into different pathways displaying a high degree of specificity and 
functional separation, there is still some degree of cross-talk between the different 
cascades (Figure 12). For example, MKK 4/7 not only activates JNKISAPK but is 
also reported to activate p38. 81  Similarly, at the transcription level, ATF-2 is 
phosphorylated and activated by all three MAP kinases, whereas c-Jun and Elk-1 are 
phosphorylated only by ERKs and JNKISAPK. However, despite all this, these 
pathways still result in transcriptional activity that is unique for a particular external 
stress. 82 
14.2 Anisomycin's Roles as a JNK/p38 Kinase Activator 
Anisomycin has been found to activate both the JNK and p38 pathways at 
sub-inhibitory concentrations.E However the precise relationship between JNKIp38 
activation and anisomycin is not yet known. 
It has recently been discovered that peptidyltransferase inhibitors can trigger 
a ribotoxic stress response that activates the JNK1 MAP kinase. 83 It has therefore 
been proposed that anisornycin, itself a peptidyltransferase inhibitor, may activate the 
SNK pathway via a ribotoxic stress response rather than activating the kinase 
pathway directly. 84 
Anisomycin is known to bind to the 60S ribosome 300 times stronger than its 
deacetylated form. 85  Since deacetylanisomycin has little effect on protein synthesis 
or JNK1 kinase activation, 86  it is proposed that the ribotoxic stress response which 
activates the INKI kinase is produced when anisomycin binds to the 60S ribosomal 
subunit. 
At sub-inhibitory levels (typically 10 nglml) anisomycin activates the kinase pathways but does not 
inflict any toxic effects on cells through protein synthesis inhibition and may even cause a slight 
stimulation of protein synthesis, presumably due to its gene-inducing effect. 
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The arguments above suggest that a series of anisomycin analogues 
displaying a range of activity towards the JNK1 kinase, should display a similar 
pattern of activity towards peptidyltransferase inhibition. Surprisingly however, there 
are no such studies reported in the literature at the time of writing. 
In a recent study of PCI2 cells, 81  it was found that anisomycin directly 
targeted the p38-pathway in a Ras independent manner. It was also found that the 
JNK pathway was directly activated by anisomycin without the involvement of the 
p38 kinase. However, here it was thought that the Ras proteins did play some kind of 
role. Finally, activation of the ERK-pathway by anisomycin required not only the 
presence of a TrkA receptor and Ras protein, but also activation of the p38 kinase. 
This latter finding demonstrates a potentially important cross talk between the p38-
and ERK-pathways (Figure 13). 
All the effects of anisomycin described in the reactions above were inhibited 
by NAC, a scavenger of reactive oxygen species. The formation of oxygen free 
radicals by anisomycin and their mode of action still remains unclear, but their 
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Figure 13 : Signal Transduction Pathways Affected by Anisomycin in 
PC12 Cells 
It has been shown that anisomycin acts exactly like a signaling agonist in 
eliciting highly specific and virtually complete homologous desensitization of 
immediate-early (IE) gene induction and stress kinase activation. 88  Following the 
desensitization of a panel of IE genes (c-fos, [os-B, c-jun, and jun-D) using 
anisomycin, re-stimulation of the cells with a range of secondary stimuli gave 
selective responses. 
It was found that re-stimulating the anisomycin-desensitized cells with 
anisomycin no longer activated the JNKISAPK and p38 MAP kinase cascades. 
Attempts to activate the JNKISAPKs with UV radiation and hyperosmolarity were 
also unsuccessful, and the activity of the p38 cascade was reduced to about 50% of 
its normal response. However, stimulating the cells with epidermal growth factors 
(EGF), tumor necrosis factor alpha (TNF-a), basic fibroblast growth factors (bFGF) 
and tetradecanoyl phorbol acetate (TPA) produced normal or augmented activation 
of these two kinase cascades. 
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These results suggest that anisomycin behaves like a true signaling agonist 
and that the anisomycin-desensitized signaling component is not involved in 
JNKISAPK or p38 activation by EGF, bFGF, TPA but might play a significant role 
in UV- and hyperosmolarity-stimulated responses. 
Arsenite 
-P INK 	 IMKK4/71 
- -- Anisomycin 
Direct 	Inactivation 
Inactivation by degradation 
Precipitation 
Figure 14 : Model of the Regulation of the M3/6 Phosphatase by Arsenite and 
Anisomycin 
Ashworth has found that anisomycin activates the JNK pathway using two 
complementary processes. 89  It was found that anisomycin not only activated 
JNKISAPK1 via its upstream kinase MKK 4/7, but also triggered the deactivation of 
the M3/6 (INK-specific) phosphatase by ubiquitination and subsequent proteolytic 
degradation of the protein. This is in contrast to the effect of arsenite (and heat 
shock) which it is thought stimulates INK phosphorylation by direct inactivation of 




It is clear that this novel property of anisomycin to activate MAP kinases has 
an important role to play in discovering and understanding more about MAP kinase 
pathways. At present the role of anisomycin as a biological tool is hampered by the 
need to use sub-inhibitory concentrations. If an analogue of anisomycin could be 
developed which activated the JNKIp38 pathways without inhibiting protein 
synthesis at high concentrations, significant progress towards understanding the 
mechanisms involved in cell signaling could be made. 
1.5 Summary of Chapter 1 
This chapter has highlighted the biological properties of anisomycin. Various 
biological systems that anisomycin shows activity towards have been discussed, as 
well as its proposed mode of action upon these systems. 
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Chapter 2 : The Synthesis of Anisomycin 
2.1 Previous Syntheses of Anisomycin 
Practical syntheses of anisomycin have met with increased interest during the 
last ten years due to reports of its high anti-tumour activity, 2 and its ability to activate 
the JNK and p38 MAP kinase pathways. 15  Over 20 syntheses of anisomycin or its 
biosynthetic precursor deacetylanisomycin 14 have been reported in the 
literature. ' 4 ' 90 However, many of these syntheses suffer from a series of protection 
and deprotection steps in the latter stages, and the need for an efficient synthesis still 
remains. 
Many early syntheses of anisomycin use deacetylanisomycin as a precursor, 
since its conversion to anisomycin by a series of 5 steps (Scheme 5) is well 
documented . 90W The synthesis requires that a distinction be made between the C(3) 
and C(4) hydroxy functionality using various protecting groups. A yield of only 45% 
is obtained for this conversion, and reflects the difficulties involved in discriminating 
between the two secondary alcohols. Consequently, recent syntheses of anisomycin 
have tried to avoid this issue. 
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10 	 16 
Reagents: (a) Na 2CO3(aq.), PhCH 2000CI, CH 2Cl2 ; (b) imidazole, TBSCI, DMF; (c) Ac 20, pyridine; 
(d) TBAF, THF; (e) 10% Pd/C, H2 , EtOH. 
Scheme 5 
Anisomycin has been synthesised from various different starting materials. 
Although most syntheses have utilised the chiral pool, a couple of groups have 
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Figure 15 : Previous Syntheses of Anisomycin 
Results and Discussion I 
The chiral functionality of anisomycin has been introduced in a variety of 
different ways (Figure 15). When the starting material is diethyl L-tartrate, the diol 
functionality is already in place. The p-methoxybenzyl group is introduced at the 2-
position by creating an electrophilic centre and reacting it with 4-
methoxyphenylmagnesium bromide (Scheme 6). This strategy is adopted in routes 3, 
4 and 6. However in all three cases, it results in diastereomers being obtained which 
have to then be separated. 
	
OMOM 	
OMOM 	 OMOM 
cJ ivVSOH 	' 
OMOM 	
OMOM OH 	 OMOM OH 
79% 	 21% 
17 	 18 19 
Reagents: (a) PMBMgCI, THE 
Scheme 6 
Another interesting point that is highlighted by these syntheses, is the 
struggle to differentiate between the C(3) and C(4) hydroxy functionalities. In diethyl 
L-tartrate there is no satisfactory way to discriminate between the two hydroxy 
groups. Consequently in routes 4 and 6, the same protecting group is applied to both 
alcohols. This results in the inevitable formation of deacetylanisomycin, whose 
conversion to anisomycin was described earlier. 
Jager did manage to discriminate between the two hydroxy groups by 
reducing one of the ester ftinctionalities, and acetal protecting the resulting 1,2-diol 
(route 3). This protecting group strategy though is far from ideal, since it results in 
the wrong alcohol being protected in the latter stages of the synthesis (Scheme 7). 
This problem could have been overcome however, by protecting the 1 ,3-diol instead 
of the 1,2-diol. 
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Reagents: (a) TBSCI, imidazole, DMF; (b) (I) Pd(OH) 2/C, H2, Boc20, dioxane; (ii) HOAc; (c) Ac 20, 
DMAP, pyridine; (d) HCl/dioxane (6 M), H 20 (1.1 eq). 
Scheme 7 
In a few syntheses of anisomycin, the wrong diastereomer has been obtained 
as a result of an asymmetric reaction. To rectify this, a series of three steps has often 
been employed which has not only increased the length of the syntheses, but also 
lowered the overall yield. 
Me 
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Reagents: (a) MsCI, pyridine, CH 2Cl2 ; (b) 1.0 M n-Bu 4NE THF solution, THF; (c) LiBr, HOAc, 
THE 
Scheme 8 
In this synthesis by Lin (Scheme 8, route 2), an asymmetric dihydroxylation 
reaction produces the wrong- diastereomer 24 as the major product. To correct this, 
the secondary alcohol is mesylated thereby making it susceptible to SN2  attack by the 
primary alcohol. The epoxide formed now has the correct stereochemistry, and is 
opened by the reaction with LiBr to give the desired diastereomer 27. A similar 
scenario exists in route 6, and is rectified in the same manner. 
In an attempt to avoid the issues described above, Greene et al (route 1) used 
a chiral auxiliary to ensure that the correct stereochemistry was obtained. Overall, as 
a consequence, his synthesis required 17 steps and resulted in only a modest yield of 
3%. 
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2.2 Retrosynthesis of Anisomycin 
It was clear from the study of previous syntheses, that if we wanted to 
produce a short efficient synthesis of anisomycin we needed to distinguish between 
the C(3) and C(4) hydroxy groups at an early stage. In addition to this, if we wanted 
to improve upon all the syntheses to date, we needed to ensure that no protecting 
group manipulation was required in the later stages of the synthesis. Bearing all this 




























Figure 16: The Retrosynthesis of Anisomycin 
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We were confident that deprotection of 28 would give anisomycin, since Lin 
had obtained anisomycin in a similar fashion. 900  We anticipated that para-toluene 
sulfonyl chloride (TsCl) would selectively react at the primary alcohol in 29, 
allowing the acetylation of the secondary alcohol to follow. We envisaged that aldol 
adduct 30 would readily react with lithium borohydride to give 29, and we were 
optimistic that aldol adduct 30 could be obtained via the reaction of a tyrosine 
derived aldehyde with the acylated Evans' auxiliary. 
Our optimism was based on the fact that DAB-1 and nectrisine have both 
been synthesised in the Hulme group by employing a highly diastereoselective syn 
glycolate aldol reaction with a serine-derived a-dibenzylamino aldehyde (Scheme 
9). 91 
TBDPSO 	 H + 	
NO Iw TBDPSO 	 N) O 
OBn 
NBn2 	 / 	
NBr 2 OBn 
Br Bn 
33 	 ent-32  
Scheme 9 
We were hopeful that a similar approach using a tyrosine derived aldehyde 31 
and the enantiomer of the acylated Evans' auxiliary ent-32, would allow us to access 
the aldol adduct 30 in good yield. 
A comparison between the reduced aldol adduct 29, and the intermediate 35 
produced in Jager's synthesis, shows that we too have successfully managed to 
discriminate between the two secondary alcohols (Figure 17). Our proposed 
synthesis also selectively protects the C(2)-OH of this intermediate rather than the 
C(3)-OH, thereby eliminating the need for protecting group manipulation in the latter 
stages, and thus fulfilling another of our objectives. 
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Figure 17: A Comparison of Two Intermediates 
2.3 Synthesis of a Tyrosine Derived NN-Dibenzylamino 
Aldehyde 
The NN-dibenzyl protected serine derived aldehyde 33 has attracted 
considerable interest within the Hulme group over the last 5 years. This interest was 
sparked by Reetz, 92 who showed that additions to this aldehyde occur highly 
stereoselectively to give anti or Felkin-Anh93 type products. The aldehyde has also 
been shown to be stable towards racemisation, therefore making its use in the aldol 
reaction extremely attractive. 
We hoped to take this work a step further by developing a NN-dibenzyl 
protected tyrosine derived aldehyde. We hoped this aldehyde would display the same 
selectivity and stability shown by its serine counterpart. 
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36 	 31 
Figure 18 : The Retrosynthesis of Aldehyde 31 
Our route to aldehyde 31 showed amine 36 to be a key intermediate (Figure 
18). Although its enantiomer is commercially available, a synthetic route to 36 is still 
required. 
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Initial efforts focused on the synthesis of 36 from the N-Boc protected 
tyrosine methyl ester 38 using a method employed by Snider. 94  Therefore, 38 was 
prepared by converting D-tyrosine to its methyl ester hydrochloride salt 37 
quantitatively using acetyl chloride and methanol (Scheme 10). The amine was then 
selectively protected using di-tert-butoxy carbamate in the presence of sodium 





37 	 38 
Reagents: (a) MeOH, AcCI (100%); (b) Boc 20, NaHCO3, EtOH (99%). 
Scheme 10 
Treatment of 38 with potassium hydroxide and methyl iodide as described by Snider, 
methylated the phenol as expected. However the presence of: 
• A quaternary carbon instead of a methine carbon at 70.2 ppm in the 13 C 
NMR. 
• An AB instead of an ABX system in the 'H NMR. 
• A parent ion at 402 mass units in the FAB mass spectrum. 
suggested that methylation a to the carbonyl group had also occurred giving rise to a 
mixture of both 39 and 40 (Scheme 11). 
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It was concluded that potassium hydroxide was not only removing the pheolic 
proton, but also the proton a to the carbonyl group, thereby allowing both centres to 
be alkylated. It was thought that a weaker base would eliminate this problem and 
allow the selective methylation of the phenol. 
Consequently, phenol 38 was treated with methyl iodide in the presence of 
potassium carbonate to give 39 in excellent yield. With no trace of the di-methylated 
material being observed, the Boc group was removed using trifluoroacetic acid to 
give the free amine 36 (Scheme 12). 
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Reagents: (a) Me!. K2CO3,  DMF (97%); (b) TFA, CH2C1 2 (100%). 
Scheme 12 
The free amine produced was NN-dibenzylated using benzyl bromide in the 
presence of potassium carbonate, and reduction of 41 with LiBFI 4 gave amino 
alcohol 42. Finally oxidation of the alcohol using Swern 95  conditions gave aldehyde 
31 quantitatively, and as a single spot by t.1.c. (Scheme 13). This proved important, 
as similar aldehyde's have been shown to be unstable to silica gel, 96 and it allowed us 
to use the aldehyde crude in subsequent reactions without the need for any 
chromatography. 
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Reagents: (a) BnBr, K 2CO3 , CH3CN (95%); (b) LiBIt4 , MeOH, Et 20 (87%); (c) (COd) 2, DMSO, 
NEt3 , CH2Cl 2 (100%). 
Scheme 13 
23.1 Enantiomeric Excess and Optical Stability of Amino Aldehyde 
We were concerned about the enantiopunty of our amino alcohol. This 
concern was brought about by the ease with which racemisation occurred when 
alkylating phenol 38 in the presence of potassium hydroxide. To allay our fears and 
determine that racemisation had not occurred again, we decided to test the optical 
purity of the amino alcohol. 
A racemic synthesis of amino alcohol 42 was carried out. The racemate 
obtained was analysed using reverse phase chiral I-IPLC (Chiracel OD-H column; 
solvent 10% propan-2-ol in hexane) in order to optimise column conditions and 
ensure good baseline peak separation. The single enantiomer was then analysed in 
the same manner, and reassuringly, showed that no appreciable racemisation had 
occurred. (material >98% ee, Appendix A). 
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In an effort to determine whether aldehyde 31 was prone to racemisation, its 
optical stability was tested indirectly via the alcohol, since it has been shown in the 
literature that aldehydes similar to 31 are unstable to silica gel. 96 
Samples of aldehyde 31 were synthesised in the usual manner from alcohol 
42 using Swern conditions. The aldehyde 31 was then treated immediately with 
DIBAL-H at —78 °C, to regenerate 42 (Scheme 14). The alcohol obtained was 
analysed by chiral HPLC using the same conditions described earlier. The results 
again showed that no significant racemisation had occurred (material >98% ee). 
Thus, aldehyde 31 had been produced with high optical purity in seven steps and 
80% overall yield from D-tyrosine. 
Ar OH 	a 	Ar H 	b 	Ar OH 
NBn2 	 NBn2 	 NBn2 
42 	 31 	 42 
Reagents: (a) (COD) 2 , DMSO, NEt 3 , CH202 (100%); (b) DIBAL-H, toluene (90%). 
Scheme 14 
2.4 Boron Mediated Aldol Reaction 
2.4.1 Synthesis of the Glycolate Chiral Auxiliary 
With amino aldehyde 31 successfully synthesised our attentions turned to the 
aldol reaction. Studies within the Hulme group and by others 97  have shown the 
glycolate equivalent 32 to be highly effective in aldol reactions. An advantage of the 
auxiliary to us, in our synthesis, was the O-benzyl protecting group. If successfully 
incorporated into our substrate, the O-benzyl protecting group would offer us the 
option of a global deprotection step in the latter stages, thereby increasing our 
synthesis' efficiency. 
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The glycolate equivalent 32 was prepared in 3 steps from D-phenylalanine via 
the Evans' auxiliary 45. Thus D-phenylalanine was either treated with NaBH 4 using 
conditions described by Meyers, 98  or with TMSC1 and LiBFL1 using a method 
described by Quagliato. 99 The amino alcohol obtained was then condensed with 
diethyl carbonate to give the Evans' auxiliary in good yield. Finally, treatment of the 
auxiliary with n-butyllithium followed by benzyloxyacetyl chloride gave glycolate 
equivalent 32 in excellent yield (Scheme 15). 
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Reagents: (a) NaBH4 , 12, THF, KOH (60%); (b) LiBH 4 , TMSCI, THF (95%); (c) K2CO3,  (EtO)2C0 
(83%); (d) BnOCH2COCI, BuLi, THF (89%). 
Scheme 15 
2.4.2 Formation of the 'Mismatched' Aldol Adduct 
With both coupling partners in hand, we were now ready to attempt the aldol 
reaction. Formation of the Z-boron enolate was carried out using standard conditions 
(Bu2BOTf, NEt3 , -78 °C -* 0 °C) and reacted with freshly prepared aldehyde 31 to 
give aldol adduct 30 as the major diastereomer. A diagnostic peak in the 'H NMR at 
4.89 (d, J 1.6 Hz) representing the C 2 proton, suggested that the syn aldol product 
Results and Discussion I 
had been obtained.' Consequently aldol adduct 30 was tentatively assigned the 
'mismatched' structure shown below (Scheme 16). 
Trace amounts (<5 mg) of two other inseparable diastereomers were also 
obtained. Again, the diagnostic peak for a syn aldol adduct was clearly visible in the 
'H NMR at 8 5.06 (d, J 3.3 Hz), suggesting that the other syn aldol adduct had been 
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Reagents: (a) (I) Bu 2 BOTf, NEt3 , CH 2Cl 2 ; (ii) 31, (75%). 
Scheme 16 
A full investigation into this and other asymmetric glycolate aldol reactions is 
presented in chapter 4. 
2.5 Synthesis of Deacetylanisomycin 
In an attempt to determine the relative stereochemistry of aldol adduct 30, we 
set about the synthesis of deacetylanisomycin. Thus aldol adduct 30 was reduced 
with LiBH4 in the presence of methanol to give diol 29 in 80% yield. The Evans' 
auxiliary was also recovered, with a moderate yield of 60% (Scheme 17). 
In solution a 3-hydroxy ketone exists in a chair-like conformation as a result of intramolecular 
hydrogen bonding. The bulk long chain adopts a more favoured equatorial position and the dihedral 
angle between a and 13 protons is —601 for the syn arrangement and —180° for the anti arrangement. As 
a result, the Karplus relationship predicts vicinal coupling constants to be --3-5 Hz for syn and 
--7-12 Hz for anti aldol adducts. 
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Reagents: (a) LiBH 4 , CH 3 0H, THF (80%). 
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The selective tosylation of the primary alcohol was then attempted by 
reacting diol 29 with TsC1 in the presence of DMAP (Scheme 18). However, rather 
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Reagents: (a) TsCI, DMAP, CH 202 ; (b) Dowex, cr (85%). 
Scheme 18 
Our suspicions were based on the fact that the salt produced, gave a more 
polar spot on the t.l.c. plate than the starting material 29. Our suspicions grew when 
the distinctive tosylate peaks in the 'H NMR (ö 2.29 (s), 6 7.83 (d, J 8.2 Hz), and ö 
7.10 (d, J 8.2 Hz)) diminished in size after washing the compound with 1% 
hydrochloric acid. This suggested to us that the tosylate counter ion was being 
exchanged for a chloride ion. After consulting with the literature and finding that 
others had experienced a similar result (Scheme 19),100  we were left in no doubt that 
what we had isolated was indeed the pyrrolidinium tosylate salt 47. 
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Reagents: (a) NEt3 , MsCI, THF (100%). 
Scheme 19 
Having obtained salt 47, we needed to address the fact that it contained a 
mixture of two counter ions. This problem was solved by passing a solution of the 
salt through a Dowex column treated with 1% hydrochloric acid. This had the 
desired effect of exchanging both counter ions for the chloride ion, thereby ensuring 
that only one salt remained. 'H NMR confirmed  this to be the case. 
The chloride salt obtained was then hydrogenated in the presence of 
Pearlman's catalyst to give deacetylanisomycin as its hydrochloride salt. This salt 
was again subjected to a Dowex column, this time treated with 1 M NaOH, to give 
deacetylanisomycin as its free base, and in excellent yield (Scheme 20). 
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Reagents: (a) H 2 , 20% Pd(OH)7, CH 30H (100%); (b) Dowex 01-1 (100%). 
Scheme 20 
A comparison of the literature 'H NMR and optical rotation data with 
compounds 54 and 14 is shown in Tables 2 and 3. The data for the two compounds 
is clearly in good agreement with that of the literature, confirming the successful 
synthesis of deacetylanisomycin, in II steps and in an overall yield of 40%. The 
result also suggests that the stereochemistry tentatively assigned to aldol adduct 30 is 
correct. 
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Table 2: A Comparison of NMR Data with Literature Data for 
Deacetytanisomcyin 
Source MHz Solvent 2-H 3-H 4-H 5-HA 5-HB 1'-H 
Ref 145 205.1 CD30D 3.91 4.02 4.30 3.14 3.66 3.00, 
3.20 
Cn 54 250 CD 30D 3.96 4.07 4.34 3.18 3.70 3.04, 
 3.24 
Ref 200 DMSO-d6 2.96 3.45 - 3.82 - 2.36 3.15 2.52, 
90(v)  3.47 3.85  2.71 
Ref 400 DMSO-d6 3.26 3.73 4.07 2.64 3.38 2.71, 
90(h)  2.86 
14 250 CD 30D 3.34 4.16 3.79 3.46 2.71 2.97, 
 2.80 
a Data obtained for hydrobromide salt 
Table 3: A Comparison of NMR and Optical Rotation Data with Literature 
Data for Deacetylanisomcyin 
Source J2,3 J3,4 J4,5A J4,5B J5A,5B J2,1' J1'A,I'B laiD 
(Hz) (Hz) (Hz) (Hz) (Hz) (Hz) (Hz) 
Ref 14' 2.8 1.5 0 4.4 12.4 8.2, 14.0 +7.2 
7.1  (c 1 .0, CH30H) 
54 2.8 1.4 0 4.2 12.5 8.3, 14.1 +8.1 
 7.1 1 (c 0.6, CH30H) 
Ref 3.5 - 2.1 5.5 11.8 7.4, 13.2 -22.5 
Cn 90(v)  6.5  (c 1.0, CH3 0H) 
tv Ref 3.4 0 2.5 5.9 12.2 7.2, 13.6 -20 
90(h)  7.2  (c 1.0, EtOH) 
14 3.8 1.4 2.0 5.7 12.4 8.3, 13.4 -19.8 
6.6  (c 1.0, CH30H) 
a Data obtained for hydrobromide salt 
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2.6 Synthesis of Anisomycin 
With the synthesis of deacetylanisomycin successfully completed, and the 
stereochemistry of aldol adduct 30 confirmed, our attentions turned towards 
completing the synthesis of anisomycin. 
Having obtained the pyrrolidinium salt 48, we next set about acetylating it. 
Unfortunately, treatment of the salt with acetic anhydride and DMAP gave another 
pyrrolidinium salt with a similar Rf value (Scheme 21). Consequently, clean 
separation of the product from the starting material using flash chromatography 







a 	Ar  
AcO 	OB  
55 
Reagents: (a) Ac 20, DMAP, CH 2C12 (54%). 
Scheme 21 
With salt 55 in hand, albeit not very much, we decided to try and globally 
deprotect it to give anisomycin. Exposure of the salt to a hydrogen atmosphere in the 
presence of Peariman's catalyst gave, as anticipated, anisomycin as its hydrochloride 
salt (Scheme 22). 
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Reagents: (a) H 2, 20% Pd(OH) 2, CH 30H (100%). 
Scheme 22 
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In an attempt to obtain anisomycin as its free base, the salt was passed 
through a Dowex column treated with I M sodium hydroxide. However, rather than 
obtaining anisomycin as expected, we instead isolated a mixture of both anisomycin 
and deacetylanisomycin (Scheme 23). It was clear therefore, that sodium hydroxide 
was not only removing the salt, but also hydrolysing the acetate ester to give 
deacetylanisomycin. 
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Reagents: (a) Dowex (OH). 
Scheme 23 
With both steps producing their own individual set of problems, we set about 
looking at a different route to anisomycin. One possible route focused on the 
selective removal of a benzyl group from the nitrogen centre of the dibenzyl 
quaternary pyrrolidinium salt 48. This would free up the salt without affecting our 
synthetic strategy, allowing us to access anisornycin using the same procedure as 
before. 
Initial attempts focused on hydrogenating the salt using differing lengths of 
time and various quantities and types of catalyst (Table 4). However, none of these 
attempts proved successful with mono-, di-, and full y-debenzylated material being 
recovered. It was not until the hydrogenation was carried out under basic conditions 
that any noticeable selectivity was observed. 
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Scheme 24 
Table 4: Conditions Used in the Selective Monobenzylation of 
Pyrrolidinium Salt 48 
Entry Reagents/Conditions Time Yield 
(Minutes)  
1 20% Pd(OH) 2/C (100% Mass eq.) 25 N/E 
2 20% Pd(OH) 2/C (10% Mass eq.) 25 50 
3 5% Pd/C (10% Mass eq.) 25 70 
NH40Ac_(0.05_mol_eq.)  
4 10% Pd/C (100% Mass eq.) 18 49  
Formic 	 mot _acid!MeOH_(1_ 	_eq.)  
5 5% Pd/C (10% Mass eq.) 10 94 
K2CO3_(3_mol_eq.)  
When the salt 48 was hydrogenated in the presence of K2CO3,  the alcohol 56, 
was isolated cleanly and in excellent yield. It was therefore concluded that the 
positive charge on the nitrogen centre appeared to increase the rate of debenzylation. 
Consequently, when the reaction was carried out under basic conditions the 
formation of a free base intermediate after hydrogenylitic removal of the first benzyl 
protecting group appeared to slow the rate of any further hydrogenation, thereby 
allowing us to access 56 in excellent yield (Scheme 25). 
50 
Results and Discussion I 
	
Bn Bn r 	Bn 	H 	
Bn 
Ne CI 	 I \ 	1e I 
Ar 	 a I Arm] 	Ar 
HO HO 	 HO 	bBn 
48 	 TS 	 56 
Reagents: (a) H 2, 5% Pd/C, K2CO3- 
Scheme 25 
Having successfully obtained 56 we again set about repeating the final two 
steps of the synthesis. This time treatment of 56 with Ac20, NEt3 , and DMAP 
proceeded as expected, and the product 57 was isolated in 92% yield (Scheme 26). 












Reagents: (a) Ac 20, NEt3 , CH2Cl2 (92%). 
Scheme 26 
When 57 was hydrogenated in the presence of Peariman's catalyst, 
anisomycin was isolated as a mixture of its salt and its free base. The formation of 
the salt was attributed to the Celite used when filtering the reaction mixture. It 
became apparent after some time that the Celite obtained from various commercial 
sources is pre-washed with acid. Consequently, when mixing amines and Celite 
together in a solvent such as methanol, there is a strong possibility of partial salt 
formation. 
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To counteract this problem it was decided to repeat the reaction with 2 
equivalents of 1 M hydrochloric acid dissolved up in the reaction mixture. It was 
hoped that anisomycin would form its hydrochloride salt during the reaction, thereby 
eliminating the problem of partial salt formation by Celite at the end of the reaction. 
Thus, as predicted, exposure of 57 to a hydrogen atmosphere in the presence of 
methanol and 1 M hydrochloric acid, gave after stirring, anisomycin as its 
hydrochloride salt in excellent yield (Scheme 27). 
a 	Ar ) 
AcO 	OH 
23 57 
Reagents: (a) H2 , 20% Pd(OH) 2/C, 1 M HCl/Et20, CH 3 0I-J (100%). 
Scheme 27 
A comparison of the literature 1 1-1 NMR and optical rotation data with 23 is 
shown in Tables 5, 6, and 7. The data for 23 is in clear agreement with that of the 
literature. This therefore suggests that we have, as thought, successfully synthesised 
anisomycin as its hydrochloride salt, in 13 steps and with a 35% overall yield. The 
result again reconfirms our earlier assignment of stereochemistry to aldol adduct 30. 
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Table 5: A Comparison of Literature NMR Chemical Shift Data with 23 
Source MHz Solvent 2-H 3-H 4-H 5-HA 511 B 1'-H Other 
Ref 14 205.1 CD3 0D 4.21 5.10 4.40 3.24 3.65 3.02, 2.23, 
.1_, 3. 3 - i O' .OL, 
6.96, 
7.28 
23 250 CD30D 4.23 - 5.08 4.38 3.22 3.63 2.99, 2.21, 
4.15 3.11 3.81, 
6.95, 
 7.26 
Table 6: A Comparison of Literature NMR Multiplicity Data with 23 
Source J2,3 J3,4 J4,5A J4,5B J5A,5B "2,1' JI'A,I'B JA, 
(Hz) (Hz) (Hz) (Hz) (Hz) (Hz) (Hz) (Hz) 
Ref 14 3.4 0 0 4.5 12.7 8.7 6.9 14.2 8.5 
23 3.0 0 0 4.3 12.8 8.8, 14.3 8.6 
 6.7  
Table 7 A Comparison of Literature Optical Rotation Data with 23 
Source lain 
Ref 14 +4.2 (c 0.5 1, CH3 0H) 
23 +4.0 (c 0.28, CH301-1) 
Ref 1 +3.9 (c 1.0, CH30H) 
Ref 90(d) +3.5 (c 1.0, CH3 0H) 
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2.7 Synthesis of 3097-Bi 
Having successfully synthesised anisomycin our attentions turned to 
synthesising 3097-BI (59), another natural product also isolated from the 
fermentation broths of Streptomyces strain SA3097. This natural product differs only 
slightly from anisomycin in having a propionate ester at the C(3) position rather than 
an acetate group. It was therefore envisaged that treatment of 56 with propionic 
anhydride as opposed to acetic anhydride would enable us to obtain, after 
a 	Ar 
H 
b 	Ar ) 




deprotection, 3097-B 1. 
Reagents: (a) (EtCO) 20, NEt3 , CH2Cl2 (89%); (b) H2,20% Pd(OH) 2/C, 1 M HCLIEt 2O, CH30H 
(100%). 
Scheme 28 
As anticipated, treatment of 56 with propionoic anhydride proceeded 
smoothly to give 58 in 89% yield. Deprotection of 58, employing the same 
conditions as that for anisomycin, then gave 3097-BI as its hydrochloride salt, in 
quantitative yield (Scheme 28). 
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2.8 Summary of Chapter 2 
In this chapter, the successful synthesis of both anisomycin and 
deacetylanisomycin has been described. The chapter began with the analysis of 
several previous syntheses of anisomycin, and it was noted that many of these 
syntheses suffered from a series of protection and deprotection steps in the latter 
stages. Bearing this in mind, we put forward our own retrosynthesis. 
In the next section, the synthesis of a tyrosine derived aldehyde was 
presented. Its employment in a 'mismatched' asymmetric boron mediated aldol 
reaction proved lucrative in setting up the stereochemistry required for both natural 
products. Consequently, it enabled us to synthesise both anisomycin and 
deacetylanisomycin from D-tyrosine in 13 steps, 35% overall yield and 11 steps 40% 
overall yield respectively. 
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Chapter 3: The Biological Evaluation of Some Anisomycin 
Derivatives 
3.1 A Review of Anisomycin SAR Studies 
Since the mid 1960's several groups have been interested in the study of 
various analogues of anisomycin. Many of these early studies focused on 
anisomycin's behaviour as an antibiotic and sought to produce analogues that would 
improve its biological activity. Following a lull during the 1980's, interest in 
anisomycin was again sparked in 1993 when it was discovered that anisomycin gave 
high anti-tumour activity in vitro. This interest has lasted for a period of ten years 
during which time it has also become apparent that anisomycin is able to act as a 
signalling agonist for the stress-activated, mitogen-activated protein kinase 
pathways, JNK and p38, in mammalian cells. It is therefore somewhat surprising, 
that at the time of writing, a structure activity relationship (SAR) study involving 
analogues of anisomycin and the JNK or p38 MAP kinase pathways has not been 
carried out. Similarly, it is also surprising, given that anisomycin bears close 
structural homology with the iminosugars, that neither anisomycin nor its family of 
naturally occurring analogues have been studied as potential glycosidase inhibitors. 
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3. 1.1 Evaluation of Antibiotic Activity 
In 1967 Grollman 45 studied the activity of several analogues of anisomycin in 
cell-free protein-synthesising systems, from both rabbit reticulocytes and 
Sacharornyces fragilis (Figure 19). He found that all the analogues tested had less 
than 1% of the activity of anisomycin. From his research he concluded that the basic 
pyrrolidine ring is important for the activity of anisomycin, since either acetylation of 
the nitrogen atom or deacetylation at the C(3)-O position renders the molecule 
inactive. Similar results were also observed when the p-methoxyphenyl group was 
brominated at the meta position suggesting that only a para substituted phenyl ring 
would be tolerated by the active site of the enzyme. These results led Grollman 10 ' to 
propose that the essential structural features required for this biological activity are a 
secondary amine group adjacent to an asymmetric carbon (R configuration) linked 
via a methylene to a sterically unhindered six-membered ring. 
M 
Compound R R' R" 1050 [1iM] 




10 Ac H H 0.05 8 7 8 
14 H H H 50 >1000 300 >1000 
60 Ac Ac H 100 >1000 >1000 >1000 
61 Ac H Br 7 >1000 500 >1000 
62 Ac (CH3)2 H 100 >1000 >1000 >1000 
Figure 19: Protein Synthesis Inhibition by Anisomycin Analogues 
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Advances in synthetic chemistry during the 1970's allowed Hall and co-
workers 102  to synthesise a more diverse range of analogues from pyrrole-2-
carboxaldehyde. These analogues were tested alongside anisomycin for antiprotozoal 
activity on Trichomonas vagina/is, Trichomonas Jbetus, and Entamoeba histolytica 
(Figure 20).103  It was found that their activity against protozoa and fungi was 
restricted primarily to anisomycin and the p-methylbenzyl and benzyl analogues. 
Interestingly, as the methoxy group changed from the para to the or/ho position on 
the aromatic ring the biological activity dropped considerably, thereby adding weight 
to the previous observations of Grollman. 
R 







(-) 10 p-OMe H 1.9 3.8 3.8 
(±) 10 p-OMe H 3.8 7.6 7.6 
(±) 63 p-Me H 16.1 16.1 8.0 
(±) 64 H H 17.0 68.1 8.5 
(±) 65 m-OMe H 60.4 60.4 60.4 
(±) 66 o-OMe H - - - 
(±) 67 p-OMe Me - - - 
(±) 68 p-OMe Ph - I 	- - 
Figure 20: Antiprotozoal Activity of Anisomycin Analogues 
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3.1.2 Evaluation of Anti-Tumor Activity 
In 1993 Kameyama2 isolated two new analogues of anisomycin, along with 
the rest of the known family of naturally occurring analogues, from the fermentation 
broths of Streptornyces. strain SA3097. These new analogues differed from 
anisomycin and demethylanisomycin 71, in that they both had a propionate ester at 
the C(3)-O position rather than an acetate group. 
The biological activity of the analogues was tested on two human tumor cell 
lines, LU99 and MCF7 (Figure 21). Kameyama observed that changing between 
acetate and propionate esters on the ring seemed to have little effect on the 
cytotoxicity. It was also noted that demethylation at the aromatic ring also had little 
effect on activity as long as the pyrrolidine ring preserved its acyl group. However, 
in contrast, it was found that deacylation of the pyrrolidine ring resulted in a 
considerable reduction of activity and additional demethylation resulted in a 
complete loss of activity. 
R'O 
Compound R R' IC 50 [nM] 
Tumor Cell Line 
LU99 MCF7 
69 EtCO Me 65 90 
70 EtCO H 85 129 
10 Ac Me 50 95 
71 Ac H 82 74 
14 H Me 23 34 
72 H H 153000 175000 
Figure 21: Tumor Ccii Line Inhibition by Anisomycin Analogues 
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Recently, Jager ' 4 synthesised some novel analogues of anisomycin from 
diethyl L-tartrate. Jager tested these compounds alongside some of the naturally 
occurring analogues for in vitro cytotoxic activity against human cell lines KB, HBL 
100 RAS A, and I-IBL 100 (as a reference, non tumour cell line). From his results he 
observed that the benzyl analogue 20, showed only a slight decrease in cytotoxicity 
against the cell lines (Figure 22). Acetylation of both hydroxyl groups at positions 3 
and 4, 77 again led to only a slight decrease in cytotoxicity. However, deacetylation 
of the pyrrolidine ring led to a strong reduction of activity and additional removal of 
the methoxy group gave rise to a complete loss of cytotoxicity. Interestingly, the 
N,O-dibenzyl compounds and the 3-0-benzoyl analogue give rise to approximately 
the same decrease in cytotoxicity as deacetylanisomycin. However, analogues which 
had different stereochemistry to that of anisomycin, were found to be inactive 
towards the cell lines. 
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RO 	OR 








73a 2R,3S,4S H Bn H 14 51 79 
205 2R,3S,4S OMe Bn H 20 45 55 
74 2R,3S,4S H H H - - - 
14 2R,3S,4S OMe H H 19 50 29 
59 2R,3S,4S H Ac H 0.40 0.094 0.079 
10 2R,3S,4S OMe Ac H 0.01 0.05 0.05 
75 2R,3S,4S H Bz H - - - 
76 2R,3S,4S OMe Bz H 24 9 18 
77 2R,3S,4S OMe Ac Ac 0.1 0.3 0.2 
78 2S,3S,4S H H H - - - 
79 2S,3S,4S OMe H H - - - 
80 2S,3R,4S OMe H H - - - 
81 2S,3R,4S OMe H Bn - - - 
a  Contains benzylated nitrogen centre. 
Figure 22: Tumor Cell Line Inhibition by Anisomycin Analogues 
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3.2 Synthesis of Anisomycin Derivatives 
The review of anisomycin based SAR studies suggests that the ester group at 
the C(3)-O position is crucial for biological activity (Figure 23). The review also 
indicates that although acetate protection of the secondary amine is detrimental to 
anisomycin's activity, acetate protection of the C(4) hydroxyl group causes only a 
slight decrease in its biological activity. It was therefore proposed that the enzyme's 
active site might be tolerant to changes to the substituent at this position and 
consequently, we decided to target the C(4) position of anisomycin to produce our 
range of analogues. 
PMB or benzyl 
group tolerated. 	 Acetylation of amine 
not tolerated. 




(2R,3S,4 Steochemis 	 I Acetylation of OH tolerated giving only a slight decrease in activity. 




Figure 23 : A Summary of SAR Studies on Anisomycin 
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As highlighted, the presence of an ester group at the C(3)-O position is 
crucial for anisomycin's biological activity. It was proposed that the ester's role 
might be to decrease the polarity of the iminosugar in order to enable it to cross cell 
membranes. It was also proposed that once inside the cell, the ester group might be 
removed by hydrolysis to give deacetylanisomycin and that this might therefore be 
the active form of the drug. 
Given these considerations, we decided to focus on synthesising the C(4)-Me 
82 and C(4)-I-I 84 analogues of anisomycin along with their deacetyl derivatives 83 
and 85 (Figure 24). It was hoped that biological systems might absorb our lipophilic 
analogues better than anisomycin. It was also proposed that if deacetylanisomycin 
was indeed the active form of the drug, and its biological activity was being 
hampered by its polarity, then we might expect to see some form of activity from our 
less polar deacetyl derivatives. 
Ar 	 Ar 	 Ar 	 Ar 
H 	 H 
Ac 	Me 	HO 	Me 	AcO 	 HO 
82 	 83 	 84 	 85 
Figure 24 : Synthetic Analogues of Anisomycin 
Previous work within the Hulme group had already allowed us to successfully 
synthesise the C(4)-Me derivative of DAB-1 104  86 and a derivative of the natural 
product CYB-3 105 87 (Figure 25). We were therefore optimistic that similar 




Figure 25: Synthetic Analogues of DAB-1 and CYB-3 
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3.2.1 Synthesis of C(4)-Me Analogue 
Our retrosynthetic analysis for the C(4)-Me derivative of anisomycin is 
shown in Figure 26. The retrosynthesis is based on similar methodology to that used 
in the synthesis of anisomycin. Thus we envisaged that the aldol reaction between 
aldehyde 31 and the chiral propionate equivalent 91 would give aldol adduct 90 as a 
single diastereomer in an analogous manner to that observed for the glycolate aldol 
reaction. From here on, we believed that the chemistry undertaken for the synthesis 
















Ar 11N7ftO < Reduction 	
Ar OH 










Ar 	 H 
+ rK NO 
NBn 2 
B  
31 	 91 
Figure 26 : The Retrosynthesis of the C(4)-Me Analogue 
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The chiral propionate equivalent was synthesised from oxazoldin-2-one 45 
using the same protocol as that used for the synthesis of 32. Thus, reaction of 45 with 
n-butyllithium gave the lithiated oxazolidin-2-one, which on condensation with 
freshly distilled propionyl chloride gave 91 in excellent yield (Scheme 29). 
The aldol reaction between imide 91 and aldehyde 31 proceeded as 
anticipated to give aldol adduct 90 as a single diastereomer and in good yield. The 
reduction of 90 with lithium borohydride gave diol 89 (82%) and the auxiliary was 
recovered in 62% yield. Treatment of the diol with TsCI selectively protected the 
primary alcohol causing it to cyclise to give the pyrrolidinium tosylate salt. 
Treatment of this salt with Dowex resin, pretreated with 1% HC1, gave the chloride 
salt in good yield without any ditosylated material being observed. 












Ar 	 d 	
Ar OH 
/ 	 NBrt2 	Me 
HO Me 
92 	 89 
Reagents: (a) BuLi, THF, C 2H5COCI (90%) ;  (b) (i) Bu2BOTf, NEt 3 , CH2Cl2 ; (ii) 31(87%); (c) L1BH 4, 
CH 1 0H, THF (82%); (d) (I) TsCI, DMAP, CH 2Cl2 ; (ii) Dowex, Cl - (83%). 
Scheme 29 
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Having successfully obtained reaction conditions to mono-deprotect the 
pyrrolidinium salt during the synthesis of anisomycin, we were confident that similar 
conditions would enable us to selectively deprotect 92. This proved to be the case 
with hydrogenolysis of the pyrrolidinium salt in the presence of 5% Pd/C and 
potassium carbonate giving the mono protected amine in good yield. Finally, 
acetylation of the secondary alcohol and deprotection of the amine functionality, 
employing the same protocol as that required for anisomycin, gave as expected the 













Reagents: (a) H 2, 5% Pd/C, K2CO3,  CH30H (93%); (b) Ac 20, NEt3, CH2Cl2 (82%); (c) H 2 , 
20% Pd(OH)2/C,  I M HCL'Et20, CH 30H (100%). 
Scheme 30 
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In order to obtain the C(4)-Me deacetyl derivative the dibenzyl salt 92 was 
hydrogenated in the presence of Peariman's catalyst to give the deacetyl derivative as 
its hydrochloride salt. As anticipated, treatment of the salt with Dowex resin, 
pretreated with 1 M sodium hydroxide, gave the C(4)-Me deacetyl derivative as its 







a 	Ar ) 
HO 	Me 
95 
b Ar ) 
HO 	Me 
83 
Reagents: (a) H 2, 20% Pd(OH)2/C, CH 30H (100%), (b) Dowex 01-U (100%). 
Scheme 31 
3.2.2 Synthesis of the C(4)-H Analogue 
The successful synthesis of the two methyl analogues was achieved by 
swapping the glycolate aldol coupling partner 32 for the chiral propionate equivalent 
91. However our next target, the C(4)-H derivative 84, required the complete 
removal of the substituent at the C(4) position and in order to address this problem, 
we developed the following retrosynthesis (Figure 27). 
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Figure 27 : The Retrosynthesis of the C(4)-H Analogue 
It was anticipated that the Claisen condensation between imidazolide 100 and 
the lithium enolate of ethyl acetate would allow us to obtain the 0-keto ester 99. It 
was then hoped that the asymmetric reduction of 99 would produce alcohol 98 which 
upon further reduction, would give diol 97. From here on we believed that the 
chemistry undertaken in the synthesis of anisomycin, would allow us to access the 
C(4)-H derivative. 
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Our decision to convert the methyl ester to its imidazolide prior to the Claisen 
condensation was based on findings reported by Hoffman. 106  He found that 13-keto 
esters formed via the reaction of a-amino esters with lithio tert-butyl acetate were 
subject to a considerable loss of enantiopurity (Scheme 32). 
0 	 0 	0 
ROMe 	a 	 ______ 	(78-90%ee) I,, 
NBn2 	 NBn2 
102 	 103 
Reagents: (a) CH 2=C(OLi)OtBu, THE 
Scheme 32 
Similar studies within the Hulme group also confirmed this to be the case. 
However, the conversion of senne and phenylalanine derived esters to their more 
reactive imidazolides prior to their employment in the Claisen condensation not only 
reduced racemisation, but eliminated the problem completely in the case of 
phenylalanine. 107 We were therefore optimistic that conversion of our tyrosine 
derived ester to its imidazolide would also reduce racemisation in the Claisen 
condensation. 
The type of base used to hydrolyse the methyl esters was also found to be 
critical in maintaining the enantiopurity of the substrate. Studies within the Hulme 
group found that when lithium hydroxide was employed as the base it gave the 
highest yields and the least racemisation. 107 Consequently, methyl ester 41 was 
treated with lithium hydroxide to give the acid 104 as a single spot and in good yield 
(Scheme 33). This was fortunate as attempts to purify the acid by column 
chromatography proved problematic and often resulted in low yields of the acid 
being recovered. It was therefore decided to use the acid crude in subsequent steps. 
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NBn2 	 NBn2 
41 104 
Reagents: (a) LiOH, THF/H 20 (95%). 
Scheme 33 
Thus, crude acid 104 was treated with NN-carbonyldiimidazole to form the 
imidazolide 100, which without isolation, was then reacted with the lithio ethyl 
acetate to give the -keto ester 99 in good yield (Scheme 34). 
0 	 0 
Ar 0H 	
a 	
Ar N 	N 
= 	 = 
NBn 2 	 NBn2 








Reagents: (a) CDI, TUF (b) (1) L1HMDS; (ii) 100 (82%). 
Scheme 34 
Previous studies within the Hulme group indicated that sodium 
cyanoborohydride was the reagent of choice for the reduction of our f3-keto esters. 105 
It was found that this reducing agent gave the corresponding -hydroxy ester in high 
yield and with excellent diastereoselectivity. Other reducing agents, in contrast, were 
found to give lower diastereoselectivities and, in the case of sodium borohydride, 
resulted in the reduction of the ester functionality. 107 
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Treatment of the -keto ester 99 with sodium cyanoborohydride gave, as 
anticipated, alcohols 98 and 105 in 83% and 2% yield respectively with no over 
reduction of the ester moiety (Scheme 35). From previous studies, we were 
optimistic that the major diastereomer had the syn stereochemistry, and consequently 
we assigned the 0-hydroxy esters the structures shown. 
OH 	0 
0 	






Ar OEt  
N Bn 2 
105 
Reagents: (a) NaCNBH 3 , CH30H, AcOH, Et 20 (85%). 
Scheme 35 
We were concerned about the enatiopurity of ester 98. This concern was 
borne from the ease with which racemisation had occurred during a similar synthesis 
employing a serine derived methyl ester. Therefore, having obtained a moderately 
polar substrate that we were confident would separate from its enantiomer using 
reverse phase chiral HPLC, we began to set about determining its enantiopurity. 
A racemic synthesis of the 3-hydroxy ester 98 was carried out. The racemate 
obtained was analysed using chiral HPLC (Chiracel OD-H column; solvent 5% 
propan-2-ol in hexane) in order to optimise column conditions and ensure good 
baseline peak separation. The single enantiomer was then analysed in the same 
manner, and reassuringly, showed that no appreciable racemisation had occurred. 
(material >98% ee, Appendix B) 
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Having successfully determined the optical purity of the f3-hydroxy ester it 
was readily reduced with lithium aluminium hydride to give diol 97 (Scheme 36). 
Disappointingly, protection of the primary alcohol with TsC1 failed to give a single 
product and instead gave a mixture of the pyrrolidiniurn salts 106 and 107. It was 
clear therefore, that in the absence of a substituent at the C(2) position, the sulfonyl 
chloride was able to attack the secondary alcohol. 
	
OH 	0 	 OH 
Ar QEt 	
p 	
Ar 	 OH 
NBn2 	 NBn2 









Reagents: (a) LiAJH 4, THF (95%); (b) TsCI, DMAP, CH 2Cl2 (-'84%). 
Scheme 36 
In order to counteract this problem the amount of sulfonyl chloride in the 
reaction mixture was reduced from 3 to 1 equivalents, and the more sterically 
demanding triisopropylbenzene sulfonyl chloride (TIBSCL) was employed. It was 
hoped that the combined steric bulk of this reagent with the NN-dibenzyl group 
might restrict the reactivity of the sulfonyl chloride to the primary alcohol. 
This was found to be the case with TIBSC1 and diol 97 reacting to give a 
single pyrrolidinium salt. The salt produced was then converted to its chloride salt 
108 using Dowex resin pretreated with 1% HCl (Scheme 37). 
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97 	 108 
Reagents: (a) (I) TIBSCI, DMAP, CH 20 2 ; ( ii) Dowex Cl- (85%). 
Scheme 37 
In an attempt to obtain the deacetyl derivative and confirm its 
stereochemistry, the dibenzyl salt was hydrogenated in the presence of Peariman's 
catalyst to give the deacetyl derivative 109 as its hydrochloride salt. The salt was 
then treated with Dowex resin (OH) to give the C(4)-H deacetyl derivative 85 as its 
free base in excellent yield (Scheme 38). 
Bn 	Bn 
NC CP 	 H 	
H 
Ar ) a 	Ar ) 	b 	Ar ) 
HO 	 HO 	 HO 
108 	 109 	 85 
Reagents: (a) H 2, 20% Pd(OH) 21C, CH 1 OH (95%) (b) Dowex 0H (100%). 
Scheme 38 
In order to confirm the relative stereochemistry of the C(4)-H derivative, a 
crystal of its hydrochloride salt was grown and submitted for X-ray analysis. 
Unfortunately, the crystal failed to give an adequate diffraction pattern, and hence its 
stereochemistry could not be obtained. 
It was proposed that the hexaflurophosphate salt of the C(4)-H derivative 
might produce a better crystal for X-ray analysis due to its relatively larger size. 
Consequently, the dibenzyl salt was resynthesised and readily converted to its 
hexafluorophosphate salt 110 using Dowex resin treated with 1% HPF 6 (Scheme 39). 
Surprisingly, the product obtained was a white crystalline solid, which readily 
crystallised from methanol, to provide a suitable crystal for X-ray analysis (Figure 
28). 
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OH 





a 	Ar ' 7 
HO 
110 
Reagents: (a) (i) TIBSCI, DMAP, CH 2C1 2 ; ( ii) Dowex PF6 (70%). 
Scheme 39 
Figure 28 : X-Ray Crystal Structure of 110 
The resulting X-ray crystal structure confirms that the stereochemistry, 
tentatively assigned after the reduction of the 0-keto ester, was in fact correct. The 
crystal structure also shows 110 to be a dibenzyl pyrrolidinium salt and therefore 
suggests that salts 48 and 92, produced during the synthesis of anisomycin and its 
methyl derivative, are also likely to be dibenzyl pyrrolidinium salts. 
In an attempt to complete the synthesis of the C(4)-H derivative, the dibenzyl 
chloride salt 108 was hydrogenated in the presence of 5% PdIC and potassium 
carbonate to give the mono protected amine 96. The secondary alcohol was then 
acetylated using acetic anhydride and the nitrogen debenzylated in the presence of 
1 M HC1 to give the C(4)-H derivative as its hydrochloride salt in quantitative yield 
(Scheme 40). 
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Ar ) 	a 	Ar 	 b 	Ar " ) 
AcO 






Reagents: (a) H 2, 5% Pd/C, K2CO3  (80%); (b) Ac 20, NEt3 , CH20 2 (87%); (c) H 2 ,20% Pd(OH) 2/C, 
I M HCl/Et,O, CH 3 0H (100%). 
Scheme 40 
3.3 Biological Evaluation of Anisomycin and its Derivatives 
Anisomycin and its synthetic derivatives were tested in vitro against almond 
3-glucosidase, yeast a-glucosidase, E. coli -galactosidase and fungal a-
arabinofuranosidase for glycosidase inhibition but were found to be inactive in all 
cases. 108 
3.3.1 A Surface Activity Relationship (SAR) Study 
A structure activity relationship study was carried out on the C(4)-H and 
C(4)-Me derivatives by testing them for activity against the p38 and JNK kinase 
signalling pathways. 0 This was achieved by stimulating RAW macrophages at 'sub-
inhibitory' concentrations (30 pmol/m1) with the analogues and assessing their 
activation, using immunoblot assays, against phosphorylated c-Jun and MAPKAP-
K2 (Figure 29 & 30). 
° The SAR study was conducted in Professor Cohen's laboratories at the University of Dundee. 
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- 	 Sigma 	E349 	E350 	E351 
— 	 j Ser3 
— — — — — — c-Jun 
E353 	E355 	E359 	E360 	E361 
Se183 
— — -- — — — — --1 c-Jun 
F20 	143798 	14377 	14378 	14380 
am an - Ser63 
-- — — — — — — — — c-Jun 
Figure 29 : Effects of Anisomycin 
and its Derivatives on the Ser-63 
Phosphorylation of c-Jun in 
RAW Macrophages 
- 	 Sigma 	E349 	E350 	E351 
MAPKAP-K2 I 	- 	 — 	 - - 
E353 	E358 	E359 	E360 	E361 
I — 	 ITh134 
MAPKAP-K2 H as am goo — 
F290 	H379B 	H377 	14379 	H380 
40 Tlu-334 
I 	 — — - - 
Figure 30 : Effects of Anisomycin and 
and its Derivatives on the Thr-334 
Phosphorylation of MAPKAP-K2 
in RAW Macrophages 
Compound R' R2 R3 
E349 (96) Bn OH H 
E350 (111) Bn OAc H 
E351 (112) H OAc H 
E353 (85) H OH H 
E358 (88) Bn OH Me 
E359 (93) Bn OAc Me 
E360 (94) H OAc Me 
E361 (83) H OH Me 
F290 (59) H OCOEt OH 
H379B (14) H OH OH 
H377 (56) Bn OH OBn 
H378 (57) Bn OAc OBn 
H380 (23) H OAc OH 
MeO 3 
Figure 31: An SAR Study of Anisomycin on the JNK and p38 Kinase 
Signalling Pathways 
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The structure activity relationship study shows that although switching the 
C(4)-hydroxyl group for a methyl group produces a noticeable decrease in 
anisomycin's activity, the complete removal of the hydroxyl group has no significant 
effect (Figure 31). These results therefore suggest that the active site of the enzyme 
is tolerant to changes to the substituent at the C(4) position and are in agreement with 
previous findings by Jager. ' 4 
The study also shows that the presence of an acetate or propionate ester group 
at the C(3)-O position is essential for activity. Removal of this ester reduces 
anisomycin's activity considerably, and renders the C(4)-Me and C(4)-H analogues 
82 and 84 inactive. This lack of activity associated with the lipophilic analogues 
suggests that deacetylanisomycin's low activity is not a result of its high polarity and 
implies that deacetylanisomycin is unlikely to be the active form of the drug. 





Me-substitution less active 
MeO  
Ac 	OH  
Deacetylation not tolerated 
except for parent structure 
Figure 32 : A Summary of The SAR Study 
A comparison of Figure 32 with Figure 23 highlights striking similarities 
between our study and previous SAR studies. In agreement with our study, other 
studies have also found the removal of the C(3)-O ester functionality to be 
detrimental to anisomycin's biological activity. Similarly, other studies have also 
found that protection of the secondary amine is not tolerated by the active site of the 
enzyme, but changes to the substituent at the C(4) position are. 45 
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These findings therefore suggest that the active site responsible for the 
activation of the p38/JNK kinase signalling pathway might be the same as that 
responsible for protein synthesis inhibition and anti-tumour activity. Shifrin 84 has 
suggested that anisomycin might activate the JNK pathway via a ribotoxic stress 
response rather than activating the kinase pathway directly. 
It is hoped that when our anisomycin analogues are tested for protein 
synthesis inhibition it will allow us to determine whether this is the case. The study 
will not only enable us to investigate Shifiin's theory but also allow us to determine 
whether any of our analogues have the ability to activate the p38/JNK pathway at 
high concentrations without causing protein synthesis inhibition. 
3.3.2 Biological Evaluation of Anisomycin Using a Chemical Genetics Approach 
Classical model organism genetics consists of both forward and reverse 
genetic approaches. In the forward genetic approach the following methods are used 
to identify genes that regulate a biological process of interest. 
• Random mutagenesis of cells or organisms. 
Phenotype-based screening of the cells and organisms. 
• Gene identification by mapping of the selected mutations. 
In contrast, the reverse genetic approach assigns a biological function to a 
gene of interest, by employing the following methods: 
• The selection of a gene of interest. 
• The creation of an organism or cell with mutated version of this gene. 
• A broad search for phenotypic differences between the wild-type and mutant 
organisms or cells. 
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Although both these approaches are extremely useful for biologists, they have 
their limitations. Firstly, it is difficult to perform forward analyses in mammalian 
systems because of the large size of mammalian genomes, their diploid nature and 
the slow rate of mammalian reproduction. Secondly, genetic mutations, particularly 
in mammals, cannot easily be turned on and off. 
These limitations have led to the development of an alternative approach, 
known as the chemical genetic approach. 109 In this approach small organic molecules 
are used, to bind to and alter the function of protein targets. This then either enhances 
or inhibits the function of the protein.' '° 
This approach has the following advantages: 
. The mutations produced can readily be turned on or off by simply adding or 
removing the compounds at will. 
Depending on whether the substrate activates or inhibits the function of their 
target proteins, they can either act like gain-of-function, or loss-of-function 
mutations. 
Using this strategy it is possible to screen a vast number of compounds to 
identify new reagents that act like conditional mutations. 
. These small organic molecules can be used to study the mechanistic basis of 
the phenotype in question, by identifying the protein targets of the reagent. 
It was decided to screen our anisomycin analogues against the development 
of Xenopus embryos using the chemical genetic approach3 This decision was based 
on the fact that a functional role for activation of the iNK pathway has been 
determined in dorsal closure, an essential morphogenic process that occurs mid-
embryogenesis in Drosophila. 111 It was anticipated that the iNK signalling pathway 
The anisomycin analogues were screened against the development of Xenopus embryos in Professor 
Field's laboratories at the University of East Anglia. 
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might play a similar role in the growth of Xenopus embryos. We were therefore 
optimistic that our analogues might bind to, and alter the function of a protein target 
during embryogenesis, to produce some interesting phenotypes. 
Preliminary results have found that analogue 56 gives rise to a new and 
previously unreported phenotype, (Figure 34). However, all the other analogues 
have been found to be either inactive or toxic towards the Xenopus embryos at the 
concentrations used in the initial screens. A comparison of the phenotype with the 
control shows that the embryos produced have flattened heads and distended bellies. 
Interestingly, the SAR study shows that 56 only weakly activates the JNK 
kinase signalling pathway and does not activate the p38 pathway. In contrast to this, 
anisomycin has been found to strongly activate both the p38 and JNK pathways but 
to be highly toxic to the Xenopus embryos. This therefore suggests that the selective 
activation of the JNK pathway might be the cause of this phenotype. A more likely 
explanation though, is that at the concentrations used in these assays anisomycin, 
rather than activating the JNKJp38 pathways, instead inhibited protein synthesis in 
the Xenopus embryos causing them to die. It is therefore hoped that a full evaluation 
of these compounds via dose-dependent assays will provide more insight into the 
mechanisms taking place. 
This result suggests that the iNK kinase signalling pathway may contribute to 
the regulation of multiple biological processes during Xenopus embryogenesis. It is 
hoped that further studies will enable us to identify the protein target of 56. 
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I] 
Figure 33: Control Xenopus Embryos 
IM 
Figure 34 : Phenotype Xenopus Embryos 
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3.4 Summary of Chapter 3 
We have successfully synthesised both the C(4)-Me and C(4)-H derivatives 
of anisomycin in excellent yield. Assessment of the structure activity relationship of 
this range of analogues on the p38 and JNK kinase signalling pathways indicated that 
acylation at C(3)-O was vital for activity. It was also found that a number of 
functional groups may be tolerated at the C(4) position without a significant loss of 
activity being observed. Finally, using a chemical genetics approach, a synthetic 
precursor to anisomycin produced a new, previously unreported, phenotype in 
developing Xenopus embryos. 
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Chapter 4: The Glycolate Aldol Reaction 
Optically active 1,2-diol derivatives are useful chiral building blocks, and the 
development of efficient methods for their preparation is strongly desired. For this 
reason, interest in the glycolate aldol reaction has increased over the last 15 years. 
The reaction produces a 1 ,2-diol by reacting the enolate of an ct-hydroxy ketone, 









Reagents: (a) (i) Bu 2 BOTf, NEt3 , CH2Cl2 ; (ii) PhCH=CHCHO. 
Scheme 41112(d) 
There are many examples in the literature where syn or anti aldol products 
have been obtained from the boron enolate of Evans' oxazolidinone-based 
glycolate' 12,97(b)  (Scheme 41). However, problems with anti stereoselection often 
arise because the E-enolate geometry required for anti aldol formation is not 
favoured by this or many of the other well known auxiliaries. Consequently in a bid 
to solve this problem, Andrus recently developed the homochiral diphenyloxapyrone 












Reagents (a) (1) NEt 3, c-Hex2 BOTf, CH2Cl2; (ii) Propanal. (b) Me 30BF4 , H 2, Pd/C. 
Scheme 42 
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In contrast to the stoichiometric approaches, catalytic glycolate aldol 
reactions have been very limited with only a few cases having been reported. Perhaps 
one of the best examples is that of Kobayashi who has used chiral tin Lewis acids to 
activate the silyl enol ether of a-alkoxy esters to produce either syn or anti diols with 
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Reagents: (a) Sn(OT0 2, Bu 2 Sn(OAc) 2, CH3CHCHCHO, CH 2Cl2 . 
Scheme 43 
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Recently, Trost reported the development of a dinuclear Zinc catalyst 126 
(Scheme 44) • 1 15 The effectiveness of this catalyst with a-hydroxyketones permitted 
the use of nearly stoichiometric amounts of both coupling partners in the aldol 
reaction. Consequently, high yields and excellent stereoselectivi ties were observed 
(dr97 :3). 
eH+H a)y r ü 
123 	 124 	 125 
	
Ph 	
01 Et /O 	Ph 
Ph h 
Zn Zn 
\ 	N 	0 	N 
I I 
126 
Reagents: (a) THF, 4 A MS. 
Scheme 44 
The osmium-catalyzed asymmetric dihydroxylation reaction provides an 
alternative approach to I ,2-diol formation. However, unlike the aldol reaction, this 
approach does not combine the creation of both stereocentres with carbon-carbon 
bond formation. Similarly, although this approach produces syn diols from E olefins, 
its application to Z alkenes is severely limited giving predominantly anti diols)' 6 
Therefore, the glycolate aldol reaction has become an invaluable tool for the 
synthetic organic chemist. 
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4.1 The Evans' Auxiliary 
The Evans' auxiliary is renowned for its use in the aldol reaction. Since its 
discovery, its use has been linked with high yields and excellent stereoselectivities. 
Consequently, many research groups have opted to use this auxiliary in an attempt to 
increase the stereoselectivity of their glycolate aldol reactions. 112 
Kuwano recently employed the glycolate aldol reaction in his synthesis of a 
key intermediate required for the total synthesis of (2R,3R)- 1 ,4-Benzodioxane-7-
carbaldehyde.' 17 He, like others, employed the Evans' auxiliary to impart good levels 
of stereoselectivity, and obtained aldol adduct 127 in high yield (99%) and with 
excellent diastereomeric selectivity (>98%) (Scheme 45). 
0 	o 	 0 	0 	OH 






'Bn 	 Bn 
32 127 
Reagents: (a) (i) Bu 2BOTf, NEt3 , CH2Cl 2 ; (ii) 3 ,4-methylenedioxybenzaldehyde. 
Scheme 45 
Holmes also utilised the glycolate aldol reaction during his investigation into 
the Claisen rearrangement of selenoxides. 97 He too used the Evans' auxiliary to 
acquire good levels of stereoselectivity, and obtained aldol adduct 128 in 64% yield 
and with >95% diastereomeric excess (Scheme 46). 
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The high stereosel ecti vi ties associated with the Evans' auxiliary are the result 
of a combination of two steric interactions (Figure 35). Firstly, the unfavourable 
interaction of the E enolate with the benzyl group on the auxiliary ensures that only 
the Z enolate is formed. This therefore ensures that only the svn aldol adduct is 
obtained when the aldol reaction proceeds via a closed 6-membered ring, 
Zimmerman-Traxler transition state.' 18,112(j) 
Figure 35 : Z vs E Enolate Formation Using the Evans' Auxiliary 
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As well as ensuring the formation of a syn aldol adduct, the Evans' auxiliary 
also determines its absolute stereochemistry. The benzyl group on the auxiliary 
controls the facial selectivity of the enolate, thereby only allowing an aldehyde to 
attack at a specific face. 
TS 3 
Figure 36: The Aldol Transition State 
The aldol reaction proceeds via a Zimmerman-Traxier transition state' 19 in 
which the dipole of the enolate and the auxiliary are opposed (Figure 36). When an 
aldehyde attacks the enolate 129, only attack on the C si face is favoured, since an 
attack on the Ca re face forces the benzyl group of the auxiliary over the transition 
state, and results in unacceptable steric crowding. 
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4.2 a-Chiral Aldehydes 
An alternative approach to increase the level of stereocontrol in the glycolate 
aldol reaction is to use an ct-chiral aldehyde. If a chiral aldehyde can impart good 
levels of facial selectivity, and control over the enolate geometry can still be 
maintained, then a useful asymmetric aldol reaction will be produced. 
Aldol reactions employing a-chiral aldehydes and achiral enolates again 
proceed via the Zimmerman-Traxler transition state. Here aldehyde 131 can attack 
the Z-enolate 132 on either face, thereby producing two possible transition states 
(Figure 37). 
In the first of the two transition states, significant steric interactions exist 
between the methyl groups on the aldehyde and the enolate (TS 4). Therefore, if the 
steric requirements of methyl group are smaller than that of the R' group, the 'anti 














TS 5 (Anti Felkin' Transition State) 
Figure 37 : Transition State Model for (Z)-Enolates with a-Chiral Aldehydes 
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This suggests that an increase in the steric requirements of R' relative to Me 
will increase the diastereofacial selectivity of the aldol reaction. 120 Consequently, 
reactions employing NN-dibenzylamino aldehydes derived from amino acids such as 
glycine should display good levels of facial selectivity. However, by the same 
rational, the serine derived aldehyde 33, may suffer from poor facial selectivity due 
to the small difference in size between its a substituents. 
There are surprisingly no examples in the literature of aldol reactions 
employing achiral glycolate enolates with a-chiral aldehydes. However, during the 
synthesis of DAB-1, the serine-derived aldehyde 33 was reacted with the achiral 
methyl ester 134, to give aldol adduct 135 in high yield (75%) and excellent 
diastereoselectivity (>98%) (Scheme 47)•91 
HOMe 
a 
OBn 	 NBn 2 OBn 	 NBn2 
134 	 135 	 33 
Reagents: (a) (I) Bu 2BOTf, 'Pr2NEt, Et20; (ii) 33 (75%). 
Scheme 47 
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4.3 Double Asymmetric Induction 
When a chiral aldehyde and chiral auxiliary are both employed in an aldol 
reaction, the two components can either work together to produce the same 
stereoisomer, or against each other to produce different stereoisomers. 
When the two chiral components work together, an aldol adduct is produced 
with increased stereoselectivity, and the reaction is termed a 'matched' aldol. When 
the two chiral components compete against each other, it is the auxiliary that usually 
wins. However, in overturning the stereoinductive capability of the aldehyde, the 
resulting stereoselectivity observed for the reaction is often less than that for the 
'matched' case. Consequently, the reaction is termed a 'mismatched' aldol. 
In an investigation into the effects of double asymmetric induction, 
Masamune subjected aldehyde 145 to a series of 'matched' and 'mismatched' aldol 
reactions (Scheme 48).121 
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When aldehyde 145 was reacted with achiral enolate 136, two aldol products 
137 and 138 were obtained in a ratio of 1.75 : I. This low diastereomeric ratio 
implied that aldehyde 145 only exerted a modest level of stereocontrol in the aldol 
reaction. 
When the same aldehyde was reacted with enolate 139, the two chiral 
components worked together to produce the same diastereomer 140 with an increase 
in diastereoselectivity. However, when the aldehyde was reacted with enolate 142, 
the auxiliary completely overturned the stereoinductive capability of 145 to produce 
the other diastereomer 144 with a diastereomeric ratio of 400:1. Consequently, this 
reaction was labelled as the 'mismatched' case, and the previous reaction was 
labelled as the 'matched' aldol. 
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4.4 Double Asymmetric Induction in the Glycolate Aldol 
Reaction 
The successful investigation by Masamune of double asymmetric induction in 
the propionate aldol reaction, inspired us to take this a step further and investigate the 
same concept in the boron mediated glycolate aldol reaction. We wondered if the 
presence of an additional oxygen atom in the boron enolate would in any way affect 
the stereoselectivity of the resulting aldol reaction. 
4.4.1 Investigation of Double Asymmetric Induction Using the Serine Derived 
Aldehyde 
Previous work within the Hulme group focused on the serine derived 
aldehyde 33. Its reaction with the achiral methyl ester 134 displayed high levels of 
stereoselectivity and gave only a single diastereomer 135 in 75% yield (Scheme 47). 
HOMe d 	TBDPSO OMeTBDPSO H 
OBn 	 NBn 2 OBn 	 NBn2 
134 	 135 	 33 
Reagents: (a) (i) Bu 2BOTf, 'Pr2NEt, Et20; (ii) 33 (75%). 
Scheme 47 
The reaction of aldehyde 33 with ent-32 also produced a single diastereomer 
containing the same stereochemistry as 135 (Scheme 49). The absence of any other 
diastereomers suggested that ent-32 and 33 were both working together to produce 
the same diastereomer 34. Consequently, the reaction was assigned as the 'matched' 
aldol. 
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Reagents: (a) (i) Bu 2 BOTf, NEt3 , CH2Cl 2 ; (ii) 33 (82%). 
Scheme 49 
Due to the high levels of stereoinduction displayed by the serine derived 
aldehyde, it was anticipated that the remaining aldol reaction might display relatively 
poor levels of diastereoselectivity. This proved to be the case, with the enolate of 32 
failing to completely overturn the stereoinductive capability of aldehyde 33. Thus, 
aldol adducts 147 and 146 were produced in a 9:1 ratio with a 79% yield (Scheme 
50), and the reaction was consequently assigned to be the 'mismatched' aldol. 
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4.4.2 Investigation of Double Asymmetric Induction Using the Tyrosine Derived 
Aldehyde 
With these results in good agreement with those of Masamune, we wished to 
determine whether other NN-dibenzylamino aldehydes derived from amino acids, 
displayed the same level of stereocontrol in the glycolate aldol reaction. 
Consequently, the tyrosine derived aldehyde 31 was subjected to the same set of 
reactions. 
In Chapter 2 we saw that the reaction between aldehyde 31 and glycolate 
equivalent 32 produced aldol adduct 30 with high stereoselectivity (>95% ds) and 
good yield (Scheme 16). The aldol adduct was then used in the synthesis of 
anisomycin and this enabled its relative stereochemistry to be confirmed. 
NO 	a 	Ar 	 N 
OBn 	 NBn 2 OBn ij 
Bn 	 Bn 
32 30 
Reagents: (a) (i) Bu 2BOTf, NEt3 , CH,C1,; (ii) 31, (75%). 
Scheme 16 
Although this reaction produced a single product, the analogous reaction 
using the serine derived aldehyde gave a mixture of two diastereomers (Scheme 50). 
This therefore implied that the stereoinductive capability of the serine derived 
aldehyde, in working against the directing effects of the Evans' oxazolidione, was 
greater than that of 31. It was thus anticipated that the reaction of 31 with the achiral 
methyl ester 134 would result in relatively low selectivity being observed. 
95 
Results and Discussion 3 
OH 	0 
32 Ar 	 OMe 	 @418 ppm 
NBn2 	OBn 
148 
0 	 OH 	0 
 a 	 J23 7.2 Hz 
HOMe 	 Ar OMe 2 @ 35  ppm 
OBn 	 iBn2 	ÔBn 
134 	 149 
OH 	0 
Ar 0Me 3.70 ppm 
NBn2 OBn 
150 
Reagents: (a) (I) Bu 2BOTf, 'Pr2NEt,CH2Cl2 ; (H)31 (71%). 
Scheme 51 
The reaction of the achiral methyl ester 134 with aldehyde 31, gave a mixture 
of three aldol adducts which -were tentatively assigned the structures shown (Scheme 
51). The fact that three aldol adducts had been obtained, indicated that at least one of 
them had to be an anti aldol product. The presence of a characteristic anti aldol peak 
(ö = 3.95 (d, J23 = 7.2 Hz)) in the 1 H NMR of 149 suggested that this compound was 
the likely candidate. In a bid to determine the structure of all three aldol adducts, 
several chemical transformations were carried out. 
The minor diastereomer 150 was reduced with lithium aluminium hydride, to 
give a diol which was identical in all respects (NMR, JR. {a] 0, Rf) to diol 29, 
produced during the synthesis of anisomycin (Scheme 52). It was therefore 
concluded that the minor diastereomer had been assigned the correct structure. 
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The aldol product suspected of having anti stereochemistry, was also reduced 
using lithium aluminium hydride. The resulting diol 151 was then fully deprotected 
in the presence of I M hydrochloric acid to give the amine as its hydrochloride salt 
(Scheme 53). An X-ray crystal structure of the salt confirmed that 152 was indeed 
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NH 2 	OH 
• HCI 
152 
Reagents: (a) LIA1H 4 , THF (78%); (b) H2, 20% Pd(OH)2/C, I M HCl/Et,O (100-,'0). 
Scheme 53 
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Having determined 148 to be a syn aldol adduct using 'H NMR (6 = 4.18 (s, 
< 1 Hz), and having correctly assigned the other syn aldol adduct, we were 
confident that the major diastereomer had been assigned the correct structure. 
However, as a final precaution, we set about confirming its relative stereochemistry. 
Initial efforts focused on a similar protocol to that employed for the anti 
diastereomer. However, deprotection of diol 153 failed to give a crystalline salt. 
Consequently, our attentions turned towards converting the diol to its acetonide. This 
was achieved, with limited success, by treating diol 153 with acetone in the presence 













Reagents: (a) LiAIH4 , THF (67%); (b) (Cl-1 3)2CO 3  12 (30%). 
Scheme 54 
Although a range of conditions are appropriate for converting a diol to its 
acetonide,' 23 our choice of reagents was based upon previous success within the 
Hulme group. However, these conditions failed to produce the acetonide in high 
yield, and unfortunately, due to time constraints, we were unable to repeat this 
experiment using different conditions. 
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The small coupling constants observed in the 'H NMR of 154, suggested that 
the interactions of H*  with its adjacent protons were all either axial-equatorial or 
equatorial-equatorial. Using this information, the acetonide was assigned the 
structure shown in Figure 38 and this therefore again confirmed that the assigned 






Figure 38: 'H NMR Coupling Between Adjacent Protons in 154 
With the structure of all three aldol adducts having been confirmed, it was 
clear that the achiral glycolate aldol reaction had not only produced the two syn aldol 
adducts as anticipated, but it had also produced a significant amount of an anti aldol 
product. 
The two syn aldol products were produced in a 4:1 ratio, which was in 
marked contrast to the analogous reaction using the serine derived aldehyde, where 
only a single diastereomer was observed. This therefore allowed us to conclude that 
stereoinductive capability of aldehyde 31 was significantly less than that of its serine 
counterpart. 
In order to complete our set of experiments, aldehyde 31 was reacted with 
imide ent-32 to give two products, which were tentatively assigned the structures 
shown (Scheme 55). 
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Reagents: (a) (I) Bu 2BOTf, NEt3 , CH 2Cl2 ; ( ii) 31. 
Scheme 55 
Despite various efforts using different chromatographic techniques, the major 
diastereomer 155 could not be isolated from recovered unreacted acylated auxiliary 
ent-32. Therefore, in an attempt to determine the relative stereochemistry of 155, the 
mixture was reduced, and a diol was isolated cleanly. The diol obtained was identical 
in all respects (NMR, IR, [a]D, Ri-) to diol 153, and was therefore confirmed to have 
the tentatively assigned structure (Scheme 56). 
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Reagents: (a) LiBH 4 , MeOH, THE 
Scheme 56 
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The minor diastereomer was reduced to give a diol using the same procedure 
as above. Again, full analysis (NMR, JR. [cLilD, Rf) revealed that the diol had the same 
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Scheme 57 
The fact that this aldol reaction had proceeded to give a single syn 
diastereomer, meant that it was in good agreement with the analogous reaction using 
the serine derived aldehyde 33. Therefore, with all three aldol reactions having been 
successfully carried out, it was concluded that the aldol reaction used in the synthesis 
of anisomycin was in fact the 'mismatched' case, and the aldol reaction described 
above was therefore the 'matched' case. 
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4.5 Investigation Into anti Aldol Product Formation 
The generation of a single anti diastereomer in both the 'matched' and achiral 
aldol reactions was thought unlikely to be a consequence of E enolate formation for 
reasons discussed earlier. As an alternative explanation for this anti aldol formation, 
it was envisaged that aldol adducts 148 and 155 may be undergoing epimerisation 













Reagents: (a) Bu 2BOTf, NEt3 , CH2Cl2 . 
Scheme 58 
To ascertain whether this was the case, aldol adduct 148 was re-subjected to 
the reaction conditions. However, after the usual work up, 'H NMR revealed that no 
appreciable epimerisation had occurred, and this therefore suggested that anti aldol 
formation was occurring via a different mechanism. 
It was thought possible that the anti aldol adduct might have been formed via 
an open transition state. 124,118(e)  When excess dibutylboron triflate is present in the 
aldol reaction it can itself form an activated aldehyde complex. This prevents the 
formation of the Zimmerman-Traxier transition state and instead produces an open 
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Figure 39 The Aldol Open Transition State 
Although the facial selectivity of the auxiliary in the open transition state is 
the same as that observed in alkylation reactions, the stereoisorner produced also 
depends on the size of the Lewis acid employed (Figure 39). 
If the Lewis acid is relatively small, the aldol reaction proceeds via TS 6 and 
results in the formation of  - the 'non-Evans' syn aldol adduct 159. On switching to a 
larger Lewis acid, steric interactions between the acid and the enolate increase, 
forcing the reaction to proceed via TS 7. This results in the formation of the anti 
aldol adduct 161 and could therefore account for the formation of aldol adduct 156 in 
our glycolate aldol reactions. 
Reports in the literature suggest that the auxiliary's presence is important for 
anti aldol formation to occur via the open transition state.  124a  However contrary to 
this, we found that anti aldol formation occurred irrespective of the auxiliary's 
presence. 
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One possible explanation is that the dibutylboron triflate chelates to both the 
oxygen atoms in the methyl ester 134 to produce enolate 162 (Scheme 59). This 
internal chelation then allows an activated aldehyde complex to attack the enolate in 
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Reagents: (a) Bu 2BOTf, 'Pr2NEt, CH2CI1. 
Scheme 59 
Although this explanation accounts for the formation of the anti aldol adduct 
149, it fails to explain why only a syn aldol product was obtained when the serine 
derived aldehyde 33 was employed in an analogous reaction. 
This may be explained however, by considering the choice of reaction 
solvent. With a Lewis basic solvent, e.g. ether, a strong complex is formed with the 
excess dibutylboron triflate which may prevent it from catalysing the formation of 
anti aldol products. 124a 
This suggests that in the aldol reaction employing the serine derived aldehyde 
33, the use of ether as the solvent is likely to have prevented the formation of anti 
aldol products. Unfortunately, the aldol reaction employing the tyrosine derived 
aldehyde 31 was conducted in CH 2C12 due to the aldehyde's insolubility in ether. It is 
possible therefore, that this switch in solvent from ether to CH 2C12 may have been 
responsible for the formation of the anti aldol product. 
Having conceded that the use of CH 2 C12 was the most likely reason for the 
formation of anti aldol products, efforts began focusing on trying to force the aldol 
reaction to go via the closed transition state. It had been proposed that the use of 
triethylamine, being less hindered, would form a stronger complex with excess 
dibutylboron triflate than with diisopropylethylarnine.124a  It was hoped that the 
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formation of this complex would therefore prevent the Lewis acid from catalysing 
the anti aldol reaction. However, efforts to remove excess dibutylboron triflate by 
adding triethylamine failed to force the reaction to go via the closed transition state. 
Similarly, attempts to see if varying the dibutylboron triflate concentration in the 
reaction mixture would have any effect on the syn:anti ratio also failed. 
It therefore seems likely, with epimerisation ruled out as a possible 
explanation, that the open transition state might be responsible for the formation of 
the anti aldol products. However, many questions still remain unanswered. For 
example, why did the 'matched' aldol reaction produce syn products with one 
aldehyde, but give a mixture of syn/anti products with another? Similarly, why did 
the addition of excess triethylamine or dibutylboron triflate not have any noticeable 
effect on the products of the achiral reaction? Consequently, in a bid to resolve these 
issues, ongoing work is continuing within the Hulme group in the hope of finding a 
suitable explanation for these problems. 
4.6 Summary Of Chapter 4 
The tyrosine derived aldehyde shows that there is a fine balance between 
different elements of stereocontrol in the glycolate aldol reaction of 
N,N-dibenzylamino aldehydes. Some of the possible explanations for the anti aldol 
adduct observed in this reaction have been investigated. 
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Chapter 5 : The Synthesis of a 1-Deoxynojirimycin 
Analogue 
The Hulme group has successfully employed both the 'matched' and 
'mismatched' glycolate aldol reactions in the synthesis of DAB-1 (11), nectrisine 
(163) and anisomycin (10). We have also exploited the aldol reaction in order to 
access the C(4)-Me derivatives and by substituting the Claisen condensation for this 
reaction, we have been able to access the C(4)-H derivatives (Figure 40). Our ability 
to vary these parameters has not only enabled us to synthesise three natural products, 
but it has also allowed us to produce a series of analogues. 
OH 	 OH 	 Ar 	 Ar 
,~ H 	 H 	 H 
HO 	OH 	HO 	Me 	 AcO 	 AcO 	Me 
163 	 86 	 84 	 82 
Figure 40: Iminosugars Synthesised Within the Hulme Group 
Having obtained this versatile and robust route to the five membered 
iminosugars, we were interested in extending our methodology to include the 
synthesis of their six membered counterparts. We hoped that a similar approach 
would enable us to synthesise the azasugars in good yield and also allow us to access 
some of their analogues. 
106 
Results and Discussion 4 
5.1 1-Deoxynojirimycin 
One azasugar, which particularly caught our attention, was 
1 -deoxynojirimycin (DNJ) 164. DNJ was isolated from Streptornyces nojiriensis in 
1967125 and has since shown potential as a chemotherapeutic agent for treating 
diabetes, cancer and viral infections (Figure 41). 126  Of similar interest to us, was the 
fact that its derivatives have been shown to inhibit the development of HIV in 
vitro. 127 It was hoped that if we could produce a synthetic route to the sugar, that had 
the same propensity for producing analogues as our previous syntheses, then this 
would enable us to produce a library of novel analogues with interesting biological 
properties. 
OH 
Compound Activity Biological organism IC50 
(.igIml) R
I R 2 
164 
HIV 
' 2 Moloney murine lukemia 1.2-2.5 H H 
164 Glucosidase 11129 Mung bean microsomes 2-5 H H 
164 Sucrase' 3° Beagle dog small intestine 0.12 H H 
165 Cyclodextrin 131 glycosyl trans ferase 
Bacillus 
stearotherinoph ilus 
>200 Bn H 
166 Maltase 13U Rabbit small intestine 0.46 CF! 3 H 
167 Maltase"' Rabbit small intestine 170 CH 3 a-D-glu 
Figure 41: 1-Deoxynojirimycin and its Biological Properties 
5.2 Previous Syntheses of 1-Deoxynojirimycin 
With the discovery over the last 20 years that DNJ possesses various different 
biological properties, synthetic interest in the natural product has increased. Over 15 
syntheses of the natural product have been reported. Many of these syntheses rely on 
the chiral pool, however a few asymmetric syntheses have also been reported 
(Figure 42). 133 
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Tetra - O- 	formation 
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OxidatioWreductic 
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ÔBn 	Route 
28% in 8 steps 
OH 
PMBO 
Amination followed  
by cycl isat ion 	I Route 233() 	 Dihdroxylation, reduction 


















hydrolysis, 	 Route 3133(0) 




13% yield in 8 steps 
Dihydroxylation then 
hydrogenation 












Route 4133(b) 	 cyclisation 
20% in 8 steps 	 deprotection 
Amination, reduction, 
then epoxide formation 	
BnO " 	 ?O CF3 
B nO 
CH 2 NBn 
OBn 
Figure 42 : Previous Syntheses of DNJ 













Reagents: (a) 0s0 4, NMO; (b) Pd(OH) 2/H2, 10% HCI (aq.). 
OH 
171 
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Syntheses of DNJ are generally short and direct, and often require less than 
10 synthetic steps. However, as a consequence, the efficiency of these routes is often 
poor and overall yields less than 15% are frequently reported. 
One reason for these low yields is due to the employment of poor 
stereoselective reactions. This is particularly highlighted in route 3 where the 
asymmetric dihydroxylation reaction gives the diols 169 and 170 in a 3:1 ratio 
(Scheme 60). These two diastereomers obtained were then found to be unstable to 
silica gel and therefore were subjected to hydrogenation conditions crude. This 
resulted in a difficult chromatographic purification (MeOU:CH 2C12 :TEA, 75:24:1) 
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Vasella and co-workers chose to synthesise DNJ from glucose (route 1). 
However in doing so, they had to ensure that they maintained the glucose 
stereochemistry at C( 1). Consequently, prior to the SN2 attack by sodium azide, the 
stereochemistry at C(1) had to be inverted. This was achieved using an 
oxidation/reduction protocol, but this therefore added a further two steps onto their 
synthesis. 
The displacement of the tosylate group using sodium azide also proved 
problematic. The reaction not only gave the azide 173 but also produced 2,5-
anhydro-D-glucononitrile 174 in 10% yield (Scheme 61). Therefore, the formation of 








"OBn 	 BnO 




Reagents: (a) NaN 3 , DMSO. 
Scheme 61 
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DNJ has also been synthesised in 8 steps from D-glucose and D-mannitol. In 
both these syntheses the piperidine ring was formed by an amine attacking an 
epoxide in order to produce the primary alcohol at the 1-position. However, this 
cyclisation also gave a seven membered ring in considerable yield, and this therefore 


















Both these syntheses rely heavily on the built-in chirality and functionality of 
their starting materials. This-therefore severely limits their potential for producing a 
wide range of analogues for biological testing. Similarly, biological systems are 
extremely sensitive towards tin. Therefore the use of tin chloride in route 5 to 
selectively protect the 1,2 and 5,6-diols in D-mannitol will cast into doubt the validity 
of biological results obtained using DNJ, or any of its analogues synthesised by this 
route (Scheme 63). 
OH 	CH20H 





Reagents: (a) Me 2C(OMe) 2, SnCl2, (CH-,OMe) 2 . 
Scheme 63 
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In conclusion, previous syntheses of DNJ have tended to be low yielding and 
have invariably suffered from poor stereoselective reactions. Their focus for being 
short and direct has led to many of these syntheses being rigid, and therefore 
incapable of offering the flexibility required to produce a large range of analogues. 
Therefore, bearing all of this in mind, we set about devising our own retrosynthetic 
analysis. 
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5.3 Retrosynthesis of I -Deoxynojirimycin 
Our retrosynthetic analysis of DNJ is shown in Figure 43. The retrosynthesis 
is based around aldol adduct 34, whose synthesis within the Hulme group has already 











TBSO 	0 	 TBSO 	0 
1L.] _Bromination TBDPSO 	 < 	TBDPSO j' 




TBSO 	0 	 OH 	0 
Weinreb amide 
TBDPSO 	 N 
1-1 
We formation f TBDPSO 	 Aux 
Protection 
NBn2 	OBn 	 NBn 2 OBn 
183 34 
Figure 43 : The Retrosynthesis of 1-Deoxynojirimycin. 
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Previous work within the group suggested that the Weinreb amide formation 
from 34 and subsequent protection of the secondary alcohol would proceed smoothly 
to give 183. From here it was envisaged that the reaction of 183 with 
(trimethylsilyl)methyl lithium would give 182 which on treatment with bromine 
would yield the ci-bromo ketone 181. 
Due to the reputation of ci-bromo ketones for being difficult to handle, it was 
decided to cyclise the ring prior to the asymmetric reduction. It was then hoped that 
the resulting piperidine ring would produce enough stereoinduction to enable the 
reduction of 180 to proceed with high stereoselectivity. This would then just leave us 
with a simple deprotection step in order for us to obtain DNJ. 
Since our route to DNJ is based on the same chemistry as that employed in 
the synthesis of our 5-membered iminosugars, we were optimistic that slight 
variations in our synthesis would allow for a similar series of analogues to be 




164 184 	 185 
Figure 44: Synthetic Analogues of DNJ 
Initial efforts focused on the final 7 steps of our synthesis in order to test our 
new methodology. In an effort to make quick progress we decided to synthesise the 
racemic C(4)-I-I derivative 185, since a large quantity of (±)98 remained from a 
previous synthesis within the group (Figure 45). 
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185 	 186 
DebenzYlation 



















Figure 45 : The Retrosynthesis for (2R,3R,5R)-3,5-Dihydroxy-2- 
(4-methoxybenzyl)piperidine 
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5.4 The Synthesis of (2R,3R,5R)-3,5-Dihydroxy-2-
(4-methoxybenzyl)piperidine 
The reduced Claisen product (±)98 (cf chapter 3) was readily converted to its 
Weinreb amide 190 in 97% yield and subsequent treatment with 
tert-butyldimethylsilyltriflate proceeded smoothly to give the protected alcohol 189 
in 84% yield (Scheme 64). 





NBn2 	 NBn 2 	 OMe 
(±) 98 	 (±) 190 
TBSO 	0 
- 	 Ar 	
Me 
NBn 2 	 OMe 
(±) 189 
Reagents: (a) (MeO)N(Me)H.HCI, A!Me 3 , THF (97%); (b) TBSOTf, 2,6-lutidine, CH 2CI, (84%). 
Scheme 64 
Treatment of 189 with (trimethylsilyl)methyl lithium failed to give the 
desired product, and instead gave the methyl ketone 191 (Scheme 65). It was 
therefore proposed that the acetic acid used in the work-up was promoting 
desilylation thus resulting in the formation of the methyl ketone. 
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TBSO 	0 
Me 	p 
Ar N  





Reagents: (a) (i) (CH 1 ) 1 SiCH 2 Li, THF; (ii) 2 M AcOH in THF, pH 7 phosphate buffer (90%). 
Scheme 65 
In an effort to prevent desilylation re-occurring, the use of acetic acid was 
removed from the work-up. This had the desired effect, and allowed us to access the 
trimethylsilylketone 188 in 100% yield (Scheme 66). Recent reports in the 
literature 134  suggested that similar ketones were unstable to silica gel and 
consequently, in view of our own experiences, it was decided to use the ketone crude 
in subsequent steps. 




NBn 2 	 OMe 	 NBn2 	 SiMe3 
(-+)189 	 (±) 188 
Reagents: (a) (i) (CH 3 )3 S1CH 2 Li, THF; (ii) pH 7 phosphate buffer (100%). 
Scheme 66 
The reaction of trimethylsilylketone 188 with bromine failed to give the a-
bromoketone 187, and instead gave a mixture of unidentifiable products. Further 
attempts to obtain the a-bromoketone were not possible due to time constraints. 
However, it is anticipated that future attempts employing N-bromosuccinimide will 
enable us to access the a-bromoketone. 
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5.5 Summary of Chapter 5 
We have begun looking at the synthesis of 1-deoxynojirimycin with a view 
towards producing a series of analogues. Our review of previous syntheses indicated 
that routes starting from natural sugars tended to be short and direct but as a 
consequence, were often low yielding and did not afford the flexibility required to 
produce a varied range of analogues. 
Our synthesis therefore, is based around the glycolate aldol reaction used to 
synthesise anisomycin. It is anticipated that by varying reactions and conditions, in a 




Chapter 6: Experimental 
6.1 General Experimental 
'H nuclear magnetic resonance (NMR) spectra were recorded using an 
internal deuterium lock for the indicated reference at ambient probe temperatures on 
Varian Gemini 200 (200 MHz), Bruker AC250 (250 MHz), Bruker AM360 (360 
MHz) or Varian Inova 600 (600 MHz) Fourier transform instruments. The data is 
presented as follows: chemical shift (in ppm on the ö scale relative to 6 TMs = 0), 
integration, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, in = 
multiplet, br = broad), coupling constant in hertz and the interpretation. ' 3 C NMR 
spectra were recorded using an internal deuterium lock for the indicated reference at 
ambient probe temperatures on Varian Gemini 200 (50.3 MHz), Bruker AC250 (62.9 
MHz) or Bruker AM360 (90.6 MHz) instruments. The data is presented as follows: 
chemical shift (in ppm on the ö scale relative to 8TMS = 0), integration and 
interpretation (Q = quaternary centre). 
Infra-red spectra were recorded on either a Biorad FTS-7, a Perkin Elmer 
Paragon 1000 FT-IR, or a Jasco FT/IR-4 10 instrument using 5 mm sodium chloride 
plates, or KBr discs. The wavelengths of maximum absorbance (Vm) are quoted in 
cm'. 
Fast atom bombardment (FAB) mass specta were performed on a Kratos 
MS50TC mass spectrometer. Electron impact (El) mass spectra were performed on a 
Finnigan 4500 mass spectrometer. The parent ion or relevant fragment are quoted, 
followed by significant fragments and their relative intensities. 
Optical rotations were measured on an AA- 1000 polarimeter or on an Optical 
Activity PoIAAr 20 instrument with a path length of 1.0 dm at the sodium D line 
(589 nm) and are reported as follows: [aID, concentration (c in g/100 cm'), and 
solvent. All optical rotations were measured at a temperature of 23 °C. 
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Mps were determined on a Gallenkamp Electrothermal Melting Point 
apparatus and are uncorrected. 
Elemental analysis was carried out on a Perkin Elmer 2400 Cl-IN Elemental 
analyser. T.l.c. was performed on Merck 60F25 4 (0.25 mm) glass backed silica plates 
and visualised by ultraviolet (UV) light and/or ammonium molybdate stain. Flash 
column chromatography was carried out on Merck Kieselgel 60 (Merck 9385) under 
positive pressure by means of a hand pump. Eluent compositions are quoted as v/v 
ratios. 
Chiral high performance liquid chromatography (HPLC) was carried out on a 
Waters 786 instrument equipped with a Chiracel OD column (internal diameter 4.6 
mm) and a UV detector. A standard flow rate of 0.5 cm 3/min was used. Preparative 
high performance liquid chromatography (HPLC) was carried out on a Gilson 
instrument equipped with a Spherisorb column (internal diameter 25 mm) and a RI 
detector. A standard flow rate of 9 cm 3/min was used. All HPLC samples were 
filtered through 0.45 Am nylon syringe filters prior to analysis. All solvents used for 
HPLC analysis were vacuum filtered and degassed prior to use. 
Reagents were purified by standard means. 135 Dichioromethane (DCM), and 
triethylamine and diisopropylethylamine were distilled from calcium hydride and 
stored over calcium hydride under an argon atmosphere. Tetrahydrofuran (THF) was 
distilled from sodium metal/benzophenone ketyl and stored under an argon 
atmosphere. Acetyl choride, acetic anhydride and propionyl chloride were distilled 
immediately prior to use. All other reagents were used as supplied. 
All experiments were performed in an inert atmosphere of argon under 
anhydrous conditions using oven dried apparatus cooled in a desiccator or flame 
e Ammonium molybdate dip prepared as follows: To water (950 cm) was added concentrated sulfuric 
acid (50 cm) followed by ammonium molybdate (50 g) and ceric sulfate (3 g). The mixture was 
stirred until all solid material had disappeared and a bright yellow solution remained. 
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dried under argon prior to use. Standard techniques for the handling of air-sensitive 
materials were employed. 116 
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Acetyl chloride (2.52 g, 2.30 cm 3 , 33.0 rnmol) was added dropwise to methanol (50 
cm3 ) at 0 °C. The mixture was stirred for ca. 15 min and D-tyrosine (2.00 g, 11.0 
mmol) was then added portionwise to the solution. The resulting solution was heated 
to reflux and held at reflux for 3 hours. Concentration under reduced pressure 
provided hydrochloride salt 37 (2.55 g, 100%) as a solid. Recrystallisation from 
methanol provided an analytical sample; mp 191-192 °C; [a] 9 -13.1 (c 0.73, 
CH30H) [lit.(ent-37), (Acros) mp 193-194 °C, [aID +11.5 (c 2, CH30H)]; Vm 
(KBr)Icni' 3343, 2888, 1745, 1615, 1593; oH (200 MHz; CD 3 0D) 7.07 (2H, d, J8.6, 
ArH), 6.78 (2H, d, J 8.6, ArH), 4.88 (2H, br s, NH2), 4.24 (1 H, t, J 6.6, C211), 3.80 
(3H, s, OMe), 3.19-3.05 (21-f, m, C3HHy + C3HxHy); & (62.9 MHz; CD 3 0D) 168.6 
(1C, Q), 156.4 (1C, Q), 129.6 (2C, CH), 123.7 (1C, Q), 114.9 (2C, CH), 53.5 (1C, 
CH), 51.6 (IC, CH3), 34.6 (1C, CH 2); (Found: C, 51.33; H, 5.90; N, 5.92. Calc. for 
C 10H 13NO3 'HCl: C, 51.84; H, 6.05; N, 6.05%). 
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Boc 	 I 
To a solution of ester hydrochloride 37 (2.59 g, 11.1 mmol) in ethanol (25 cm 3)  was 
added sodium hydrogen carbonate (2.82 g, 33.5 mmol) and di-tert-butoxy carbamate 
(2.42 g, 11.1 mmol). The resulting solution was stirred for 15 hours and then filtered, 
and concentrated under reduced pressure to give 38 (3.25 g, 99%) as a solid, Rf 
[CH2C12 :CH30H (95:5)] 0.50; mp 102-104 °C; [al u -49.3 (c 0.54, CHCI 3 ) [lit.(ent-
38), (Aldrich) mp 100-104 °C, [aI D +51 (c 1, CHC13)]; Vmax (KBr)/cm' 3358, 2983, 
1734, 1687; SH (200 MHz; CDC1 3 ) 6.97 (2H, d, J8.4, Ar!]), 6.72 (2H, d, J8.4, Ar!]), 
5.00 (1H, d, J 8.5, NH), 4.53 (1H, q, J 8.6, C2!]), 3.71 (3H, s, OMe), 2.99-3.02 (2H, 
M, C3ILvHy ± C 3HH), 1.41 (911, s, 'Bu). ö (62.9 MHz; CDC1 3) 172.6 (1C, Q), 
155.3 (2C, Q), 130.1 (2C, CH), 126.9 (IC, Q), 115.4 (2C, CH), 80.2 (1C, Q), 54.5 
(IC, CH), 52.2 (IC, CH3), 37.3 (1C, CH2), 28.1 (3C, CH 3 ); (Found: C, 61.02; H, 
7.12; N, 4.75. CaIc. for C 15 H21 N05: C, 61.02; H, 7.11; N, 4.74%). 
All spectroscopic data was in good agreement with that of the literature. 137 
123 
Experimental 








To a solution of phenol 38 (0.200 g, 0.670 mmol) in DMF (25 cm 3)  was added 
potassium carbonate (0.280 g, 2.03 mmol), and a solution of methyl iodide (0.48 g, 
0.21 cm3 , 3.3 mmol) in DMF (2 cm3). The resulting solution was stirred for 24 hours, 
and then added to ice. The organic phase was separated off, and the aqueous phase 
was extracted with EtOAc (3 x 20 cm3 ). The combined organic extracts were dried 
and concentrated under reduced pressure. The residue was chromatographed on silica 
gel [hexane:EtOAc (7:3)] to give 39 (0.186 g, 97%) as an oil, R f [hexane:EtOAc 
(7:3)] 0.48; [aI D -52.8 (c 1.43, CHC13) [lit.(ent-39), 138 [a]0 +59.2 (c 1.8, CHC13)]; 
(neat)/cm- 1 3433, 3364, 1713, 1745, 1612, 1513; 6n  (200 MHz; CDC1 3) 7.01 
(2H, d, 18.6, ArII), 6.79 (2H, d, 18.6, ArH), 5.03 (1H, d, 18.0, NH), 4.50 (1 H, q, I 
3.0, C211), 3.73 (3H, s, OMe), 3.67 (31-I, s, OMe), 2.89-3.08 (2H, rn, C3HHy + 
C3 HxHy), 1.38 (91-1, s, 'Bu); 8C (62.9 MHz; CDC13) 172.3 (IC, Q), 158.4 (IC, Q), 
154.9 (1C, Q), 130.1 (2C, CH), 127.7 (1C, Q), 113.8 (2C, CH), 79.7 (1C, Q), 55.0 
(1C, CH3), 54.4 (1C, CH), 52.1 (1C, CH3), 37.3 (1C, CH2), 28.1 (3C, CH 3); m/z 
(FAB) 310 ([M + H], 12%), 254 (57), 210 (72), 192 (53), 150 (63), 121 (82); 
HRMS (FAB) (Found: [M + H] +, 310.1654. C1 6H24N05 requires m/z, 310.1654). 
All spectroscopic data was in good agreement with that of the literature. 138 
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To a solution of Boc-protected ester 39 (0.290 g, 0.939 mmol) in CH 2C12 (10 cm 3) 
was added trifluoroacetic acid (1.39 g, 0.930 cm 3 , 12.2 mmol). The solution turned 
pink immediately and was stirred for 2 hours. The reaction was quenched by the 
addition of a saturated solution of sodium carbonate until the solution was rendered 
alkaline as judged by litmus paper. The organic phase was separated, and the 
aqueous phase was extracted with CH 202 (3 x 10 cm3). The combined organic 
extracts were dried and concentrated under reduced pressure to give 36 (0.194 g, 
100%) as an oil, R f [hexane:EtOAc (I:1)] 0.1;[all) -7.76 (c 1.26, CHC1 3) [lit.(ent-
36), [a] D +11 (c 0. 15, CHC1 3)]; Vm (neat)/cm' 3374, 2951, 1735, 1611, 1513; 8 H 
(200 MHz; CDC13) 7.01 (2H, d, 1 8.6, Arlf), 6.75 (2H, d, 1 8.6, ArH), 3.69 (3H, s, 
OMe), 3.62 (3H, s, OMe), 3.62-3.56 (IH, m, C2H), 3.69-3.66 (111, dd, 1 13.6, 5.3, 
C3HxHy), 2.72 (1 H, dd, J 13.6, 7.7, C3HHy), 1.46 (2H, brs, NH2); & (62.9 MHz; 
CDCI3) 175.3 (1C, Q), 158.3 (IC, Q), 130.1, (2C, CH) 128.8 (IC, Q), 113.8 (2C, 
CH), 55.7 (1C, CH), 55.0 (IC, CH3), 51.8 (IC, CH 3), 39.9 (IC, CH2); m/z (FAB) 210 
([M + H]+, 100%), 193 (29), 150 (56), 121 (58); HRMS (FAB) (Found: [M + H] + , 
210.1130. C 11 H 1 6NO3 requires m/z, 210.1130). 
All spectroscopic data was in good agreement with that of the literature. 94,  
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To a solution of amino ester 36 (6.55 g, 31.3 rnmol) in acetonitrile (40 cm 3 ) was 
added potassium carbonate (21.6 g, 157 mmol) followed by benzyl bromide (21.4 g, 
14.9 cm3 , 125 mmol). The mixture was stirred for 48 hours. Water (30 cm 3) was 
added and the aqueous phase was extracted with EtOAc (3 x 75 cm3). The combined 
organic extracts were dried, and concentrated under reduced pressure. The residue 
was chromatographed on silica gel [hexane:EtOAc (4 : 1)] to give 41(11.59 g, 95%) 
as an oil, Rf [hexane:EtOAc (7:3)] 0.66; [a]D +73.25 (c 1.12, CHCI3); Vmax 
(neat)/cm 3028, 2834, 1731, 1612, 1581, 1513; SH (200 MHz; CDC1 3) 7.32-7.16 
(Ion, m, ArH), 6.94 (2H, d, J 8.7, ArH), 6.78 (2H, d, J 8.7, AnT), 3.96 (2H, d, J 
13.9, NCHxHyPh x 2), 3.81 (3H, s, OMe), 3.73 (3H, s, OMe), 3.63 (1 H, t, J 7.9, 
C211), 3.54 (2H, d, J 13.9, NCHxHyPh x 2 ), 3.08 (1 H, dd, J 13.9, 7.9, C3HAFIB), 2.93 
(1H, dd, J 13.9, 7.9, C3HAIIB); 6c (50.3 MHz; CDCI3) 172.7 (1C, Q), 158.0 (1C, Q), 
139.2 (3C, Q), 130.1 (2C, CH), 128.6 (4C, CH), 128.0 (4C, CH), 126.8 (2C, CH), 
113.5 (2C, CH), 62.4 (IC, CH), 55.2 (1C, CH3), 54.3 (2C, CH2) 51.0 (IC, CH3), 34.8 
(IC, CH2); m/z (FAB) 390 ([M + H], 33%), 330 (15), 268 (40), 121 (15), 91(100); 







To a solution of ester 41(12.2 g, 31.4 mmol) in ether (40 cm 3)  was added methanol 
(5.1 cm3) followed by lithium borohydride (2.73 g, 125 mmol). The solution was 
heated to reflux and held at reflux for 4 hours. The reaction was quenched by the 
addition of saturated aq. ammonium chloride (50 cm 3). The organic phase was then 
separated, and the aqueous phase was extracted with EtOAc (3 x 75 cm'). The 
combined organics were washed with brine (2 x 150 cm 3)  then dried, and 
concentrated under reduced pressure to give a solid, which was recrystallised from 
toluene to give 42 (9.86 g, 87%) as a solid, Rf [hexane:EtOAc (7:3)] 0.45; mp 112-
113 °C; [aI D -54.4 (c 2.00, CHC13); Vma,, (KBr)/cm' 3332, 3024, 2923, 1611, 1512; 
6 H (200 MHz; CDC1 3) 7.40-7.22 (1 OH, m, ArR), 7.04 (2H, d, J 8.8, ArH), 6.84 (2H, 
d, J 8.8, ArH), 3.94 (2H, d, J 13.2, NCH,HyPh x 2), 3.80 (3H, s, OMe), 3.57-3.44 
(1H, m, CHAHBOH), 3.50 (2H, d, J 13.2, NCH XHY x 2), 3.35 (IH, dd, J 10.3, J4.4, 
CHAHBOH), 3.12-2.98 (3H, m, C 2H + C3HI-Iy + C3 HxHy), 2.47-2.34 (1H, m, 
CHAHBOH); (62.9 MHz; CDC1 3 ) 157.9 (1C, Q), 139.0 (2C, Q), 130.9 (1C, Q), 
129.7 (2C, CH), 128.9 (4C, CH), 128.4 (4C, CH), 127.1 (2C, CH), 113.8 (2C, CH), 
60.7 (1C, CH), 60.2 (1C, CH 2), 55.1 (1C, CH3), 53.0 (2C, CH2), 30.6 (IC, CH2); 
(Found: C, 79.62; H, 7.36; N, 3.85. C24H27NO2 Calc. for C24H27 NO2: C, 79.70; H, 
7.50; N, 3.90%). 
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Via reduction of aldehyde 31. 
To a solution of aldehyde 31 (see below), (0.192 g, 0.535 mmol) in toluene (3 cm 3) 
at -78 °C was added diisobutylaluminium hydride [2.23 cm  (1.0 M in hexanes), 2.23 
mrnol]. The mixture was stirred at -78 °C for 5 mm, then quenched by sequential 
addition of water (0.050 cm 3 ), aq. Sodium hydroxide (50 mm 3 ; 1 M), and water (10 
cm3). The resulting mixture was allowed to warm to room temperature and extracted 
with CH202 (3 x 25 cm3). The combined organics were dried, and concentrated 
under reduced pressure. The residue was chromatographed on silica gel 
[hexane:EtOAc (7:3)] to give alcohol 42 (0.173 g, 90%) as a solid, chiral HPLC (S 
enantiorner) R t = 19.4 minutes, (R enantiomer) Rt = 22.7 minutes [hexane-propan-2-
ol (9: 1)], >98% ee. 
128 
Experimental 






To a solution of oxalyl chloride (0.17 g, 0.12 cm 3,  1.3 mmol) in CH202 (10 cm3 ) at - 
78 °C was added dropwise a solution of DMSO (0.13 g, 0.12 cm 3 , 1.7 mmol) in 
CH2Cl2 (0.5 cm3). The mixture was stirred for Ca. 5 min whereupon it became 
cloudy. A solution of alcohol 42 (0.200 g, 0.60 mmol) in CH 202 (3.0 cm 3) at -78 °C 
was introduced via cannula. The resulting clear solution was stirred at -78 °C for I 
hour. Triethylamine (0.72 g, 1.0 cm 3 , 7.0 mmol) was added and the resulting cloudy 
solution was allowed to warm to room temperature. Water (10 cm 3)  was added 
producing two clear phases. The organic phase was separated and the aqueous phase 
was extracted with CH 2C1 2 (3 x 10 cm3). The combined organics were washed 
sequentially with 1% HC1 (20 cm 3),  water (20 CM),  saturated aq. sodium bicarbonate 
(20 cm3 ) and brine (20 cm 3),  then dried and concentrated under reduced pressure to 
give aldehyde 31(0.198 g, 100%) as an oil which was a used in the aldol reaction 
without further purification, Rf [hexane:EtOAc (7:3)] 0.69; [a]D +70.3 (c 2.00, 
CHCI3 ); Vma., (neat)/cm' 3026, 2833, 2716, 1727, 1611, 1583, 1512; 1-1 (200 MHz; 
CDC13) 9.61 (1 H, s, CHO), 7.22-7.05 (1 OH, m, Ar!]), 6.96 (2H, d, J8.8, Ar!]), 6.71 
(2H, d, J 8.8, Ar!]), 3.73 (2H, d, .1 13.8, NCHAHBPh x 2), 3.68 (3H, s, OMe), 3.57 
(2H, d, J 13.8, NCHAHBPh x 2), 3.41 (1 H, t, J 6.8, C21-!), 2.99 (1H, dd, J 14.0, 6.8, 
C3HxHy ), 2.78 (1 H, dd, J 14.0, 6.8, C3 FIxHy); ö (69.2 MHz; CDCI 3 ) 202.2 (1C, 
CH), 157.9 (1C, Q), 138.8 (2C, Q), 130.8 (1C, Q), 130.2 (2C, CH), 128.6 (4C, CH), 
128.2 (4C, CH), 127.2 (2C, CH), 113.7 (2C, CH), 68.4 (1C, CH), 55.1 (IC, CH3), 






To a solution of D-phenylanaline (10.0 g, 60.6 mmol) in THF (200 cm 3 ) at 0 °C was 
added sodium borohydride (5.52 g, 146 mrnol), and a solution of iodine (15.3 g, 60.6 
mmol) in THF (30 cm3 ). The reaction was heated to reflux and held there for 24 
hours, and then re-cooled to 0 °C and quenched, carefully, by the addition of 
methanol (20 cm3). The solution was stirred at room temperature for a further 30 
minutes. The mixture was then concentrated under reduced pressure before being 
dissolved in a 20% aqueous potassium hydroxide solution (200 cm 3) and then 
allowed to stir for a further 18 hours. The resulting mixture was extracted with 
CH2 C1 2 (3 x 75 cm 3), and the combined organic phase was dried, and concentrated 
under reduced pressure. The residue was chromatographed on silica gel 
[CH2C12 :CH3 0H (95:5)] to give 44 (5.45g, 60%) as a white solid. R f [hexane:EtOAc 
(1:1)] 0.29; mp 87-88 °C; [a]D +22.2 (c 1.3, EtOH) [lit.,' 40 mp 88-89 °C, [aID +22.1 
(c 1.5, EtOH)]; Vm (KBr)Icm' 3422, 3357, 2876, 1577, 1493; ö, (200 MHz; 
CDCI3 ) 7.35-7.09 (5H, m, ArT!), 3.62 (1H, dd, J 10.7, 3.9, CIHAHB), 3.38 (1H, dd, J 
10.7, 7.0, CIHAHB), 3.10 (1 H, dddd, J 8.6, 7.0, 5.1, 3.9, CA,  2.78 (1H, dd, J 13.6, 
5. 1, C 3HHy), 2.50 (1 H, dd, 1 13.6, 8.6, C3 HxHy), 2.27 (2H, br s, NH2); E (62.9 
MHz; CDC13) 138.5 (IC, Q), 129.0 (2C, CH), 128.4 (2C, CH), 126.2 (IC, CH), 65.9 
(1C, CH2), 54.0 (1C, CH), 40.5 (1C, CH 2); (Found: C, 70.83; H, 8.66; N, 9.18. 
C9H 13N0 requires C, 71.52; H, 8.61; N, 9.27%). 
All spectroscopic data was in good agreement with that of the literature. 140 
130 
Experimental 
Method B' 37 
To a solution of lithium borohydride (2.67 g, 118 mmol) in THF (50 cm') at 0 °C 
was added trimethylsilyl chloride (26.3 g, 30.9 cm 3 , 242 mmol). The mixture was 
warmed to room temperature and allowed to stir for 20 minutes before being 
recooled to 0 °C. D-phenylanaline (10.0 g, 60.6 mmol) was added and the solution 
was warmed to room temperature and left to stir for 24 hours. The solution was again 
recooled and quenched by the dropwise addition of methanol (50 cm 3),  followed by 
2.5 M aqueous sodium hydroxide (50 cm 3). The organic phase was separated, and the 
aqueous phase was extracted with CHC13 (3 x 100 cm3 ). The combined organic 
extracts were dried and concentrated under reduced pressure to give a solid which 
was recrystallised from toluene to give 44 (8.65 g, 95%) as a white solid, mp 86-88 
oc. 







To a flask containing D-phenylalaninol (5.00 g, 33.1 mmol) was added diethyl 
carbonate (8.01 cm 3 , 7.81 g, 66.2 mmol) and potassium carbonate (0.457 g, 3.31 
mmol). The mixture was heated to carefully to 135-140 °C, and the ethanol 
produced was allowed to distil off as it was formed (over ca 2 hours). The mixture 
was cooled to room temperature and diluted with CH 202 (75 cm 3) before being 
filtered to remove any of the remaining potassium carbonate. The organic phase was 
washed with saturated aq. sodium bicarbonate (50 cm 3)  then dried, and concentrated 
under reduced pressure to give a solid which was recrystallised from [hexane:EtOAc] 
to give 45 (4.87 g, 83%) as a white solid, R,[hexane:EtOAc (1:1)] 0.29; mp 87-88 
°C; [a] D —4.38 (c 1. 1, EtOT-L) [lit., 141  rnp 86-88 °C; [aID —4.58 (c 1.1, EtOH)]; Vmax 
(KBr)/cm' 3282, 2924, 1752, 1709, 1548, 1496; 5H  (250 MHz; CDC1 3 ) 7.36-7.15 
(5H, m, ArH), 6.11 (IH, br s, NJ]), 4.44-4.36 (1H, m, C41f), 4.09 (1H, dd, J 12.7, 
5.4, C 5HAHB), 4.15-4.02 (1H, m, C5HAHB),  2.90 (1H, dd, J 13.3, 6.5, CHHPh), 
2.82 (1 H, dd, J 13.3, 6.2, CHxHyPh); 8, (62.9 MHz; CDC1 3 ) 159.5 (1C, Q), 135.7 
(1C, Q), 128.9 (2C, CH), 128.8 (2C, CH), 127.0 (IC, CH), 69.4 (1C, CH2), 53.6 (1C, 
CH), 41.2 (1C, CH2); (Found: C, 68.03; I-I, 6.05; N, 7.74. C, 0H,,NO2 requires C, 
67.80; H, 6.21; N, 7.91%). 
All spectroscopic data was in good agreement with that of the literature. 141 
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(4R)-3-(2'-Benzyloxy-1 '-oxoethyl)-4-phenylmethyloxazolidin-2-one 32 
rK N )~ 0 
OBn Br' 
To a solution of oxazolidinone 45 (2.00 g, 11.3 mmol) in THF (50 cm 3) at -78 °C 
was added n-butyllithiu.m (7.29 cm 3 , 1.55 M in hexaries, 11.3 mmol) and the solution 
turned orange. The solution was allowed to stir for 15 minutes before 
benzyloxyacetyl chloride (1.78 cm 3 , 2.08 g, 11.3 mmol) was added causing the 
orange colour to disappear. The mixture was left to stir for 1 hour and was then 
quenched by the addition of a saturated aqueous solution of ammonium chloride (50 
cm3). The organic phase was separated and the aqueous phase was extracted with 
CH202 (3 x 50 cm 
 3);  the combined organic phase was washed sequentially with 
saturated aq. sodium bicarbonate (75 cm 3) and brine (75 cm  3)  then dried, and 
concentrated under reduced pressure. The residue was chromatographed on silica gel 
[hexane:EtOAc (4:1)] to give 32 (3.27 g, 89%) as a white solid, R 1 [hexane:EtOAc 
(7:3)] 0.37; mp 69-70 °C; [aI D -57.4 (c 1.52, CHCI 3 ) [lit.,97(a)  mp 67-69 °C, [aID - 
57.45 (c 2.0, CHCI3)]; Vmax (KBr)/cm' 3031, 2909, 2841, 1766, 1708, 1603, 1497; 
(200 MHz; CDC1 3) 7.45-7.18 (IOH, m, ArE), 4.80-4.62 (5H, m, CH2OBn + 
OCH2Ph + C411), 4.27 (1 H, t, J9.2, C5H4HB), 4.21 (1H, dd, J9.2, 3.7, C 5HAHB), 3.33 
(I H, dd, J 13.2, 3.3, CHHyPh), 2.82 (1 H, dd, 1 13.2, 9.2, CHxHyPh); 8 c (62.9 MHz; 
CDCI 3 ) 170.0 (1C, Q), 153.2 (IC, Q), 137.0 (1C, Q), 134.8 (1C, Q), 129.3 (2C, CH), 
128.9 (2C, CH), 128.4 (2C, CH), 127.9 (2C, CH), 127.8 (1C, CH), 127.3 (1C, CH), 
73.8 (IC, CH2), 69.5 (IC, CH 2), 67.1 (1C, CH2), 54.6 (1C, CH), 37.6 (IC, CH 2). 










Synthesised in analogous manner to the R-enantiomer from ent-45. Thus, to 
oxazolidinone ent-45 (2.50 g, 14.2 rnmol) in THF (50 cm3 ) at -78 °C was added ii-
butyllithium (9.16 cm 3 , 1.55 M in hexanes, 14.2 mmol) followed by benzyloxyacetyl 
chloride (2.24 cm3 , 2.62 g, 14.2 mmol) to give ent-42 (4.19 g, 92%) as a white solid, 
mp 68-70°C; [aID +57.1 (c 1.72, CHC1 3 ) Pit-," 2(g) mp 67-69 °C, MD  +56 . 0 (c 1.71, 
CHC13)]. 




To a solution of glycolate equivalent 32 (0.66 g, 2.0 mmol) in CH 2Cl2 (5 cm') at 
-78 °C was added triethylamine (0.27 g, 0.37 cm.  3 , 2.7 mmol) followed by dropwise 
addition of dibutylboron triflate (1.0 M in CH 2C1 2 ; 2.5 cm3 , 2.5 mmol). The solution 
was stirred at -78 °C for 45 minutes, then allowed to warm to 0 °C over 30 minutes 
and stirred at 0 °C for 1.25 hours. The solution was then recooled to -78 °C and a 
-78 °C solution of aldehyde 31(0.200 g, 0.557 mmol) in CI-1 202 (3 cm  3)  was added 
dropwise via cannula. The reaction mixture was stirred at -78 °C for 1 h, and allowed 
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to warm to 0 °C over a period of 4 hours. The reaction was quenched by the addition 
of methanol (8 cm) followed by pH 7 phosphate buffer (5 cm 3). Hydrogen peroxide 
(30% aq. solution; 5 cm  in methanol (5 cm) was added dropwise to the solution and 
the mixture was stirred and warmed to room temperature over Ca. i hour. The 
organic phase was separated and the aqueous phase was extracted with CH 202 (3 x 
20 cl-n3 ); the combined organic phase was washed sequentially with saturated aq. 
sodium bicarbonate (25 cm 3 ) and brine (25 cm 3)  then dried, and concentrated under 
reduced pressure. The residue was chromatographed on silica gel [hexane:EtOAc 
(7:3)] to give 30 (0.286 g, 75%) as a foam, Rf [hexane:EtOAc (7:3)] 0.42; [a]D -47.0 
(c 2.75, CHC13); Vm (neat)/cm -1 3334, 3027, 2930, 1771, 1709, 1611, 1512; 8YI  (200 
MHz; CDC1 3 ) 7.38-6.86 (20H, m, ArH), 7.08 (2H, d, J 8.6, ArH), 6.66 (2H, d, J 8.6, 
ArH), 4.89 (1H, d,J 1.6, C2 H), 4.67 (1 H, dddd, J9.9, 6.8, 3.1, 2.5, CA,  4.52 (1 H, 
s, OH), 4.25 (1 H, dd, J8.8, 6.8, C5HAHB), 4.24 (1 H, d, J 11.4, OCHSHTPh), 4.20-
4.16 (1H, m, CSHAHB), 4.06 (1H, dd, 1 9.5, 1.6, C3'H), 3.91 (2H, d, J 13.2, 
NCHHPh x 2), 3.69 (3H, s, OMe), 3.58 (1H, ddd, .1 9.5, 7.7, 4.6, C4ff), 3.46 (2H, 
d, J 13.2, NCHHyPh x 2 ), 3.31 (1H, dd, 1 13.4, 3. 1, C4HCHAIHNPh), 3.30 (1 H, d, J 
11.4, OCHsH7Ph), 3.14 (1 H, dd, 1 14.6, 4.6, C5'HEHF), 2.74 (1 H, dd, J 13.4, 9.9, 
C4HCHMHNPh), 2.72 (1H, dd, J 14.6, 7.7, C5'HEHF); öc (62.9 MHz; CDC13) 170.0 
(1G. Q), 157.7 (1C, Q), 153.4 (1C, Q), 138.3 (2C, Q), 137.5 (1C, Q), 135.1 (1C, Q), 
131.7 (1C, Q), 130.1 (2C, CH), 129.2 (2C, CH), 128.8 (5C, CH), 128.7 (3G. CH), 
128.4 (4C, CH), 127.7 (2C, CH), 127.1 (2C, CH), 126.7 (2C, CH), 113.5 (2C, CH), 
76.9 (1C, CH), 71.1 (IC, CH, 70.9 (1G. CH2), 66.9 (1 C, CH2), 59.9 (IC, CH), 55.7 
(IC, Gil3), 55.0 (1G. Gil), 37.5 (2C, CH2), 30.1 (2C, CH 2); m/z (FAB) 685 ([M + 
H], 5%), 307 (28), 289 (16), 154 (100), 136 (93); HRMS (FAB) (Found: [M + H], 
685.3260. C43 H45N206 requires m/z, 685.3278). 
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(2S,3S,4R)-13enzyloxy-4-N,N,-d ibenzy lam ino-3-hydroxy-5-(4-
methoxyphenyl)pentan-1-oi 29 
OH 
(( E 0H 
MeO - 	
NBn2 	OBri 
To a solution of aldol adduct 30 (0.148 g, 0.216 rnmol) in THF (10 cm 3 ) at 0 °C was 
added methanol (0.040 cm 3,  1.1 mmol) and LiBH4 (0.024 g, 1 .1 minol). The solution 
was warmed to room temperature and stirred for 18 hours then re-cooled to 0 °C and 
quenched by the addition of 1 M sodium hydroxide (1 cm 3). The organic phase was 
separated and the aqueous phase was extracted with CH202 (3 x 20 cm 3);  the 
combined organic phase was washed with brine (30 cm 3), dried, and concentrated 
under reduced pressure. The residue was chromatographed on silica gel 
[hexane:E.tOAc (7:3)] to give the diol 29 (0.088 g, 80%) as a foam, Rf 
[hexane:EtOAc (7:3)] 0.18; [aI D -29.6 (c 1.1, CHC13 ); v 1 (neat)/cm 3344, 2927, 
1609, 1510; 8H  (360 MHz; CDCI 3) 7.37-6.96 (15H, m, ArIf), 7.04 (2H, d, J 8.7, 
An]), 6.73 (2H, d, J 8.7, ArIf), 4.46 (1H, d, J 11.8, OCHAHBPh), 3.96 (2H, d, 1 14.5, 
NCHxHyPh x 2), 3.90 (1 H, d, J 11. 8, OCHAHBPh), 3.74 (3H, s, OMe), 3.72 (1H, dd, 
J 8.1, 3.5, C3H), 3.69 (1H, dd, J 11.7, 4.8, CHSHTOH), 3.52 (IH, dd, .1 11.7, 3.8, 
CHsH1OH), 3.42 (2H, d, J 14.5, NCHHyPh x 2), 3.40-3.31 (2H, rn, C2H + C41-I), 
3.08 (1H, dd, J 14.1, 5.8, C SHAIHN), 2.70 (1 H, dd, 114.1, 7.2, C5HMHN), 2.52 (1H, br 
s, OH), 1.78 (IH, br s, 010; 6c  (62.9 MHz; CDC13) 157.9 (1C, Q), 138.7 (1C, Q), 
138.2 (1C, Q), 131.6 (IC, Q), 130.0 (2C, CH), 129.0 (4C, CH), 128.4 (4C, CH), 
128.1 (2C, CH), 127.2 (2C, CH), 127.1 (2C, CH), 127.0 (2C, CH + Q), 113.8 (2C, 
CH), 77.6 (IC, CH), 72.1 (1C, CH), 70.9 (LC, CH2), 61.6 (1C, CT-I2), 59.0 (1C, CH), 
55.1 (IC, CH3), 54.0 (2C, CH 2), 31.0 (IC, CH 2); m/z (FAB) 512 ([M + H], 25%), 
330 (21), 154 (24), 91(100); HRMS (FAB) (Found: [M + H], 512.2801. C33H38N0 4 
requires m/z, 512.2801). 
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Via reduction of methyl ester 150. 
A solution of methyl ester 150 (0.0168 g, 0.0312 mmol) in THF (6cm 3 ) was placed 
at -78 °C and lithium aluminium hydride (0.15 cm 3 , 1.0 M in THF, 0.15 mmol) was 
added. The solution was slowly warmed to room temperature and stirred for 18 hours 
before being quenched by the addition of 1 M aqueous sodium hydroxide (2 cm 3). 
The mixture was diluted with CH 2 C1 2 (10 cm3) and saturated aq. sodium potassium 
tartrate (20 cm 3)  was added. The biphasic mixture was stirred vigorously for 15 
hours by which time two clear phases were apparent. The organic phase was 
separated and the aqueous phase was extracted with CH 2Cl2 (3 x 20 cm. 3 ). The 
combined organics were dried, and concentrated under reduced pressure. The 
remaining residue was chromatographed on silica gel [hexane:EtOAc (7:3)] to give 
29 (0.0115 g, 72%) as an oil. 
All spectroscopic data was identical to that obtained for the compound above. 
(2R,3S,4S)-4-benzyloxy-1 ,1-dibenzyl-3-hydroxy-2-(4-





To a solution of the alcohol 29 (0.110 g, 0.215 mmol) in CH2C12 (5 cm 3 ) at 0 °C was 
added DMAP (0.118 g, 0.967 mmol) and toluene sulfonyl chloride (TsC1) (0.123 g, 
0.646 mmol). The solution was stirred for 18 hours then diluted with CH2C1 2 (20 
cm3) and water (25 CM)  . The organic phase was separated and washed with 1% HC1 
(2 x 25 cm 3)  then dried and concentrated under reduced pressure. The residue was 
chromatographed on silica gel [CH2C12:MeOH (100:0) —> (95:5)] to give a white 
foam. The salt obtained was subjected to ion exchange chromatography [Dowex Cl - , 
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(prepared by treating Dowex I -X2 with 1% aqueous hydrochloric acid followed by 
flushing with methanol until the eluent returned to pH 7)] eluting with methanol to 
give the chloride salt 48 (0.096 g, 85%) as a foam, R f [CH2C1 2 :MeOH (95:5)] 0.05; 
[a]0 +4.1 (c 0.8, CHC13); Vm (neat)/cm 3147, 1612, 1513; H  (360 MHz; CDC13) 
7.73-6.71 (17H, m, ArH), 6.69 (2H, d, J8.7, ArIf), 5.66 (1H, d, J 13.5, OCHAHBPh), 
5.04 (2H, s, NCHHPh x 2), 4.71 (1H, br s C4H'), 4.42 (2H, s, NCHHPh x 2), 
4.26 (IH, s, CA,  4.26-4.18 (IH, m, C 5HSHT), 4.20 (1H, d, J 13.5, OCHA HBPh), 
3.82 (1H, dt, J 12.2, 2.9, C211), 3.69 (3H, s, OMe), 3.66 (1H, br d, J 12.2, CH1 HNAr), 
3.50 (1 H, t, J 12.2, CHM HNAr), 3.09 (1 H, dd, J 13.3, 3. 1, C 5 HsH), 2.18 (1H, brs, 
011); öc (62.9 MHz; CDC1 3 ) 158.5 (IC, Q), 137.1 (IC, Q), 133.5 (2C, CH), 133.0 
(2C, CH), 130.7 (1C, CH), 130.5 (2C, CU), 129.3 (3C, CH), 128.1 (3C, CH), 128.0 
(1C, Q), 127.5 (4C, CH), 127.4 (IC, Q), 126.9 (1C, Q), 114.1 (2C, CH), 80.2 (IC, 
CH), 75.1 (1C, CH), 72.3 (1C, CU), 71.8 (IC, CH2), 63.8 (IC, CHI), 63.5 (1C, CH 2), 
62.2 (1C, CH2), 55.0 (1C, CH 3), 27.7 (IC, CH 2); m/z (FAB) 494 ([M]+.  75%), 282 
(11), 154 (43), 136 (32), 121 (14), 91(100); HRMS (FAB) (Found: [M] +, 494.2695. 
[C33H36NO 3]Cl requires m/z, 494.2695). 






A solution of the chloride salt 48 (0.112 g, 0.212 mmol) and Peariman's catalyst 
[0.112 g; 20% Pd(OH) 2/C] in methanol (5 cm 3)  was exposed to a hydrogen 
atmosphere (1 atm) and stirred vigorously for 24 hours. The mixture was then 
filtered through a pad of Celite and concentrated under reduced pressure to give 54 
(0.055 g, 100%) as a white solid, mp 225-227 °C; [a]n +8.1 (c 0.55, MeOH) [lit.,4 
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mp 224-226 °C]; Vm (KBr)/cm' 3358, 3252, 2950, 1613, 1585, 1513; ö (250 
MHz; CDC13) 7.36 (2H, d, J 8.8, Ar!]), 7.00 (2H, d, J 8.8, Ar!]), 4.34 (1H, dd, J 4.2, 
1.4, C4!]), 4.07 (1H, dd, J2.8, 1.4, C311), 3.87 (3H, s, OMe), 3.96 (1H, ddd, J8.3, 
7.1, 2.8, C21-I), 3.70 (IH, dd, .1 12.5, 4.2, C5HAHB), 3.24 (IH, dd, J 14.1, 7.1, 
CH,HyAr), 3.18 (1H, d, J 12.5, C5HAHB), 3.04 (1H, dd, J 14.1, 8.3, CHxHyAr); 5c 
(62.9 MHz; CDC1 3) 158.5 (IC, Q), 129.2 (2C, CH), 128.0 (IC, Q), 113.4 (2C, CH), 
74.1 (1C, CH), 73.8 (IC, CH), 63.4 (IC, CH), 53.8 (IC, CH3), 50.6 (IC, CH2), 30.2 
(1C, CH2); m/z (FAB) 224 ([M + H], 100%), 206 (13), 150(11), 121 (54), 91(58); 
FIRMS (FAB) (Found: [M + H], 224.1284. [C 12H 18NO3]Cl requires m/z, 
224.1287). 





The HC1 salt 54 was subjected to ion-exchange chromatography [Dowex OH] 
(prepared by treating Dowex 1 -X2 with 1 M aqueous NaOH, followed by methanol 
until the eluent returned to pH 7). Eluting with methanol gave the free base 
(quantitative recovery) as a white solid, mp 173-175 °C; [a]o -19.8 (c 1.0, MeOH) 
[lit.,4 mp 176-178 °C, [aID -20 (c 1.0, MeOH)]; Vm (KBr)/cm' 3400, 3271, 2916, 
1612, 1512; oH (250 MHz; CDC1 3) 7.29 (2H, d, J8.8, Ar!]), 6.92 (2H, d, J8.8, Ar!]), 
4.16 (1H, dd,J3.8, 1.2, C3!]), 3.85 (3H, s, OMe), 3.79 (1H, dt,J5.7, 1.6, C4ff), 3.46 
(I H, dd, J 12.4, 5.7, C5HAHB), 3.34 (1H, ddd, J 8.3, 6.6, 3.8, C211), 2.97 (1H, dd, J 
13.4, 8.3, CHxHyAr), 2.80 (1H, dd, J 13.4, 6.6, CHxHyAr), 2.71 (1 H, dd, J 12.4, 2.0 
C5HAHB); Oc (62.9 MHz; CDC1 3) 157.7 (1C, Q), 131.2 (IC, Q), 129.1 (2C, CH), 
112.9 (2C, CH), 76.9 (1C, CH), 76.2 (1C, CH), 62.2 (IC, CH), 53.7 (1C, CH3), 51.7 
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(1C, CH2), 32.7 (1C, CU2); m/z (FAB) 224 ([M + H]', 100%), 121 (48), 91(14); 
HRMS (FAB) (Found: [M + H], 224.1285 C 12H 1 8NO3 requires m/z, 224.1287). 
All spectroscopic data was in good agreement with that of the literature. 4 
(2R,3S,4S)-3-Acetoxy-4-benzyloxy-1 ,1-dibenzyl-2-(4-
methoxybenzyl)pyrrolidinium chloride 55 





AcO 	OBn I 
To a solution of the chloride salt 48 (0.123 g, 0.232 mmol) in CH 2CL2 (5 cm 
3)  was 
added DMAP (0.011 g, 0.090 mmol) and freshly distilled acetic anhydride (0.025 g, 
0.029 cm3 , 0.30 mmol). The solution was stirred for 18 hours then diluted with water 
(10 cm 3). The organic phase was separated and the aqueous phase was extracted with 
CH2C12 (3 x 20 cm3). The combined organics were dried and concentrated under 
reduced pressure. The residue was chromatographed on silica gel [CH 2 C1 2 :MeOH 
(1:19)] to give the ester 55 (0.072 g, 54%) as a foam, Rf [CH2C12:MeOH (95:5)] 
0.10; [aID +41.0 (c 1.22, CUCI 3 ); Vmax (neat)/cm' 3376, 3031, 2956, 1751, 1612, 
1512; 8H(360  MHz; CDC1 3) 7.86-7.09 (15H, m, ArH), 6.96 (2H, d,J8.7, Ar!]), 6.78 
(2H, d, J 8.7, Ar!]), 6.56 (1H, d, J 13.6, NCH,I HBPh), 6.04 (IH, d, J 12.5, 
NCHxHyPh), 5.03 (1H, br d, J5.0, C3!]), 4.61 (1 H, d, .J 12. 0, OCHSHTPh), 4.55 (1H, 
d, J 12.5, NCHHyPh ), 4.49 (1H, dd, J 13.3, 2.8, CH1 ,fHNAr), 4.41 (1 H, d, J 12.0, 
OCHHPh ), 4.27 (1H, br t, J 6.8, C41- ), 4.20 (1H, d, J 13.6, NCHAHBPh ), 4.01 
(1H, dd, J 13.2, 6.8, C5HEUF), 4.00-3.95 (1H, m, C21]), 3.76 (3H, s, OMe), 3.39 (1H, 
t, J 13.3, CHMHNAr ), 3.22 (IH, dd, J 13.2, 6.8, CSHEHF), 2.23 (3H, s, COCH3); 
6v  J62.9 MHz; CDC1 3 ) 168.4 (IC, Q), 158.7 (1C, Q), 136.0 (IC, Q), 133.8 (2C, CH), 
133.4 (2C, CH), 131.1 (1C, CH), 130.8 (1C, CU), 129.5 (2C, CH), 129.4 (4C, CU), 
128.6 (2C, CU), 128.4 (1C, CU), 127.8 (2C, CU), 127.2 (1C, Q), 126.6 (IC, Q), 
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125.9 (1C, Q), 114.4 (2C, CH), 78.8 (IC, CH), 74.3 (IC, CH), 72.6 (1C, CH), 72.4 
(IC, CH2), 62.4 (1C, CH2), 62.2 (1C, CH2), 58.6 (IC, CH2), 55.1 (1C, CH3), 27.5 
(1C, CH2), 20.9 (IC, CH 3); m/z (FAB) 536 ([M + H], 69%), 446 (35), 174 (15), 121 
(39), 91 (100); HRMS (FAB) (Found: [M + H], 536.2808. [C35H38NO4}CF 







A solution of the chloride salt 55 (0.070 g, 0.12 rnmol) and Peariman's catalyst 
[0.070g; 20% Pd(OH)2/CJ in methanol (5 cm) was exposed to a hydrogen 
atmosphere (1 atm) and stirred vigorously for 24 hours. The mixture was then 
filtered through a pad of Cëlite and concentrated under reduced pressure to give 
anisomycin as its hydrochloride salt 23 (0.036 g, 100%), mp 187-188 °C; [aID +4.0 
(c 0.28, CH3 0H) [lit., 142 187— 188 °C, [aID +4.2 (c 0.51, C1-1 3 0H)]; Vm (KBr)/cm 
3395, 3291, 3252, 1749, 1612, 1514; 8H  (250 MHz; CD 3 0D) 7.26 (211, d, J 8.6, 
An]), 6.95 (21-I, d, J 8.6, ArH), 5.08 (1 H, d, J 3. 0, C 3H), 4.38 (1 H, d, J 4.3, C41]), 
4.23-4.15 (IH, m, C2H), 3.81 (3H, s, OMe), 3.63 (IH, dd, .1 12.8, 4.3, CSHAHB), 3.22 
(1H, d, J 12.8, C5HAHB), 3.11 (IH, dd, J 14.3, 6.7, CHxHyAr), 2.99 (1H, dd, J 14.3, 
8.8, CHxHyAr), 2.21 (3H, s, COCH3); S (62.9 MHz; CD 30D) 169.8 (1C, Q), 159.6 
(1C, Q), 130.0 (2C, CH), 127.9 (1C, Q), 114.5 (2C, CH), 77.3 (IC, CH), 72.4 (1C, 
CH), 62.7 (1C, CH), 54.7 (1C, CH 3), 51.6 (1C, CH 2), 31.2 (1C, CH2), 19.7 (1C, 
CH3); m/z (FAB) 266 ([M + H], 77%), 206 (55), 149 (22), 134 (59), 121 (26), 91 








To a solution of the chloride salt 48 (0.049 g, 0.093 mmol) in methanol (5 cm  3)  was 
added 5% Pd/C (0.0049 g) and potassium carbonate (0.045 g, 0.32 mmol). The 
mixture was exposed to a hydrogen atmosphere (1 atm) and stirred vigorously for 10 
minutes. The suspension was filtered through a pad of Celite and concentrated under 
reduced pressure. To the residue was added CH 202 (25 cm3) and water (25 cm3). The 
organic phase was separated and the aqueous phase was extracted with CH 2C12 (3 x 
10 cm  3);  the combined organic phase was then washed with saturated aq. sodium 
bicarbonate (25 cm  3)  then dried and concentrated under reduced pressure. The 
residue was chromatographed on silica gel [hexane-EtOAc (7:3)] to give pyrrolidine 
56 (0.035 g, 94%) as an oil, Rf [hexane: EtOAc (1:1)] 0.33; [aID -96.1 (c 0.4, 
CHCI 3); (neat)/cm' 3419, 2917, 1610, 1511; 6 (250 MHz; CDC13) 7.33-7.19 
(12H, m, ArM), 6.84 (2H, d, J 8.7, ArM), 4.46 (1 H, d, J 11.9, OCHAHBPh), 4.39 (1H, 
d, J 11.9, OCHAHBPh ), 4.14 (1H, d, J 12.9, NCHvHyPh), 3.82-3.77 (1 H, m, C 3 11), 
3.80 (1H, dd, .1 6.6, 4.1, C411), 3.79 (3H. s, OMe), 3.33 (1H, d, J 12.9, NCH xHyPh), 
3.32 (1H, dd, J 10.5, 6.6, C 5HSHT), 2.97-2.81 (3H, m, CHMHNAr, + CHMHNAr + 
C21]), 2.20 (IH, dd, J 10.5, 4.4, C5HSHT); 3 (62.9 MHz; CDC1 3) 157.9 (1C, Q), 
138.4 (IC, Q), 137.8 (1C, Q), 130.8 (1C, Q), 130.1 (2C, CH), 128.7 (2C, CH), 128.3 
(2C, CH), 128.2 (2C, CH), 127.5 (3C, CH), 127.0 (1C, CH), 113.8 (2C, CH), 82.6 
(1C, CH), 75.4 (1C, CH), 71.2 (IC, CH2), 68.2 (IC, CH), 58.4 (1C, CH2), 57.7 (1C, 
CH2), 55.1 (IC, CH 3), 32.5 (IC, CH2); ml-7 (FAB) 404 ([M + H], 16%), 307 (19), 
154 (100), 136 (72), 91(30); HRMS (FAB) (Found: {M + H}, 404.2226. C26H3 0NO3 
requires m/z 404.2226). 
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To a solution of the alcohol 56 (0.026 g, 0.065 mmol) in CH202 (4 cm 
 3)  was added 
freshly distilled acetic anhydride (0.013 g, 0.015 cm 3 , 0.13 mmol), and triethylarnine 
(0.013 g, 0.018 cm3 , 0.13 mmol). The solution was stirred for 18 hours and then 
quenched by the addition of saturated aq. sodium bicarbonate (25 cm 3 ). The organic 
phase was separated and the aqueous phase was extracted with CH 2Cl2 (3 x 15 cm 3); 
the combined organic phase was dried and concentrated under reduced pressure. The 
residue was chromatographed on silica gel [hexane:EtOAc (7:3)] to give the ester 57 
(0.026 g, 92%) as a colourless oil, Rf [hexane: EtOAc (7:3)] 0.49; [aI D -105.7 (c 1.1, 
CFJCI3); Vnax (neat)/cm - 1 2932, 1738, 1612, 1583, 1512; 6H  (250 MHz; CDC13) 7.33-
7.20 (1 OH, m, ArH), 7.07 (2H, d, J 8.8, An]), 6.81 (2H, d, J 8.8, ArH), 4.91 (1 H, dd, 
J 5.0, 1.5, C 3 11), 4.62 (1 H, d, J 12. 1, OCHAHBPh), 4.45 (1 H, d, J 12. 1, OCHAHBPh), 
4.05 (1 H, d, J 13. 1, NCHHyPh), 3.82-3.71 (1 H, m, C411), 3.77 (3H, s, OMe), 3.38 
(I H, d, J 13. 1, NCHxHyPh), 3.33 (1H, dd, J 10.7, 6.7, C 5HSHT), 3.10 (1H, dt, J 9.6, 
5.0, CA, 2.96 (1H, dd, J 13.6, 5.0, CHMHNAr), 2.76 (1H, dd, J 13.6, 9.6, 
CHMHNAr), 2.32 (IH, dd, J 10.7, 4.9, C5HSHT), 2.11 (3H, s, COCH3); 8, (62.9  MHz; 
CDC13) 170.2 (IC, Q), 157.9 (IC, Q), 138.2 (IC, Q), 137.9 (1C, Q), 130.6 (IC, Q), 
129.6 (3C, CH), 128.9 (2C, CH), 128.2 (3C, CH), 127.5 (2C, CH), 127.4 (1C, CH), 
127.0 (IC, CH), 113.8 (2C, CH), 81.0 (IC, CH), 77.8 (1C, CH), 71.3 (IC, CH 2), 66.5 
(1C, CH), 58.3 (2C, CH 2), 55.1 (1C, CH3), 33.1 (1C, CH2), 21.1 (1C, CH3); m/z 
(FAB) 446 ([M + H], 35%), 356 (10), 324 (10), 217 (19), 91(100); HRMS (FAB) 











To a solution of the pyrrolidine 57 (0.019 g, 0.043 mmol) and Peariman's catalyst 
[0.019 g; 20% Pd(OH) 2/C] in methanol (3 cm 
3)  was added hydrochloric acid (0.09 
cm3 , I M in ether, 0.09 mmol). The solution was exposed to a hydrogen atmosphere 
(1 atm) and stirred vigorously for 1 hour. The mixture was then filtered through a 
pad of Celite and concentrated under reduced pressure to give anisomycin as it's 
hydrochloride salt 23 (0.013 g, 100%) as a solid. 






To a solution of the alcohol 56 (0.0803 g, 0.258 mmol) in CH2Cl2 (6 cm 3) was added 
freshly distilled propanoic anhydride (0.067 g, 0.066 cm 3 , 0.52 mmol), and 
triethylamine (0.052 g, 0.072 cm 3 , 0.52 mmol). The solution was stirred for 18 hours 
and then quenched by the addition of saturated aq. sodium bicarbonate (15 cm 3). The 
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organic phase was separated and the aqueous phase was extracted with CH202 (3 x 
15 cm 3);  the combined organic phase was dried and concentrated under reduced 
pressure. The residue was chromatographed on silica gel [hexane-EtOAc (4:1)] to 
give the ester 58 (0.0848g, 89%) as a colourless oil, Rf [hexane: EtOAc (7:3)] 0.49; 
{a]D —80.0 (c 0.58, CHC13); Vmax (neat)/cm -1 3061, 2937, 1735, 1612, 1583, 1512; 6H 
(360 MHz; CDC1 3) 7.44-7.31 (1 OH, m, An]), 7.17 (2H, d,J8.7, ArR), 6.91 (2H, d, .J 
8.7, ArIf), 5.12 (1 H, dd, 15.1, 1.5, CA,  4.73 (111, d, J 12. 1, OCHA HB Ph), 4.57 (1H, 
d, J 12.1 OCHA HBPh), 4.14 (1H, d, 1 13. 1, NCHxHyPh), 3.91 (1H, ddd, 16.7, 4.9, 
1. 5 ., C411), 3.87(3H, s, OMe), 3.47 (1H,d,J13.1,NCHxHyPh), 3.43 (1H,dd,J 10. 8, 
6.7, C 5HSHT), 3.23 (1 H, dt, 19.4, 5. 1, C21-1), 3.04 (1 H, dd, 1 13.8, 5. 1, CHMHNAr), 
2.88 (1 H, dd, J 13.8, 9.4, CHMHNAr), 2.50 (2H, q, 1 7.6, CH2CH3), 2.44 (1 H, dd, I 
10.8, 4.9, C5HsH), 1.27 (3H, t, 7.6, CH2CH3); 6, (62.9 MHz; CDCI 3 ) 173.6 (1C, Q), 
157.9 (1C, Q), 138.3 (1C, Q), 138.0 (1C, Q), 130.6 (IC, Q). 129.6 (2C, CH), 128.8 
(2C, CH), 128.1 (2C, CH), 128.0 (2C, CH), 127.5 (2C, CH), 127.4 (1C, CH), 126.9 
(1C, CH), 113.7 (2C, CH), 81.1 (1C, CH), 77.5 (IC, CH), 71.3 (1C, CH 2), 66.5 (IC, 
CH), 58.4 (1C, CH2), 58.3 (1C, CH 2), 55.0 (1C, CH 3), 33.1 (IC, CH 2), 27.6 (1C, 
CH2), 9.0 (1C, Cl-I3); m/z(FAB) 460 ([M + H] +. 31%),458 (46), 338 (53), 174 (54) 





N HCI I 
MeO I 
EtOCO 	OH 
To a solution of the pyrrolidine 58 (0.028 g, 0.062 mmol) and Peariman's catalyst 
[0.028 g; 20% Pd(OH)2/C] in methanol (3 cm 3)  was added hydrochloric acid (0.12 
145 
Experimental 
cm3 , I M in ether, 0.12 mmol). The solution was exposed to a hydrogen atmosphere 
(1 atm) and stirred vigorously for 18 hours. The mixture was then filtered through a 
pad of Celite and concentrated under reduced pressure to give 3097-B! as it's 
hydrochloride salt 59 (0.020 g, 100%) as a colourless solid, mp 213-215 °C; [aID 
+6.3 (c 0.16, CH30H); Vm (KBr)Icm' 3346, 3251, 2876, 1730, 1612, 1581, 1514; 
8H(250 MHz; CD 30D) 7.32 (2H, d, J 8.7, ArK), 7.01 (2H, d, f 8.7, ArK), 5.17 (1 H, 
d,J2.9, C3H), 4.43 (1 H, d,J3.9, C4H), 4.30-4.23 (IH, m, C2H), 3.87 (3H, s, OMe), 
3.69 (1H, dd, J 12.8, 3.9, C S HAHB), 3.29 (IH, d, J 12.8, C5HAHB), 3.17 (1H, dd, J 
14.3, 6.9, CHxHyAr), 3.05 (1 H, dd, J 14.3, 8.7, CH xHyAr), 2.60 (2H, m, CH2CH3), 
1.28 (3H, t, J7.5, CH2CH3); 8, (62.9 MHz; CD3 0D) 172.3 (IC, Q), 158.7 (1C, Q), 
129.0 (2C, CH), 127.0 (1C, Q), 113.6 (2C, CH), 76.2 (!C, CH), 71.5 (1C, CH), 61.8 
(1C, CH), 53.8 (IC, CH3), 50.7 (1C, CH 200.3 (IC, CH2), 26.2 (IC, CH2), 7.4 (1C, 
CH3); m/z (FAB) 280 ([M + H], 100%), 136 (94), 154 (95), 107 (73), 121 (76), 91 




(4R)-3-(1 '-Oxopropyl)-4-phenylmethyloxazolidin-2-one 91 
11 
10 
To a solution of oxazolidinone 45 (2.50 g, 14.1 mmol) in THF (50 cm') at -78 °C 
was added n-butyllithium (8.45 cm3 , 1.67 M in hexanes, 14.1 mmol) and the solution 
turned orange. The solution was allowed to stir for 15 minutes before freshly distilled 
propionyl chloride (4.17 cm 3 , 3.91 g, 42.3 mmol) was added causing the orange 
colour to disappear. The mixture was left to stir for 2 hours and was then quenched 
by the addition of a saturated aqueous solution of ammonium chloride (50 cm'). The 
organic phase was separated and the aqueous phase was extracted with CH 2C12 (3 x 
30 cm 3);  the combined organic phase was washed sequentially with saturated aq. 
sodium bicarbonate (100 cm 3) and brine (100 cm) then dried, and concentrated 
under reduced pressure. The residue was chromatographed on silica gel 
[hexane:EtOAc (4:1)] to give 91(2.96 g, 90%) as an oil, Rf [hexane:EtOAc (7:3)] 
0.48; [all)  -95.1 (c 1.0, EtOH) [lit.(ent-91),'4 ' [a]0 +92.9 (c 1.01, EtOH)}; vmax  
(neat)/cm' 2980, 1781, 1703, 1604, 1497; 8 1 (250 MHz; CDCI3) 7.54-7.35 (5H, m, 
ArH), 4.11 (1H, dddd, J 9.8, 9.3, 6.8, 3.4 C4H), 4.37-4.33 (lI-I, m, C 5H4H B), 4.34 
(1H, dd, J 9.9, 9.3, CsHH), 3.46 (1 H, dd, J 13.3, 3.4, CHHPh), 3.12 (2H, q, J 
7.4, CHCH), 2.93 (IH, dd, 13.3, 9.8, CHxHyPh), 1.37 (3H, t, J 7.4, CH2CH3); 
E (62.9 MHz; CDCI3) 174.2 (1C, Q), 153.6 (IC, Q), 135.4 (1C, Q), 129.5 (2C, CH), 
129.0 (2C, CH), 127.4 (IC, CH), 66.3 (1C, CH 2), 55.3 (IC, CH), 38.0 (1C, CH 2), 
29.3 (IC, Cl-I2), 8.4 (1C, CH3); m/z (FAB) 234 ([M + H], 96%), 218 (48), 178 (89), 
117 (76), 91(78); HRMS (FAB) (Found: [M + H], 234.1136. C13H16NO3 requires 
m/z 234.1130). 







To a solution of propionate equivalent 91(0.202 g, 0.858 mmol) in CFI 2 C1 2 (3 cm 3) 
at 0 °C was added, dropwise, dibutylboron triflate (0.92 cm 3 , 1.0 M in CH202, 0.92 
rnmol) followed by triethylamine (0.10 g, 0.13 cm 3 , 0.95 mmol). The solution was 
stirred at 0 °C for 15 mm, then cooled to -78 °C and a -78 °C solution of aldehyde 31 
(0.200 g, 0.557 mmol) in CH2C12 (3 cm  3)  was added dropwise via cannula. The 
reaction mixture was stirred at -78 °C for 1 hour, and allowed to warm to 0 °C over a 
period of 4 h. The reaction was quenched at 0 °C by the addition of methanol (5 cm3 ) 
followed by pH 7 phosphate buffer (1 cm 3). Hydrogen peroxide (30% aq. solution; 
5 cm  in methanol (5 cm  3)  was added dropwise to the solution and the mixture was 
stirred and allowed to warm to room temperature over Ca. 1 hour. The organic phase 
was separated and the aqueous phase was extracted with CH 2 Cl2 (3 x 20 cm3); the 
combined organic phase was washed sequentially with saturated aq. sodium 
bicarbonate (25 cm3) and brine (25 cm) then dried, and concentrated under reduced 
pressure. The residue was chromatographed using preparative HPLC [hexane:EtOAc 
(7:3)] to give 90 (0.144 g, 87%) as an oil, Rf [hexane:EtOAc (7:3)] 0.40; R 
[hexane:EtOAc (7:3)] = 11.08 minutes; [aiD -48.7 (c 2.00, CHC13); Vm (neat)/cm' 
3370, 2929, 1773, 1703, 1612, 1511; 8 H (200 MHz; CDC1 3) 7.36-6.90 (17H, m, 
ArT!), 6.87 (2H, d, J 8.7, ArT!), 4.65-4.58 (2H, m, C 4H + 011), 4.22-4.09 (2H, m, 
C5H2), 3.91 (1H, dd, J 9.0, 2.5, C3 .H), 3.87 (2H, d, J 12.8, NCHA HBPh x 2), 3.81 
(3H, s, OMe), 3.72 (1H, qd, J 6.9, 2.5, C2 'H), 3.40 (2H, d, J 12.8, NCI-I AHBPh x 2), 
3.33 (1 H, dd, J 13.3, 3.0, C4HCHMHNPh), 3.13-2.97 (2H, m, C4 H+ C5'HxHy), 2.85-
2.76 (1H, m, C5'HxHy), 2.67 (1H, dd, 1 13.3, 10.0, C4HCHMHNPh), 0.61 (3H, d, I 
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6.9, C2 'I-IMe); öc (62.9 MHz, CDC1 3) 175.3 (IC, Q), 158.5 (1C, Q), 153.8 (1C, Q), 
139.0 (2C, Q), 136.0 (1C, Q), 132.3 (1C, Q), 130.7 (2C, CH)), 129.9 (2C, CH), 129.5 
(4C, CH), 129.3 (2C, CH), 129.0 (4C, CH), 127.8 (2C, CH), 127.7 (IC, CH), 114.4 
(2C, CH), 70.5 (IC, CH), 66.6 (IC, CH 2), 61.6 (IC, CH), 56.4 (IC, CH3), 55.7 (1C, 
CH), 54.3 (2C, CH2), 40.6 (IC, CH), 38.1 (1C, CH2), 31.2 (1C, CH 2), 8.7 (IC, CH3); 
rn/z (FAB) 593 ([M + H], 59%), 307 (16), 154 (100), 136 (70), 121 (16), 91(51); 






NBn2  Me 
To a solution of aldol adduct 90 (0.281 g, 0.475 mrnol) in THF (20 cm 3 ) at 0 °C was 
added methanol (0.076 g, 0.096 cm 3 , 2.4 mmol) and LiBH4 (0.052 g, 1.1 rnmol). The 
solution was warmed to room temperature and stirred for 18 hours then re-cooled to 
0 °C and quenched by the addition of I M aqueous sodium hydroxide (2 cm 3). The 
organic phase was separated, and the aqueous phase was extracted with CH 202 (3 x 
20 cm 3);  the combined organic phase was washed with brine (30 cm 3), dried, and 
concentrated under reduced pressure. The residue was chromatographed on silica gel 
[hexane:EtOAc (7:3)] to give the diol 89 (0.162 g, 82%) as an oil, R f [hexane:EtOAc 
(7:3)] 0.12; [aID -31.72 (c 1.95, CHC13); Vm (neat)/cm' 3397, 3027, 2933, 1611, 
1583, 1512; 8 1, (250 MHz; CDC13) 7.34-7.10 (IOH, m, Ark]), 7.13 (2H, d, J 8.7, 
ArR), 6.88 (2H, d, J 8.7, Ar!!), 4.74 (1 H, s, CHOII), 3.90-3.78 (1 H, m, CA, 3.88 
(2H, d, J 12.7, NCH4HBPh x 2), 3.82 (3H, s, OMe), 3.68 (1H, dd, J 10.6, 4.2, 
CLIMHNOH), 3.58 (1H, dd, J 10.6, 6.0, CHMHOH), 3.36 (2H, d, J 12.7, NCHAHBPh 
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x 2), 3.07-2.97 (IH, m, C4FT), 3.02 (IH, dd, J 17.2, 9.1, C 5IIHy), 2.67 (IH, S, 
CH20H), 2.55 (1 H, dd,.J 17.2, 8.4, C 5HxHy), 1.52 (1H, m, CA,  0.39 (3H, d,J6.8, 
C14JvIe); öc (62.9 MHz, CDC1 3) 158.0 (IC, Q), 138.4 (2C, Q), 131.7 (1C, Q), 130.0 
(2C, CH), 129.0 (4C, CH), 128.3 (4C, CH), 127.2 (2C, CH), 113.9 (2C, CH), 71.6 
(IC, CH), 67.6 (IC, CH 2), 60.3 (1C, CH), 55.1 (IC, CH3), 53.5 (2C, CH 2), 35.8 (IC, 
CH), 31.7 (IC, CH 2), 8.2 (1C, CH3); m/z (FAB) 420 ([M -I- H]+, 67%), 330 (66), 298 
(62), 240 (21), 208 (15), 121 (75), 91 (100); HRMS (FAB) (Found: [M + H], 
420.2538. C2 7 H34NO3 requires m/z, 420.2539). 
(2R,3R,4S)-1 ,1 -dibenzyl-3-hydroxy-2-(4-methoxybenzyl)-4-methylpyrrolidinium 
chloride 92 
Bn Bn 	I 
CI° 
rvieo( 1 	I 
HO 	Mel 
To a solution of the diol 89(0.125 g, 0.297 mmol) in CH20 2 (10 cm3) at 0 °C was 
added DMAP (0.163 g, 1.34 mmol) and TsC1 (0.170 g, 0.892 mmol). The solution 
was stirred for 18 hours then diluted with CH202 (25 cm3) and water (25 cm 3 ). The 
organic phase was separated and washed with 1% aqueous hydrochloric acid (2 x 25 
cm3) then dried and concentrated under reduced pressure. The residue was 
chromatographed on silica gel {CH2C1 2 :MeOH (100:0) —> (95:5)] to give a white 
foam. The salt obtained was subjected to ion exchange chromatography [Dowex Cl -; 
prepared by treatment of Dowex I -X2 with 1% aqueous hydrochloric acid followed 
by flushing with methanol until the eluent returned to pH 7)] eluting with methanol 
to give the chloride salt 92 (0.108 g, 83%) as an amorphous solid, R f [CH2 C12 :MeOH 
(95:5)] 0.05; [aID -41.3 (c 3.08, CHC13); Vm (neat)/cm 3182, 2960, 1612, 1513; 6H 
(360 MHz; CDC1 3) 7.76 (2H, d, 17.0, Art!), 7.44-7.30 (1 OH, m, Art!), 6.83 (1H, d, I 
3.6, C3 HOII), 6.69 (2H, d, J8.6, ArH), 5.78 (1 H, d, J 13.4, NCHAHBPh), 5.24 (1H, 
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d, J 13.0, NCH xHyPh), 5.09 (IH, d, J 13.0, NCHxHyPh), 4.14 (111, d, J 13.4 
NCHAHBPh), 3.95-3.92 (2H, m, C 3H + CHA HBAr), 3.69 (311, s, OMe), 3.66-3.56 
(2H, m, CHAHBAr + C5HAI -IB), 3.31-3.28 (1H, m, C211), 3.26-3.04 (IH, m, C411), 
2.56 (1 H, br t, J 11. 1, C5HAHB), 0.91 (3H, d, J6.8, C4HMe); 8c (62.9 MHz; CDC13) 
158.2 (1C, Q), 133.4 (2C, CH), 133.2 (2C, CH), 130.5 (3C, CH), 130.2 (IC, CH), 
129.1 (2C, CH), 129.0 (2C, CH), 127.8 (IC, Q), 127.4 (1C, Q), 126.8 (IC, Q), 113.9 
(2C, CH), 74.4 (1C, CH), 74.3 (IC, CH), 61.2 (1C, CH 2), 60.6 (1C, CH2), 59,9 (IC, 
CH2), 5 5. 0 (IC, CH 3), 38.7 (IC, CH), 26.8 (1C, CH 2), 17.0 (IC, CH3); m/z (FAB) 
402 ([M], 66%), 312 (65), 190 (63), 121 (76), 91(100); HRMS (FAB) (Found: 







A solution of the chloride salt 92 (0.044 g, 0.10 mmol) and Pearlman's catalyst 
[0.044 g; 20% Pd(OH)2/C} in methanol (5 cm 3)  was exposed to a hydrogen 
atmosphere (I atm) and stirred vigorously for 24 hours. The mixture was then 
filtered through a pad of Celite and concentrated under reduced pressure to give 95 
(0.026 g, 100%) as a white solid, mp 191-192 °C; [ct] 0 +33.3 (c 0.27, CH30H); 
Vm (KBr)/cm' 1 3356, 2956, 2920, 1614, 1577, 1516; oH (250 MHz; CD30D) 7.40 
(2H, d, J 8.1, ArR), 7.03 (2H, d, J 8.1, Ark!), 4.05 (1H, br s, C 34), 3.90 (3H, s, 
OMe), 3.84-3.83 (1 H, m, C 211), 3.74 (1 H, dd, J 11.4, 7.5, C 5H,4 HB), 3.27 (1 H, dd, J 
14.2, 6. 1, CHxHyAr), 3.05 (1 H, dd, J 14.2, 8.6, CHxHyAr), 2.97 (111, dd, J 11.4, 3.2, 
C5HAHB), 2.24-2.12 (1H, m, Cd]), 1.19 (3H, d, J 7.3, C4HMe); 5,. (62.9 MHz; 
CD 30D) 157.9 (IC, Q), 128.7 (2C, CH), 127.4 (IC, Q), 112.9 (2C, CH), 74.5 (1C, 
CH), 63.1 (1C, CH), 53.2 (1C, CM 3), 48.6 (IC, CH2), 39.7 (IC, CH), 30.1 (1C, CH2), 
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15.1 (1C, CH3); m/z (FAB) 222 ([M + H], 68%), 206 (47), 134 (52), 121 (40), 91 






The HCl salt 95 was subjected to ion-exchange chromatography [Dowex OH] 
(prepared by treating Dowex 1 -X2 with 1 M aqueous NaOH, followed by methanol 
until the pH of the eluent returned to 7). Eluting with methanol gave the free base 
(quantitative recovery) as a white solid, Rf [CH2C12:MeOH (95:5)] 0.04; mp 108-110 
°C; [a}o +5.7 (c 0.35, CH30H); 	(KBr)/cm1 3420, 3260, 2951, 1612, 1584, 
1512; 6H (250 MHz; CD 3 0D) 7.28 (2H, d, J8.7, ArH), 6.92 (2H, d, J8.7, ArH), 3.84 
(3H, s, OMe), 3.71 (1H, dd, J 2.4, 1.7, C3 H), 3.37 (1H, dd, J 11. 1, 7.8, CSHA HB), 
3.19-3.11 (1 H, m, C211) 2.99 (1H, dd, J 13.6, 6.8, CH MHNAr), 2.74 (1H, dd, J 13.6, 
7.6, CHAIHNAr), 2.38 (1H, dd, 1 11.1, 5.7, C S HAHB), 2.24-2.15 (1H, m, C411), 1.07 
(3H, d, 17.2, C4HMe); ö (62.9 MHz; CD30D) 157.7 (1C, Q), 131.2 (1C, Q), 129.1 
(2C, CH), 112.9 (2C, CH), 77.9 (1C, CH), 63.1 (1C, CH), 53.7 (1C, CH 3), 50.9 (1C, 
CH2), 41.7 (1C, CH), 33.3 (1C, CH2), 16.5 (1C, CH3 ); rn/z (FAB) 222 ([M + 
100%), 121 (17), 91 (95), 57 (66); HRMS (FAB) (Found: [M + H], 222.1495. 







To a solution of the chloride salt 92 (0.0782 g, 0.178 mmol) in methanol (5 cm 
3)  was 
added 5% Pd/C (0.0078 g) and potassium carbonate (0.074 g, 0.54 mmol). The 
mixture was exposed to a hydrogen atmosphere (1 atm) and stirred vigorously for 20 
minutes. The suspension was filtered through a pad of Celite and concentrated under 
reduced pressure. To the residue was added CH 202 (25 cm3 ) and water (25 
CM)  . The 
organic phase was separated and the aqueous phase was extracted with CH 202 (3 x 
20 cm 3);  the combined organic phase was washed with saturated aq. sodium 
bicarbonate (50 cm 3)  then dried and concentrated under reduced pressure. The 
residue was chromatographed on silica gel [hexane:EtOAc (7:3)] to give pyrrolidine 
88 (0.0518 g, 93%) as an oil, Rf [hexane:EtOAc (1:1)] 0.33; [aID -78.3 (c 1.5, 
CHC1 3 ); Vmax (neat)/cm' 3419, 2954, 1611, 1583, 1512, 1246; 8H  (250 MHz; CDC1 3) 
7.33-7.23(511, m, ArIf), 7.26 (2H, d,J8.7, An!), 6.85 (2H, d,.J8.7, ArH), 4.10 (1H, 
d, J 12.7, NCH.4HBPh), 3.78 (311, s, OMe), 3.50 (1H, dd, J4.7, 2.6, C31!), 3.16 (1 H, 
d, J 12.7, NCHAHBPh), 113 (in, dd, .19.4, 7.9, C 5HSHT), 2.94 (1H, dd,.1 13.4, 8.9, 
CHxHyAr), 2.87 (111, dd, J 13.4, 5.3, CHxHyAr), 2.57 (111, dt, .18.9, 5.0, CA,  2.35 
(I H, hr s, 011), 2.03-1.94 (1 H, m, C 4!!), 1.67 (1H, dd, .19.4, 7.9, C S HsHT), 0.91 (311, 
d, J7.i, CH-Me); 8., (62.9 MHz; CDC13) 157.8 (IC, Q), 138.6 (1C, Q), 131.4 (1C, Q), 
130.1 (2C, CH), 128.8 (2C, CH), 128.1 (2C, CH), 126.9 (IC, CH), 113.7 (2C, CH), 
78.8 (IC, CH), 69.3 (1C, CH), 60.2 (1C, CH2), 58.2 (IC, CH 2), 55.1 (1C, CH3), 40.1 
(1C, CH), 32.9 (1C, CH2), 18.0 (1C, CH3); m/z (FAB) 312 ([M + H] 4 , 73%), 190 
(65), 121 (41), 91(100); HRMS (FAB) (Found: [M + H], 312.1963. C2 0H26NO2 
requires m/z 312.1964). 
153 
Experimental 
(2R,3R,4S)-3-Acetoxy- 1 -benzyl-2-(4-methoxybenzyl)-4-methylpyrro lid ine 93 
Bn 
MeO 
JD"~ 2 3 5 
AcO 	Me 
To a solution of the alcohol 88 (0.0322 g, 0.104 mmol) in CH 2C12 (5 cm  3)  was added 
freshly distilled acetic anhydride (0.021 g, 0.020 cm 3 , 0.21 rnmol), and triethylarnine 
(0.021 g, 0.030 cm3 , 0.21 mmol). The solution was stirred for 18 hours before being 
diluted with CH202 (10 cm 3) and saturated aq. sodium bicarbonate (20 cm 3 ). The 
organic phase was separated and the aqueous phase was extracted with CH 202 (3 x 
10 cm  3);  the combined organic phase was dried and concentrated under reduced 
pressure. The residue was chromatographed on silica gel [hexane:EtOAc (7:3)] to 
give the ester 93 (0.0300g, 82%) as a colourless oil, R f [hexane:EtOAc (7:3)] 0.31; 
[a]0 -73.96 (c 0.70, CHC1 3); Vmax (neat)/cm' 2959, 2789, 1734, 1612, 1512 cm - 1 ; 6H 
(250Hz; CDC13), 7.31-7.22 (51-1, m, AnT), 7.10 (2H, d, J 8.6, ArH), 6.80 (2H, d, J 
8.6, ArH), 4.62-4.58 (1H, m, C 3H), 3.96 (11-1, d, J 12.9, NCH,HyPh), 3.77 (31-1, s, 
OMe), 3.24 (1H, d, .1 12.9, NCHxHyPh), 3.12 (1H, dd, J 9.3, 7.5, C5HAIHN), 2.94-
2.80 (2H, m, CHAHBAr+ C2H), 2.83 (1H, dd, J 14.2, 8.9, CHAHBAr), 2.11-2.03 (1 H, 
M, C4!]), 2.06 (31-1, s, COCLI3), 1.80 (1H, t, J9.3, C5HMHN), 0.99 (3H, d, J 7.0, 
C41-IMe); 6, (62.9 Hz; CDC13) 170.8 (1C, Q), 157.9 (IC, Q), 138.3 (1C, Q), 131.1 
(IC, Q), 129.8 (2C, CH), 129.1(2C, CH), 128.2 (2C, CH), 127.0 (IC, CH), 113.8 
(2C, CH), 80.9 (1 C, CH), 67.1 (1C, CH), 60.0 (IC, Cl-I 2), 58.8 (1C, CH2), 55.2 (IC, 
CH3), 38.3 (1C, CH), 33.8 (IC, CM2), 21.2 (IC, CH3), 17.1 (1C, CH3); m/z (FAB) 
354 ([M + HJ, 39%), 352 (52), 294 (34), 232 (63), 172 (28), 121 (75), 91(100); 







To a solution of the pyrrolidine 93 (0.0407 g, 0.115 mmol) and Peariman's catalyst 
[0.0407 g; 20% Pd(OH)2/C1 in methanol (5 cm 3)  was added hydrochloric acid (0.23 
cm3 , I M in ether, 0.23 mmol). The solution was exposed to a hydrogen atmosphere 
(1 atm) and stirred vigorously for 18 hours. The mixture was then filtered through a 
pad of Celite and concentrated under reduced pressure to give the hydrochloride salt 
94 (0.0341 g, 100%) as a colourless oil, [aID +20.0 (1.35, CH30H); Vm (neat)/cm' 
3398, 2934, 1740, 1612, 1582, 1514 cm'; 6H  (250Hz; CD 3 0D), 7.33 (2H, d, 17.9, 
ArH), 7.01 (2H, d, J7.9, ArH), 5.05 (1H, br s, CH). 4.15 (1H, br s, C-) M, 3.87 (3H 5 
s, OMe), 3.73 (IH, m, CHHy ), 3.19-3.04 (3H, m, CHA HBAr + CHA HBAr + 
C5HxHy), 2.63 (IH, br s, C 4H), 2.26 (3H, s, COCH3), 1.26 (3H, d, 16.7, CFIMe); 
(62.9 MHz; CD 3 0D) 170.2 (1C, Q), 159.4 (IC, Q), 130.0 (2C, CH), 127.8 (1C, 
Q), 114.4 (2C, CH), 78.5 (1C, CH), 62.9 (IC, CH), 54.7 (1C, CH3) 50.1 (IC, CH 2) 
39.3 (1C, CH), 31.4 (1C, CH 2), 19.8 (1C, CH 3), 16.3 (1C, CH 3); m/z (FAB) 264 ([M 
+ H], 100%), 204 (60), 142 (19), 121 (49); HRMS (FAB) (Found: [M + H], 
264.1593. [C 1 5 H22No3]Cr requires m/z 264.1600). 
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To a solution of methyl ester 41 (1.97 g, 5.06 inmol) in tetrahydrofuran:water 
(30 cm3 [4:1]) was added lithium hydroxide (1.06 g, 25.3 mmol). The solution was 
heated to reflux and held there for 18 hours, and then acidified to pH 2. The organic 
phase was separated, and the aqueous phase was extracted with CH 2Cl2 (3 x 25 cm3). 
The combined organics were washed with water (20 cm 3), dried, and then 
concentrated under reduced pressure to give acid 104 (1.81 g, 95%) as a foam, which 
was used in the Claisen condensation reaction without further purification, R f 
[hexane: EtOAc (7:3)] 0.3; [aI D +25.8 (c 0.6, CHC1 3) [lit.(ent-104),' 43 [aID —31.4 (c 
1.0, CHCI3)]; Vm (neat)/cm' 3029, 2934, 2835, 1704, 1612, 1513; 6H (360MHz; 
CDCI3) 9.25 (1H, br s, OH), 7.29-7.25 (1 OH, m, Ar!!), 7.11 (2H, d, J8.4, ArR), 6.82 
(2H, d,J8.4, ArH), 4.00-3.82 (4H, in, NCHHPh x 2 +NCH xHyPh x 2), 3.86-3.83 
(I H, m, CA,  3.78 (3H, s, OMe), 3.30 (1 H, dd, J 14.5, 6.3, C3HAHB). 3.17 (1H, dd, J 
14.5, 8.5, C 3HA HB); & ( 62.9 MHz; CDC1 3 ) 175.5 (1C, Q), 158.2 (1C, Q), 137.3 (2C, 
Q), 130.2 (2C, CH), 129.8 (1C, Q), 128.9 (4C, CH), 128.4 (4C, CH), 127.5 (2C, CH), 
113.7 (2C, CH), 62.9 (IC, CH), 55.2 (1C, CH3), 54.4 (2C, CH2), 33.3 (IC, CH2); m/z 
(FAB) 367 ([M + H], 83%), 330 (22), 254 (40), 154 (38), 91, (100); HRMS (FAB) 
(Found: [M + H}, 376.1903. C 24H26NO3 requires m/z 376.1913). 
All spectroscopic data was in good agreement with that of the literature, 143 
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To a solution of the acid 104 (1.81 g, 4.83 mmol) in THF (20 cm 3 ) was added 
carbonyldiimidazolide (1.56 g, 9.65 mmol). The mixture was stirred for 2.5 hours, 
and then cooled to -78 °C. Meanwhile a separate flask containing ethyl acetate (1.65 
cm 3,  1.49 g, 16.9 mmol) was cooled to -78 °C, and lithium hexamethyldisilazide, 
(15.9 cm3 , 1.06 M in THF, 16.9 mmol) was added. The solution was stirred at -78 °C 
for 20 minutes and then transferred to the flask containing the imidazole via cannula. 
The combined solution was stirred at -78 °C for 2 hours and then quenched by the 
addition of 1% HC1 (20 cm 3) and diluted with CH202 (20cm). The organic phase 
was separated and the aqueous phase was extracted with CH 202 (3 x 75 cm3); the 
combined organics were washed sequentially with water (100 cm 3) and brine (100 
cm 3)  then dried, and concentrated under reduced pressure. The residue was 
chromatographed on silica gel [hexane:EtOAc (95:5)] to give 99 (1.76 g, 82%) as a 
white solid, Rf [hexane:EtOAc (10:1)] 0.32; mp 83-85 °C; [aI D +75.3 (c 1.0, 
CHCI3); Vmax (KBr)/cm 1 2936, 1745, 1716, 1612, 1584, 1513; 811 (360MHz; CDC13) 
7.36-7.19 (101-I, m, ArH). 7.05 (2H, d, .J 8.7, AnT), 6.78 (2H, d, J 8.7, ArH), 4.01 
(2H, q, J 7.2, OCH2CH3), 3.83 (2H, d, J 13.5, NCHHyPh x 2), 3.76 (3H, s, OMe), 
3.65 (1H, d, J 15.8, C2HAHB), 3.59 (11-1, dd, J 9.3, 3.7, CH), 3.54 (2H, d, J 13.5, 
NCHHyPh x 2), 3.34 (1 H, d, J 15.8, C2HAHB), 3.13 (1 H, dd, J 13.6, 9.3, C5HSHT), 
2.89 (IH, dd, J 13.6, 3.7, C5 HsHr), 1.09 (3H, t, J 7.2, OCH2CH3); 6, (62.9 MHz; 
CDC13) 202.2 (IC, Q), 167.1 (1C, Q), 157.8 (1C, Q), 138.6 (2C, Q), 130.9 (IC, Q), 
130.3 (2C, CH), 128.9 (4C, CH), 128.4 (4C, CH), 127.3 (2C, CH), 113.7 (2C, CH), 
68.3 (1C, CH), 60.9 (IC, CH2), 55.1 (1C, CH3), 54.4 (2C, CH2), 46.6 (1C, CH 2), 27.4 
(1C, CH2), 13.8 (IC, CH 3); (Found : C, 75.19; H, 6.83; N, 3.11. C28H 31 N04 requires 
C, 75.51; H, 6.97; N, 3.15%). 
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Ethyl (3R,4R)-4-dibenzylamino-3-hydroxy-5-(4-methoxyphenyl)pentaflOate 98 









To a solution of 13-keto ester 99 (1.54, 3.47 mmol) in ether (30 cm3 ) was added 
methanol (6.59 cm. 3 , 5.21 g, 163 nimol). The solution was adjusted to pH 4 by the 
addition of a few drops acetic acid, and then cooled to 0 °C. Sodium 
cyanoborohydride (2.15 g, 34.6 mmol) was added cautiously and the mixture was 
allowed to warm to room temperature. The solution was stirred for 18 hours and then 
quenched by the addition of a saturated aqueous solution of ammonium chloride (20 
cm3 ). The organic phase was separated and the aqueous phase was extracted with 
CH2C12 (3 x 75 cm3 ). The combined organics were dried, and concentrated under 
reduced pressure. The remaining residue was chromatographed on silica gel 
[hexane:EtOAc (9:1)] to give 98(1.28 g, 83%) and 105 (0.0307 g, 2%) both as oils, 
Data for (3R,4R) diastereomer 
98: obtained (1.28 g, 83%) as a colourless oil, 
Rf [hexane:EtOAc (10:1)] 0.38; [all)  -36.0 (c 2.2, CHC13); Vmax (neat)/cm' 3591, 
3025, 2933, 1731, 1611, 1581, 1511; 61-1 (360MHz; CDC1 3) 7.35-7.25 (10H, m, 
ArH), 7.11 (2H, J 8.5, ArH), 6.88 (2H, d, J 8.5, ArT!) 4.11-4.05 (2H, m, NCH 4 H B Ph 
x 2), 4.08 (2H, q, J 7.2, OCH2CH3), 4.01-3.98 (1H, m, C 3 1-1), 3.81 (3H, s, OMe), 
3.44 (2H, d, J 13.4, NCHAHBPh x 2), 3.11-3.09 (1 H, m, C411), 2.82-2.74 (2H, m, 
C5HHy + C5 HxHy), 2.39 (1H, dd, J 15.7, 9.6, C2HSHT), 2.12 (IH, br d, J 15.7, 
C2HsH7-), 1.21 (3H, t, J7.2, OCH2CH3); & (62.9 MHz; CDCI3) 172.7 (1C, Q), 157.9 
(IC, Q), 139.1 (2C, Q), 131.7 (IC, Q), 129.9 (2C, CH), 128.9 (4C, CH), 128.3 (4C, 
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CH), 127.1 (2C, CH), 113.9 (2C, CH), 67.8 (1C, CH), 62.9 (1C, CH), 60.4 (1C, 
CH2), 55.1 (1C, CH3), 54.3 (2C, CH2), 39.7 (1C, CH 2), 29.9 (IC, CH2), 14.0 (1C, 
CH3); m/z (FAB) 448 ([M + H], 97%), 330 (88), 326 (89), 121 (37), 91(100); 
HRMS (FAB) (Found: [M + H], 448.2480. C 28 H34N04 requires m/z 448.2488); 
Chiral HPLC (R enantiomer) Rt = 16.0 minutes, (S enantiomer) Rt = 24.4 minutes 
[hexane-propan-2-ol (19: 1)], >98% ee. 
Data for (3S,4R) diastereomer 105: 
Obtained (0.0307 g, 2%) as a colourless oil, 
Rf [hexane:EtOAc (10:1)] 0.34; [aI D -25.9 (c 0.81, CHC13); Vm (neat)/cm 3501, 
2934, 2833, 1728, 1612, 1584, 1512; 8F1  (200 MHz; CDC1 3) 7.39-7.25 (IOH, m, 
Ar/f), 7.20 (2H, d, J 8.8, ArH) 6.92 (2H, d, J 8.8, Ar!!) 4.33-4.25 (1H, m, C311), 
4.18 (2H, q, J7.0, OCH2CH3), 3.90 (31-I, s, OMe), 3.82 (2H, d, J 13.7, NCHAHBPh x 
2), 3.68 (21-I, d, J 13.7, NCHAHBPh x 2), 3.19-2.97 (2H, m, C4H± C 5HHy), 3.10 
(1H, dd, .J 9.0, 6.3, C5HxHy), 2.80 (1H, dd, 1 16.4, 2.7, C2HSHT), 2.38 (1H, dd, J 
16.4, 9.8, C2HSHT), 1.32 (3H, t, 17.0, OCH 2CH3); 8, (62.9 MHz; CDC1 3) 173.4 (1C, 
Q), 158.0 (IC, Q), 139.7 (2C, Q), 133.1 (1C, Q), 130.5 (2C, CH), 128.9 (4C, CH), 
128.4 (4C, CH), 127.1 (2C, CH), 113.9 (2C, CH), 69.2 (1C, CH), 63.0 (1C, CH), 
60.8 (IC, CH2), 55.5 (1C, CH3), 54.8 (2C, CH2), 39.7 (IC, CH2), 31.5 (IC, CH2), 
14.3 (1C, CH3); m/z (FAB) 448 ([M + H] +, 88%), 330 (96), 326 (96), 121 (78), 91 








A solution of ethyl ester 98 (0.697 g, 1.56 mrnol) in THF (30 cm 3 ) was placed at 
-78 °C and lithium aluminium hydride (7.8 cm 3 , 1.0 M in THF, 7.8 mmol) was 
added. The solution was stirred at -78 °C for 6 hours then quenched by the addition 
of 1 M aqueous sodium hydroxide (10 cm 3). The resulting mixture was allowed to 
warm to room temperature and diluted with CH202 (20 cm 3).  Saturated aq. sodium 
potassium tartrate (40 cm 3)  was added and the biphasic mixture was stirred 
vigorously for 15 hours by which time two clear phases were apparent. The organic 
phase was separated and the aqueous phase was extracted with CH 202 (3 x 50 cm3 ). 
The combined organics were dried, and concentrated under reduced pressure. The 
remaining residue was chromatographed on silica gel [hexane:EtOAc] (7:3 —* 1:1)] 
to give 97(0.598 g, 95%) as an oil, Ri [hexane:EtOAc (3:1)] 0.33; [aI D -38.3 (c 1.7, 
CHC13); Vm (neat)/cm' 3388, 3028, 2933, 2835, 1612, 1583, 1512; 6H  (250 MHz; 
CDC13) 7.39-7.18 (1 OH, m, ArH), 7.12 (2H, d,J8.7, Ar!]), 6.88 (2H, d,J8.7, ArH), 
4.80 (1H, s, 01-1), 3.90 (21-I, d, J 13.2, NCH4H8Ph x 2), 3.82 (3H, s, OMe), 3.77 (1H, 
dd. J 8.9, 2.7, C3H'), 3.65 (2H, br s, CH20H), 3.39 (2H,d, J 13.2, NCH AHBPh x 2), 
3.08 (1 H, dd, J 14.3, 6.4, C5HxHy), 2.89 (1H, td, J 6.4, 2.7, C411), 2.60 (1H, dd, J 
14.3, 6.4, C5 HxHy), 1.82 (1H, s, C 3 HOH), 1.65-155 (1H, m, C 2HSHT), 1.35-1.23 
(1H, m, C 2HSHT); ö (62.9 MHz; CDC1 3 ) 158.0 (1C, Q), 138.5 (2C, Q), 131.8 (IC, 
Q), 129.9 (2C, CH), 128.9 (4C, CM), 128.4 (4C, CH), 127.2 (2C, CH), 113.9 (2C, 
CH), 70.5 (1C, CH), 63.8 (IC, CH), 61.2 (1C, CH 2), 55.1 (1C, CH 3), 53.6 (2C, CH2), 
35.6 (1C, CH 2 ), 31.1 (IC, CH2); rn/z (FAB) 406 ([M + H] +, 69%),330 (71), 284 (69), 








T Ne cP 
HO 
To a solution of the alcohol 97 (0.587 g, 1.45mmol) in CH2Cl2 (20 cm 3) at 0 °C was 
added DMAP (0.292 g, 2.39 mmol) and triisopropylbenzene sulfonyl chloride 
(TIBSCI) (0.483 g, 1.59 mmol). The solution was stirred for 18 hours before being 
diluted with CH 2Cl2 (20 cm 3 ) and water (25 CM)  . The organic phase was separated 
and washed with 1% HC1 (2 x 30 cm 3)  then dried and concentrated under reduced 
pressure. The residue was chromatographed on silica gel [CH 2Cl2 :MeOH (100:0) -> 
(95:5)] to give a white foam. The salt obtained was subjected to ion exchange 
chromatography [Dowex Cl -; prepared by treating Dowex I -X2 with % aqueous 
hydrochloric acid followed by flushing with methanol until the eluent returned to pH 
7] eluting with methanol to give the chloride salt 108 (0.520 g, 85%) as an 
amorphous solid, Rf [CH 2 C12 :CH30H (95:5)] 0.07; [all)  -55.2 (c 0.75, CHC13 ); V",ax  
(neat)/cm -1 3198, 1611, 1584, 1513; 8H  (360 MHz; CDC1 3) 7.78-7.29 (10H, m, An]), 
7.33 (2H, d, J 8.5, An]), 6.74 (1 H, s, OH), 6.67 (2H, d, J 8.5, AnT), 5.72 (1H, br d, J 
13.5, NCHxHyPh), 5.12 (ill, d, J 13.1, NCHAHBPh), 5.07 (1H, d, J 13.1, 
NCHAHBPh), 4.34 (1H, br s, C31f), 4.28 (1H, d, J 13.5, NCHxHyPh), 3.97 (1 H, br d, 
J 12.0, CHSHTAr), 3.92-3.86 (1H, m, C5HMHN), 3.69 (3H, s, OMe). 3.56 (1H, br t, J 
12.0, CH SHTAr), 3.39 (1H, br t, J 10.5, C211), 3.10 (1H, dt, 11.3, 8.3, C5HMHJV), 2.63 
(1H, dt, 14.6, 7.3, C4HEHF), 1.95-1.87 (1H, m, C4HEHF);  E (62.9 MHz; CDC1 3 ) 
158.9 (1C, Q), 134.1 (2C, CH), 133.6 (2C, CH), 131.2 (2C, CH), 131.1 (1C, CH), 
130.8 (1C, Q), 129.8 (2C, CH), 129.6 (2C, CH), 128.6 (IC, CH), 128.0 (1C, Q), 
127.9 (1C, Q), 114.5 (2C, CH), 76.7 (IC, CH), 68.2 (IC, CH), 63.1 (1C, CH2), 62.4 
(IC, CH2), 56.3 (1C, CH2), 55.5 (IC, CH3), 31.9 (IC, CH 2) 28.1 (1C, CH2); m/z 
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(FAB) 388 ([M]', 98%), 296 (48), 210 (24), 176 (71), 91(100); HRMS (FAB) 
(Found: [M], 338.2267. [C 26H30NO21 +C1 requires m/z 388.2277). 





	 No PF 
HO 
To a solution of the alcohol 97 (0.458 g, 1.13 mmol) in CH2Cl2 (20 cm3) at 0 °C was 
added DMAP (0.228 g, 1.86 mmol) and TIBSC1 (0.377 g, 1.24 mmol). The solution 
was stirred for 18 hours before being diluted with CI-I 2Cl2 (20 cm 3) and water (25 
cm3). The organic phase was separated and washed with 1 01/0 HCI (2 x 30 cm) then 
dried and concentrated under reduced pressure. The residue was chromatographed on 
silica gel {CH 2C12:MeOH (100:0) —+ (95:5)] to give a white foam. The salt obtained 
was subjected to ion exchange chromatography [Dowex PF 6 ; prepared by treating 
Dowex 1 -X2 with 1% aqueous hexafluorophosphoric acid followed by flushing with 
methanol until the eluent returned to pH 7] eluting with methanol to give the 
hexafluoride salt 110 (0.420 g, 70%) as a white solid. Recrystallisation from 
methanol provided an analytical sample, Rf [CH 2C12 :CH30H (95:5)] 0.05; mp 211-
212 °C; [c]ij -38.44 (c 1.9, (CH02C0); Vm (KBr)Icm' 3581, 3419, 2962, 1613, 
1586, 1513; 8H  (360 MHz; (CD3)2C0) 7.87-7.55 (1 OH, m, An]), 7.40 (214, d,J8.8, 
ArH), 6.95 (211, d, J8.8, ArH), 5.28 (1H, d, J 13.3, NCHxHyPh), 5.18 (1 H, d, J 13.4, 
NCHcH rPh), 4.89 (1H, d, J 13.3, NCHxHyPh), 4.69 (1H, d, J 13.4, NCHSHTPh), 
4.50 (1 H, br s, C3H), 4.00 (1 H, ddd, J 12.6, 8.4, 3.3, C5HEHF), 3.82 (3H, s, OMe), 
3.73 (3H, br s, CHMHNAr + CHMHNAr + C2H), 3.57 (IH, br q, J 11.1, CSHEHF), 
2.65-2.56 (IH, m, C41J14H8),  2.42 (1H, dddd, J 12.7, 11.9, 8.4, 2.4 C4HAHB); 5 (62.9 
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MHz; (CD3 )2C0) 158.1 (1C, Q), 132.6 (2C, CH), 132.4 (2C, CH), 129.9 (1C, CH), 
129.8 (2C, CH), 129.4 (2C, CH), 128.5 (1C, CH), 128.4 (2C, CH), 127.2 (IC, Q), 
126.5 (1C, Q), 126.3 (1C, Q), 113.2 (2C, CH), 73.9 (1C, CH), 66.6 (1C, CH), 60.6 
(IC, CH2), 60.1 (IC, CH2), 53.9 (1C, CH 2), 53.8 (1C, CH3), 30.6 (IC, Cl-I2), 25.7 
(1C, CH2); m/z (FAB) 388 ([M], 100%), 296 (11), 176 (24), 154 (47), 136 (41), 91 
(75); HRMS (FAB) (Found: [M], 338.2281. [C26H30NO21+PF6 requires m/z 
388.2277). 





A solution of the chloride salt 108 (0.243 g, 0.574 mmol) and Peariman's catalyst 
[0.243 g; 20% Pd(OH) 2/C] in methanol (7 cm 3) was exposed to a hydrogen 
atmosphere (1 atm) and stirred vigorously for 24 hours. The mixture was then 
filtered through a pad of Celite and concentrated under reduced pressure to give 109 
(0.133 g, 95%) as a white solid, mp 261-263 °C; [a]0+15.2 (c 1. 12, CH30H); Vm 
(KBr)/cm 1 3330, 3302, 2955, 1614, 1556, 1516; 6H  (250MHz; CD30D) 7.35 (2H, d, 
.1 8.7, ArM), 6.99 (2H, d, 1 8.7, ArM), 4.39-4.36 (1 H, m, CA,  3.87 (3H, s, OMe), 
3.67 (1 H, ddd, 1 8.5, 6.6, 2.8, CA,  3.55 (1 H, ddd, J 11. 5, 9.9, 8.2, CSHSHT), 3.57-
3.23 (11-I, m, C 5 H5Hr), 3.24 (111, dd, 1 14.2, 6.6, CR y HyAr), .3.02 (1H, dd, J 14.2, 
8.5, CHxHyAr), 2.32 - 2.10 (2H, m, C 4HMHN + C4HMHN); & (62.9 MHz; CD30D) 
158.4 (IC, Q), 129.2 (2C, CH), 128.0 (1C, Q), 113.4 (2C, CH), 69.1 (1C, CH), 66.0 
(IC, CH), 53.8 (IC, CH3), 42.3 (1C, CH2), 32.2 (1C, CH 2), 30.8 (1C, CH2); in/z 
(FAB) 208 ([M + H], 97%), 154 (100), 136 (85), 121 (15); HRMS (FAB) (Found: 







The HC1 salt 109 was subjected to ion-exchange chromatography [Dowex OH] 
(prepared by treating Dowex I -X2 with I M aqueous NaOH, followed by methanol 
until the pH of the eluent returned to 7). Eluting with methanol gave the free base 
(quantitative recovery) as a white solid, R f [CH2 C1 2 : MeOH (95:5)] 0.06; mp 127-
128 °C; [a]0 -30.9 (c 1.36, CH30H); Vmax (KBr)/cm 3426, 3290, 2961, 1612, 1583, 
1512; 8H  (250 MHz; CD 3 0D) 7.23 (2H, d,J8.7, ArH), 6.87 (2H, d,J8.7, ArH), 4.06 
(1H, ddd, J4.9, 3.1, 1.5, CA,  3.79 (3H, s, OMe), 3.17 (1 H, ddd, J 11. 1, 8.5, 7.5, 
C5HAHB), 2.96 (1 H, dd, J 7.1, 3.2, CHxHyAr), 2.90 (11-I, dd, J 7.1, 2.5, CHxHyAr), 
2.79 (1 H, ddd, J 11. 1, 9.7, 4.7, C5HAHB), 2.85-2.67 (1 H, m, CA,  2.01 (1H, dddd, J 
13.7, 9.7, 7.5, 4.9, C4HMHN), 1.83 (1 H, dddd, J 13.7, 8.5, 4.7, 1.5, C4HMHN); ö (62.9 
MHz; CD 30D) 158.6 (IC, Q), 132.1 (IC, Q), 130.0 (2C, CH), 113.8 (2C, CH), 71.9 
(IC, CH), 66.2 (1C, CH), 54.6 (1C, CH 3), 43.6 (1C, CH2), 35.0 (1C, CH204.1 (1C, 
CH2); m/z (FAB) 208 ([M + H]F, 100%), 190 (11), 121 (27), 91(69); HRMS (FAB) 
(Found: [M + H], 208.1333. C 12H 1 8NO2 requires rn/z 208.1338). 
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To a solution of the chloride salt 108 (0.269 g, 0.634 mmol) in methanol (10 cm3 ) 
was added 5% Pd/C (0.027 g) and potassium carbonate (0.263 g, 1.90 mmol). The 
mixture was exposed to a hydrogen atmosphere (1 atm) and stirred vigorously for 20 
minutes. The suspension was filtered through a pad of Celite and concentrated under 
reduced pressure. To the residue was added CH 202 (25 cm. 3) and water (25 
CM)  . The 
organic phase was separated and the aqueous phase was extracted with CH 202 (3 x 
25 cm  3);  the combined organic phase were washed with water (25 cm 3) and then 
dried and concentrated under reduced pressure. The residue was chromatographed on 
silica gel [hexane:EtOAc (1:1)] to give pyrrolidine 96 (0.150 g, 80%) as an oil, Rf 
[hexane:EtOAc (1:1)] 0.36; [a}D -104.0 (c 1.18, CHC13); Vm (neat)/cm' 3418, 2934, 
1611, 1583, 1512; 8H  (250 MHz; CDC13) 7.41-7.26 (7H, m, ArIf), 6.89 (2H, d, J 8.7, 
An]), 4.20 (11-1, d, J 13.0, NCHAHBPh), 3.96 (1H, br s, CA,  3.83 (3H, s, OMe), 
3.26 (1H, d, J 13.0, NCHAHBPh), 3.05 (1H, dt, J 8.8, 3.7, C2H), 2.98-2.86 (2H, m, 
CHSHTAr + CHSHTAr), 2.49 (1H, ddd, J 8.5, 6.0, 3.7, C5HMHN), 2.20-2.06 (1 H, m, 
C 5 HMHN), 1.99 (1H, ddd, 13.7, 6.4, 3.7 CHi,vHy), 1.75-1.63 (IH, m, C4HxHy); 
E (62.9 MHz; CDC13) 158.4 (IC, Q), 139.4 (IC, Q), 131.9 (IC, Q), 130.7 (2C, CH), 
129.3 (2C, CH), 128.7 (2C, CH), 127.4 (IC, CH), 114.2 (2C 5  CH), 72.5 (1C, CH), 
71.3 (1C, CH), 58.3 (IC, CH 2), 55.7 (IC, CH3), 51.9 (IC, CH203.4 (1C, CH 2), 32.7 
(IC, CH2); m/z (FAB) 298 ([M + H]+, 90%), 176 (93), 154 (62), 91(100); 1-IRMS 
(FAB) (Found: [M + H], 298.1805. C 19H24NO2 requires rn/z 298.1805). 
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To a solution of the alcohol 96 (0.0643 g, 0.216 mmol) in CH 202 (5 cm3 ) was added 
freshly distilled acetic anhydride (0.044 g, 0.041 cm 3,  0.43 mmol), and triethylarnine 
(0.044 g, 0.061 cm3 , 0.43 mrnol). The solution was stirred for 18 hours and then 
quenched by the addition of saturated aq. sodium bicarbonate (20 cm 3). The organic 
phase was separated and the aqueous phase was extracted with CH2C1 2 (3 x 20 cm 3); 
the combined organic phase was dried and concentrated under reduced pressure. The 
residue was chromatographed on silica gel [hexane:EtOAc (7:3)] to give the ester 
111 (0.0638g. 87%) as a colourless oil, Rf [hexane:EtOAc (1:1)] 0.58; [aID-I23.l (c 
0.26, CHC13); V max (neat)/cfli' 2935, 2791, 1733, 1612, 1581, 1513; ö (250 MHz; 
CDC13) 7.40-7.33 (5H, m, ArH), 7.22 (2H, d, J 8.7, ArH), 6.86 (2H, d, J 8.7, ArH), 
5.01 (114, ddd, J 8.8, 5.1, 3.4, C31]), 4.12 (IH, d, J 13.1, NCHA HBPh), 3.39 (3H, s, 
OMe), 3.36 (IH, d, .113.1 NCHAHBPh), 2.97 (1H, dd, J8.7, 1.8, C 5HxHy), 2.94 (IH, 
dd,.113.3, 5. 1, CHSHTAr), 2.78 (1H, dd, J 13.3, 9.5, CHSHTAr), 2.66 (1 H, dt, .19.5, 
5.1, C2H), 2.17 (2H, m, C4HA,IHN + C5HxHy), 2.14 (3H, s, COCH3), 1.69-1.54 (1H, 
M, C4HMHN); 5(62.9 MHz; CDC13) 171.1 (1C, Q), 158.4 (1C, Q), 138.8 (1C, Q), 
131.5 (IC, Q), 130.2 (2C, CH), 129.6 (2C, CH), 128.7 (2C, CH), 127.5 (IC, CH), 
114.3 (2C, CH), 75.2 (IC, CH), 68.8 (1C, CH), 58.8 (1C, CH 2), 55.7 (1C, CH3), 52.1 
(1C, CH2), 33.8 (IC, CH2), 31.1 (1C, Cl-i 2), 21.7 (IC, CH3); m/z (FAB) 340 ([M + 
fl] 70%), 280 (28), 218 (52), 121 (43), 91(100); FIRMS (FAB) (Found: [M + H], 
340.1916. C21 H26NO3 requires m/z 340.1913). 
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(2R,3R)-3-Acetoxy-2-(4-methoxybenzyl)pyrrolidine hydrochloride 112 
H 







To a solution of the pyrrolidine 111 (0.0527 g, 0.155 mmol) and Peariman's catalyst 
[0.0527 g; 20% Pd(OH) 2/C] in methanol (5 cm 3) was added hydrochloric acid [0.31 
cm  (1 M in ether), 0.31 mmol]. The solution was exposed to a hydrogen atmosphere 
(1 atm) and stirred vigorously for 20 hours. The mixture was then filtered through a 
pad of Celite and concentrated under reduced pressure to give 112 (0.0450 g, 100%) 
as a pale brown oil. [aI D -46.3 (c 0.56, CHC1 3 ); Vmax (neat)/cm 3398, 2934, 1741, 
1613, 1581, 1515; oH (250 MHz; CD 3 0D) 7.32 (2H, d, J 8.4, ArII), 7.00 (2H, d, J 
8.4, ArH), 5.40 (1H, br s, C31-f), 4.02 (1H, br s, CA,  3.86 (3H, s, OMe), 3.54 (2H, 
br q, J 8.6, C 5HSHT+ CS HSHT), 3.18 (1H, dd, J 14.1, 6.2, CHAHBAr), 3.06 (1 H, dd, J 
14.1, 8.4, CHAHBAr), 2.52-2.44 (1H, m, C4HMHN), 2.31-2.18 (IH, m, C 4HMHN ), 
2.27 (3H, s, COCH3); 8, (62.9 MHz; CD 3 0D) 169.3 (IC, Q), 158.6 (1C, Q), 129.1 
(2C, CH), 127.1 (IC, Q), 113.6 (2C, CH), 72.4 (1C, CH), 64.1 (1C, CH), 53.8 (1C, 
CH3), 42.4 (IC, CH2), 30.7 (IC, CH 2), 29.9 (1C, CH2), 19.0 (IC, CH3); m/z (FAB) 
250 ([M + H] +, 100%), 190 (36), 128 (22), 121 (32), 91(41); HRMS (FAB) (Found: 
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Synthesised in analogous manner to 30 from S-imide ent-32 to give two 
diastereomers one of which 155 was inseparable from the imide ent-32. Thus 
glycolate equivalent ent-32 (0.660 g, 2.03 mmol), dibutylboron triflate (2.5 cm3 , 
1.0 M in CH202, 2.5 rnmol), and triethylamine (0.27 g, 0.37 cm 3, 2.7 mmol) in 
CH2C12 (3 cm3), along with aldehyde 31(0.200 g, 0.557 mmol) in CH2C12 (3 cm) 
gave, after chromatography using preparative HPLC [hexane:EtOAc (7:3)], 156 
(0.145 g, 38%) as an oil, Rf[hexane: EtOAc (7:3)] 0.40; R [hexane:EtOAc (7:3)] = 
11.98 minutes; [aID +42.2 (c 1.39, CHC13); Vm (neat)/cm 3516, 3029, 1777, 1707, 
1611, 1584, 1512; 8H  (360 MHz; CDCI 3) 7.39-7.05 (20H, m, ArII), 6.87 (2H, d, J 
8.7, Art]), 6.77 (2H, d, 1 8.7, ArII), 5.08 (1H, d, J 9.2, C 2 'H'), 4.50-4.43 (IH, m, 
C4H), 4.30 (1 H, d, J 11.7, OCHA HBPh), 4.25 (1H, J 11.7, OCHAHBPh), 4.19 - 4.16 
(I H, m, C3I]), 4.14 (1 H, dd, 19.1, 2.4, C 5HxHy), 4.07 (1H, dd, 19.1,7.6, C 5 HxHy). 
3.91 (2H, d, J 14.2, NCHSHTPh), 3.84 (3H, s, OMe), 3.62 (2H, d, 1 14.2, 
NCHsHPh), 3.33 (IH, dd, 1 13.4, 3.3, C4HCHAIHNPh), 3.23 (1H, br t, J 7.0, C4']]), 
2.88 (2H, d, J 7.1, C5'HEHF + C5'HEHF), 2.65 (114, dd., 1 13.4, 9.9, C4HCHMHATPh); 
ö (62.9 MHz, CDC13) 172.7 (1C, Q), 157.7 (1C, Q), 154.3 (1C, Q), 139 (2C, Q), 
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136.5 (1C, Q), 135.0 (1C, Q), 132.0 (1C, Q), 130.4 (2C, CH), 129.3 (2C, CH), 128.8 
(2C, CH), 128.7 (2C, CH), 128.6 (4C, CH), 128.2 (2C, CH), 127.9 (5C, CH), 127.2 
(1C, CH), 126.4 (2C, CH), 113.2 (2C, CH), 76.9 (IC, CH), 72.5 (1C, CH2), 71.7 (1C, 
CH), 66.7 (1C, CH2), 60.1 (1C, CH), 55.7 (IC, CH), 55.2 (1C, CH3), 54.0 (2C, CH2), 
37.3 (IC, CH2), 30.1 (IC, CH2); m/z (FAB) 685 ([M + H], 26%), 683 (30), 330 
(100), 563 (15), 121 (44), 91(100); HRMS (FAB) (Found: [M + H], 685.3279. 
C43H45N206 requires m/z 685.3278). 
Methyl 	 (2S,3R,4R)-2-benzyloxy-4-dibenzyta min o-3-hydroxy-5-(4- 
methoxyphenyl)pentanoate 148 and Methyl (2R,3R,4R)-2-benzyloxy-4-
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To a solution of diisopropylethylamine (0.46 cm 3 , 0.34 g, 2.6 mmol) and 
dibutylboron triflate (2.46 cm 3,  1.0 M in CH202, 2.46 mmol) in CH2C12 at -78 °C, 
was added a solution of methyl ester 134 (0.366 g, 2.03 mmol) in CH 2C12 (3 cm 3) via 
cannula. The resulting solution was allowed to stir for 1.5 hours before a -78 °C 
solution of amino aldehyde 31(0.200 g, 0.557 inmol) in CH2C12 (3 cm 3)  was added, 
again, via cannula. The mixture produced was left to stir at -78 °C for 2 hours. The 
reaction was quenched by the addition of methanol (5 cm 3) followed by pH 7 
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phosphate buffer (5 cm 3 ). Hydrogen peroxide (30% aq. solution; 5 cm3 in methanol 
(10 cm 3)  was added dropwise to the solution and the mixture was stirred and warmed 
to room temperature over Ca. 1 hour. The organic phase was separated and the 
aqueous phase was extracted with CH 202 (3 x 20 cm 
3);  the combined organic phase 
was washed sequentially with saturated aq. sodium bicarbonate (30 cm 3) and brine 
(30 cm3) then dried, and concentrated under reduced pressure. The residue was 
chromatographed using preparative HPLC [hexane:EtOAc (7:3)] to give 148 (0.1245 
g, 42%),149 (0.0607 g, 20%) and 150 (0.0283 g, 9%) all as oils. 
Data for (2S,3R,4R) diastereomer 
148: obtained (0.1245 g, 42%) as a colourless oil, 
Rf[hexane:EtOAc (7:3)] 0.57; R [hexane:EtOAc (7:3)] = 13.78 minutes; [aI D -27.3 
(c 5.77, CHC13); Vm (neat)/cm' 3557, 2951, 1751, 1611, 1512; 6u  (360 MHz; 
CDC1 3 ) 7.41-7.11 (15H, m, ArH), 7.17 (2H, d,J8.6, ArIf), 6.86 (2H, d,J8.6, ArR), 
4.43 (1H, d, 1 10.6, OCHAHBPh), 4.18 (1H, br s, CA,  4.16 (1H, br d, 15.5, C311), 
3.84 (311, s, OMe), 3.79 (2H, d, 1 13.7, NCHHyPh x 2), 3.71 (1H, d, 1 10.6, 
OCHAHBPh), 3.66 (3H, s, OMe), 3.64 (2H, d, .1 13.7, NCI-1HyPh x 2), 3.22 (1H, q, 
16.0, C41]), 3.10 (1H, dd,J 14.2, 6.6, C5HMHN), 2.98(111, dd,J 14.2, 6.5, C5HMHN), 
2.29 (1H, br s, OH); o (62.9 MHz; CDC13) 171.7 (1C, Q), 157.6 (1C, Q), 139.8 (2C, 
Q), 136.9 (1C, Q), 132.9 (1C, Q), 130.2 (2C, CH), 129.0 (4C, CH), 128.1 (4C, CH), 
128.0 (2C, CH), 127.9 (2C, CH), 127.6 (1C, CH), 126.8 (2C, CH), 113.5 (2C, CH), 
78.2 (IC, CH), 73.4 (1C, CH), 72.3 (1C, CH 2), 60.0 (1C, CH), 55.1 (1C, CH3), 54.1 
(2C, CH2), 51.8 (1C, CH3), 30.9 (IC, CH 2); m/z (FAB) 540 ([M + H], 35%), 418 
(54), 330 (63), 121 (37), 91(100); HRMS (FAB) (Found: [M + H] +, 540.2736. 
C34H38N05 requires m/z 540.2750). 
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Data for (2R,3R,4R) diastereomer 
obtained (0.0607 g, 29%) as a colourless oil, 
Rf [hexane:EtOAc (7:3)] 0.53; R [hexane:EtOAc (7:3)] = 18.14 minutes; [aID +0.63 
(c 1.88, CHC13 ); Vm ax (neat)/cm -1 3504, 3028, 2951, 1739, 1612, 1584, 1512; 8H  (360 
MHz; CDC13) 7.44-7.14 (15H, m, ArH), 7.00 (2H, d,J8.6, ArH), 6.86 (2H, d,J8.6, 
ArH), 4.66 (1 H, d, J 11.6, OCHAHBPh), 4.37 (1 H, dd, .17.2, 2.6 C 3 H), 4.23 (1 H, d,.1 
11.6, OCHAHBPh), 3.95 (1H, d, J 7.2, C2H), 3.91 (3H, s, OMe), 3.89 (2H, d,.1 14.4, 
NCH,HPh x 2), 3.74 (3H, s, OMe), 3.68 (2H, d, J 14.4, NCHxHPh x 2), 3.27 (1H, 
ddd, .1 8.5, 5.5, 2.6, C4R), 2.98 (1H, dd,.1 14.2, 8.5, C5HMHN), 2.89 (1H, dd, J 14.2, 
5.5, C5HMHN), 2.54 (1 H, br s, OR); & (62.9 MHz; CDC1 3) 172.4 (1C, Q), 158.3 (IC, 
Q), 140.4 (2C, Q), 137.1 (1C, Q), 132.9 (IC, Q), 131.0 (2C, CH), 129.1 (4C, CH), 
128.9 (2C, CH), 128.7 (2C, CH), 128.5 (4C, CH), 128.4 (1C, CH), 127.1 (2C, CH), 
113.9 (2C, CH), 80.0 (1C, CH), 73.0 (1C, CH2), 71.3 (1C, CH), 60.3 (IC, CH), 55.8 
(1C, CH3), 54.8 (2C, Cl-I2), 52.5 (1C, CH 3), 31.2 (1C, Cl-I2); m/z (FAB) 540 ([M + 
H] + , 65%), 538 (52), 418 (55), 330 (64), 121 (58), 91(100); HRMS (FAB) (Found: 
[M + H], 540.2747. C34H38N05 requires rn/z 540.2750). 
Data for (2R,3S,4R) diastereomer 
obtained (0.0283 g, 9%) as a colourless oil, 
Rf [hexane:EtOAc (7:3)] 0.45; R [hexane:EtOAc (7:3)] = 19.45 minutes; [a]D -18.03 
(c 0.92, CHC1 3); Vm (neat)/cm' 3357, 3029, 2951, 2837, 1755, 1611, 1583, 1512; 
H (250 MHz; CDC13) 7.49-6.88 (15H, m, ArR), 7.05 (2H, d, .18.6, ArR), 6.74 (211, 
d, J 8.6, ArR), 4.53 (IH, d,.111.7, OCHAHBPh), 4.14 (1H, dd, J9.1, 2. 1, C3R), 4.03 
(211, d,J 13.3, NCHHyPh x 2), 3.82 (3H, s, OMe), 3.80 (3H, s, OMe), 3.70 (1 H, d, J 
2.1, CA, 3.59-3.43 (1 H, m, C 4H), 3.53 (2H, d, J 13.3, NCHxHyPh x 2), 3.48 (1H, 
d,J 11.7, OCHAHBPh), 3.24 (1 H, dd,.1 14.4, 5.0, C S HMHN), 2.65 (1 H, dd,.1 14.4, 7.9, 
CSHMHN); 6 (62.9 MHz; CDCI 3) 171.6 (IC, Q), 158.0 (1C, Q), 138.2 (2C, Q), 137.6 
(1C, Q), 131.2 (IC, Q), 129.9 (2C, CH), 128.9 (4C, CH), 128.5 (4C, CH), 127.9 (2C, 
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CH), 127.2 (2C, CH), 126.9 (3C, CH), 113.8 (2C, CH), 78.1 (IC, CH), 72.5 (1C, 
CH), 71.6 (1C, C112), 59.0 (1C, CH), 55.1 (1C, CH3), 53.7 (2C, CH2), 52.0 (1C, 
CH3), 31.3 (1C, CH2); m/z (FAB) 540 ([M + H] +, 89%),450 (63), 418 (47), 330 (53), 
181 (40), 121 (65), 91(100); HRMS (FAB) (Found: [M + H]+ , 540.2757. C 34H38N05 




 3 	OH 
MeO
):D~ NBn2  ÔBn 
Via reduction of methyl ester 149. 
Synthesised in analogous manner to diol 29. Thus methyl ester 149 (0.039 g, 0.073 
mmol) in THF (6 cm3) along with lithium aluminium hydride (0.50 cm 3 , 1.0 M in 
THF, 0.50 mmol) gave after stirring for 18 hours diol 151 (0.029 g, 78%), as an oil, 
Rf [hexane:EtOAc (7:3)] 0.12; [aID -7.63 (c 0.76, CHCI3); (neat)/cm' 3419, 
2931, 1611, 1587, 1512; S- (250 MHz; CDC13) 7.36-7.05 (15H, m, ArH), 7.02 (2H, 
d, J 8.7, ArH), 6.80 (2H, d, J 8.7, An-f), 4.47 (1H, d, J 11.8, OCHAHBPh), 4.31 (1H, 
d,J11.8, OCHAHBPh), 4.18 (1 H, br t, J 5.5, C 311), 3.82 (3H, s, OMe), 3.71 (2H, d,J 
13.9, NCHHyPh x 2), 3.63 (2H, d, J 13.9, NCHxHyPh), 3.53 (2H, d, J3.5, CH20H), 
3.47 (1 H, dt, J6.0, 3.5, CA,  3.12 (1H, dt, J7.6, 5.5, C4!!), 2.99 (1H, dd, J 14.2, 7.6, 
C5HsH1), 2.87 (1H, dd, J 14.2, 5.5, C 5HSHT); 5c (62.9 MHz; CDC1 3) 157.7 (1 C, Q), 
139.7 (2C, Q), 137.6 (1C, Q), 132.9 (IC, Q), 130.4 (2C, CH), 128.7 (4C, CH), 128.4 
(2C, CH), 128.1 (4C, CH), 127.8 (2C, CH), 127.7 (IC, CH), 126.7 (2C, CH), 113.5 
(2C, CH), 78.7 (IC, CH), 71.4 (IC, CH), 71.2 (IC, CH2), 60.4 (1C, CH2), 60.1 (1C, 
CM), 55.2 (1C, CH3), 54.3 (2C, CH2), 31.1 (1C, CH2); m/z (FAB) 512 ([M + H]+, 
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25%), 510 (34), 330 (41), 390 (24), 121 (19), 91 (100); HRMS (FAB) (Found: [M + 
H], 512.2818. C33H38N04 requires m/z 512.2801). 
Via reduction of aldol adduct 156. 
Synthesised in analogous manner to diol 29. Thus, to aldol adduct 156 (0.123 g, 
0.180 mmol) in THF (10 cm 3)  was added methanol (0.36 cm 3 , 0.028 g, 0.90 mmol) 
and lithium borohydride (0.020 g, 0.90 mmol). The resulting solution was stirred at 
room temperature for 18 hours to give the diol 151 (0.068 g, 75%) as an oil. 
All spectroscopic data was identical to the compound synthesised above. 
(2R,3R,4R)-2-Benzyloxy-4-N,N-dibenzyla min o-5-(4-methoxy phenyl) pentane- 1,3-
diol 153 





Via reduction of methyl ester 148. 
Analogous to the above protocol, thus methyl ester 148 (0.0982 g, 0.182 mmol) in 
THF (8 cm3 ) along with lithium aluminium hydride (0.55 cm 3,  1.0 M in THF, 0.55 
mmol) gave after stirring for 18 hours diol 153 (0.0619 g, 67%), as an oil, R f 
[hexane:EtOAc (7:3)] 0.21; [aID -34.0 (c 1.68, CHC13); Vmax (neat)/cm' 3444, 3031, 
2933, 1611, 1511; 6H (600 MHz; CDC1 3 ) 7.26-6.98 (15H, m, ArH), 7.02 (2H, d, J 
8. 1, ArfI), 6.72 (2H, d, J8.1, ArH), 4.20 (1H, d, J 11.2, OCHAHBPh), 3.80 (1H, br s, 
C3H), 3.77 (IH, d, J 11.2, OCHA HBPh), 3.72 (3H, s, OMe), 3.66 (2H, d, J 13.7, 
NCJJHyPh), 3.55 (2H, d, J 13.7, NCHxHyPh), 3.55-3.5 1 (IH, m, CIRcHT), 3.41 
(IH, dd, ill .7, 4.2, CIH5HT), 3.35 (IH, q, J4.2, C21-I), 3.02 (1H, q, .16.3, C4H), 2.95 
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(I H, dd, J 14.1, 6.2, C5HMHN), 2.84 (1 H, dd, J 14.1, 6.8, CSHMHIVAr), 2.31 (1H, br s, 
OH), 2.89 (1H, br s, OH); 8,(62.9 MHz; CDCI 3) 158.2 (1C, Q), 140.5 (2C, Q), 138.4 
(1C, Q), 133.8 (1C, Q), 130.8 (2C, CH), 129.5 (4C, CH), 128.8 (2C, CH), 128.7 (4C, 
CH), 128.2 (1C, CH), 128.1 (2C, CH), 127.4 (2C, CH), 114.1 (2C, CH), 79.3 (IC, 
CH), 73.0 (1C, CH2), 72.4 (1C, CH), 62.6 (IC, CH2), 61.1 (IC, CH), 55.7 (1C, CH3), 
54.9 (2C, CH2), 31.3 (1C, CH2); m/z (FAB) 512 (EM + Hf, 65%), 390 (13), 240 (9), 
121 (19), 91(100); HRMS (FAB) (Found: [M + H], 512.2801. C 33 H38N04 requires 
m/z 512.2801). 
Via reduction of aldol adduct 155. 
Synthesised in analogous manner to diol 29. Thus, to a solution of crude aldol adduct 
155 (1.13 g) in THF (20 cm) was added methanol (1.0 cm 3,  0.79 g, 25 mmol) and 
lithium borohydride (0.55 g, 25 mmol). The resulting solution was stirred at room 
temperature for 18 hours to give the diol 153 (0.151 g) as an oil. 
All spectroscopic data was identical to the compound synthesised above. 
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(1 'R,4R,5R)-5-Benzyloxy-2,2-trimethyl-4- Li '-N,N-dibenzylamino-2 '-(4-
methoxyphenyl) ethyll-1,3-dioxane 154 
To a solution of diol 153 (0.0597 g, 0.117 mmol) in acetone (50 cm3 ) was added a 
few mg of iodine. The resulting solution was heated to reflux and held there for 3 
hours before being cooled to room temperature. 1 M aqueous sodium hydroxide (1 
cm 3)  was added until the solution lost its brown appearance, and the organic phase 
was separated. The aqueous phase was extracted with CHC1 3 (3 x 15 cm3) and the 
combined organic phase was washed with water (50 cm 3)  then dried, and 
concentrated under reduced pressure. The residue was chromatographed on silica gel 
[hexane:EtOAc (10:1)] to give 154 (0.0195 g, 30%) as an oil, Rf [hexane:EtOAc 
(7:3)] 0.75; [a]D -36.0 (c 0.30, CHC1 3 ); Vmax (neat)/cm -1 3061, 2935, 1611, 1584, 
1512; 8H  (360 MHz; CDC1 3) 7.19-6.99 (15H, m, ArH), 6.93 (2H, d, J8.7, An]), 6.69 
(2H, d, J 8.7, ArIf), 4.41 (111, d, J 12.0, OCHAHBPh), 4.17 (1H, d, J 12.0, 
OCHAHBPh), 4.04 (1 H, dd, J4.0, 2.6, C411), 3.86 (1H, dd, J 12.7, 2.6, C6HSHT), 3.76 
(311, s, OMe), 3.75 (1H, dd, 1 12.7, 2.6, C6HSHT), 3.71 (2H, d, 1 14.0, NCHxHyPh), 
3.40 (211, d, 1 14.0, NCH xHyPh), 3.26 (1H, dt, 10.0, 3.8, C1'I]), 3.23 (lH, q, J 2.6, 
C511), 3.03 (1H, dd, J 14.8, 3.6, C2'HMHN), 2.79 (IH, dd, J .14.8, 10.0, C2'HMHN), 
1.38 (3H, s, C2Me), 1.35 (3H, s, C2Me); 8,, (62.9 MHz; CDC1 3 ) 157.4 (1G. Q), 140.0 
(2C, Q), 138.1 (1G. Q), 133.9 (1C, Q), 130.5 (2C, CH), 128.6 (4C, CH), 128.2 (2C, 
CH), 128.0 (4C, CH), 127.7 (2C, CH), 127.4 (1C, CH), 126.6 (2C, CH), 113.1 (2C, 
CH), 98.8 (1C, Q), 72.8 (1C, CH), 71.1 (1C, CH 2), 69.8 (1C, CH), 61.6 (IC, CH 2), 
60.4 (1C, CH), 55.2 (IC, CH 3 ), 54.5 (2C, CH2), 32.0 (1C, CH2), 28.6 (1C, CH 3), 19.3 
(1C, CH 3 ); m/z (FAB) 552 ([M + Hf, 19%), 550 (27), 430 (24), 330 (28), 121 (23), 
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91 (100); HRMS (FAB) (Found: [M + H], 552.3114. C36H42N04 requires m/z 
552.3116). 




NH 2 	OH 
MeO CI 
To a solution of the diol 151 (0.0213 g, 0.0417 mmol) and Pearlman's catalyst 
[0.0213 g; 20% Pd(OH)2/C} in methanol (3 cm 3)  was added hydrochloric acid (0.084 
cm3 , 1 M in ether, 0.084 mmol). The solution was exposed to a hydrogen atmosphere 
(1 atm) and stirred vigorously for 18 hours. The mixture was then filtered through a 
pad of Celite and concentrated under reduced pressure to give the hydrochloride salt 
152 (0.0116 g, 100%) as a white solid, mp 197-199 °C; [a]D +45.3 (c 0.23, CH3 0H); 
Vm (KBr)/cm 3322, 3009, 2933, 1610, 1576, 1513; 6H  (250 MHz; CD30D) 7.32 
(2H, d, J 8.7, Ar!]), 7.02 (2H, d, J 8.7, Ar!]), 3.93-3.86 (1H, m, C2!]), 3.91 (1H, dd, 
J8.9, 5.0, C3!]), 3.88 (3H, s, OMe), 3.81-3.79 (1H, rn, C 4!]), 3.76 (IH, dd,J7.8, 3. 1, 
CIHAHB), 3.71 (1H, dd, J7.8, 2.5, C I HAHB), 3.25 (1H, dd, J 14.5, 3.7, C5HxHy), 2.85 
(1H, dd, J 14.5, 10.8, C 5HxHy); & (62.9 MHz; CD30D) 158.6 (1C, Q), 129.6 (2C, 
CH), 127.3 (1C, Q), 113.6 (2C, CH), 71.4 (1C, CH), 69.5 (1C, CH), 62.7 (1C, CH2), 
54.9 (1C, CH), 53.8 (IC, CH3), 31.0 (IC, CH2); m!z (FAB) 242 ({M + H], 99%), 
150 (29), 135 (28), 121 (100), 91(32); HRMS (FAB) (Found: [M + H] +, 242.1397. 








Bn2 	 OMe 
To a suspension of NO-di methylhydroxylaminehydrochloride (0.763 g, 7.83 mmol) 
in THF (5 cm3 ) at 0 °C was added trimethyl alum inium (3.9 cm 3 , 2.0 M in toluene, 
7.8 mmol). The clear solution produced was allowed to stir for 30 minutes before 
being added to a solution of ethyl ester 98(0.500 g, 1.11 mmol) in THF (15 cm 
3)  at 0 
°C via cannula. The mixture produced was warmed to room temperature and stirred 
for 4 hours, before being quenched by the addition of saturated aq. sodium potassium 
tartrate (50 cm3). The biphasic mixture was stirred vigorously for 15 hours by which 
time two clear phases were apparent. The organic phase was separated and the 
aqueous phase was extracted with CH 2Cl2 (3 x 25 cm 3). The combined organics were 
dried, and concentrated under reduced pressure. The remaining residue was 
chromatographed on silica gel [hexane:EtOAc (4:1)] to give 190 (0.503 g, 97%) as a 
white solid, Rf [hexane:EtOAc (7:3)] 0.12; nip 123-125 °C; Vm (KBr)/cm 3457, 
3026, 2934, 1643, 1613, 1584, 1512; öj (250 MHz; CDC13) 7.40-7.29 (IOH, m, 
An -1), 7.21 (2H, d, J 8.6, ArH), 6.90 (2H, d, J 8.6, ArH), 4.23 (21-1, d, J 13.5, 
NCHHyPh x 2), 4.04 (1 H, ddd, J 10.2, 5.2, 2.0, C31f), 3.85 (3H, s, ArOMe), 3.60 
(3H, s, NOMe), 3.52 (2H, d, J 13.5, NCHxHyPh x 2), 3.15 (1H, dd, J 13.4, 4.5, 
C 5HAIHN), 3.18 (3H, s, NMe), 3.01 (1H, dd, J 13.4, 9.4, C5HMHN), 2.89 (1H, dd, J 
16.7, 10.2, C2HsH1), 2.71 (1 H, dt, J9.4, 4.8, C411), 2.11 (1H, br d, J 16.7, C2HSHT); 
(62.9 MHz; CDC1 3) 174.7 (IC, Q), 158.4 (1C, Q), 140.5 (2C, Q), 132.8 (1C, Q), 
130.7 (2C, CH), 129.5 (4C, CH), 128.7 (4C, CH), 127.4 (2C, CH), 114.4 (2C, CH), 
68.4 (1C, CH), 63.7 (1C, CH), 61.6 (1C, CH3), 55.7 (IC, Cl-I3), 55.4 (2C, CH 2), 37.2 
(1C, CH2), 32.3 (IC, CH3), 29.9 (IC, CH2); m/z (FAB) 463 ({M + H]t, 22%), 330 
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(24), 121 (22), 91(100); HRMS (FAB) (Found: [M + H], 463.2591. C 28H35N204 
requires m/z 463.2597). 
(3RS,4RS)-3-tert-ButyldimethylsilylOXy-4-N,N-dibeflzylamiflO-5-(4-
methoxyphenyl)pentanoic acid methoxy methyl amide 189 
OTBS 0 
Me 
Bn2 	 OMe 
MeO 
To a solution of alcohol 190 (0.381 g, 0.827 mmol) in CH 2Cl2 (5 cm 
3)  was added 
2,6-lutidine (0.57 cm 3,  0.53 g, 4.9 mmol), and tert-butyldimethylsilyl triflate (0.57 
cm3 , 0.53 g, 4.9 mmol). The solution was stirred at room temperature for 4 hours 
before being quenched by the addition of water (20 cm 3). The organic phase was 
separated and the aqueous phase was extracted with CH 202 (3 x 20 cm 3);  the 
combined organic phase was washed with brine (30 cm 3) then dried, and 
concentrated under reduced pressure. The residue was chromatographed on silica gel 
[hexane:EtOAc (4:1)] to give 189 (0.397 g, 84%) as a white solid, R f [hexane:EtOAc 
(7:3)] 0.31; mp 108-109 °C; Vmax (KBr)/cm1 3027, 2925, 2800, 1666, 1611, 1581, 
1511; 6H (2SO MHz; CDC1 3) 7.30-7.18 (1 OH, m, ArH), 7.22 (2H, d,J8.6, ArH), 6.91 
(2H, d, J 8.6, ArH), 4.31 (111, ddd, J 6.7, 5.0, 2. 1, C3!!), 4.15 (2H, d, J 13.4, 
NCH1,yHyPh x 2), 3.84 (3H, s, ArOMe), 3.66 (3H, s, NOMe), 3.46 (2H, d, J 13.4, 
NCHxHyPh x 2), 3.18-2.90 (2H, m, C 2HSHT + C41T), 3.14 (1H, dd, J 12.1, 5.6, 
C5HAHB), 3.07 (3H, s, NMe), 2.96 (IH, dd, J 12.1, 6.4, C5HAHB), 2.59 (IH, dd, J 
16.9, 5.0, C2HsHr), 0.86 (9H, s, 'Bu), 0.00 (3H, s, SiCH3), -0.02 (3H, s, SiCI-13); 
5 (62.9 MHz; CDC1 3) 177.5 (IC, Q), 158.3 (1C, Q), 141.2 (2C, Q), 133.1 (1C, Q), 
130.7 (2C, CH), 129.6 (4C, CH), 128.5 (4C, CH), 127.1 (2C, CH), 114.3 (2C, CH), 
71.7 (1C, CH), 62.6 (1C, CH), 61.5 (IC, CH 3), 56.1 (2C, CH 2), 55.7 (IC, Cl-I 3), 37.8 
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(IC, CH2), 32.4 (IC, CH 3), 31.1 (1C, CH2), 26.5 (3C, CH 3), 18.7 (1C, Q), -3.9 (1C, 
CH3), -4.5 (1C, CH 3); m/z (FAB) 577 ([M + H] 49%), 455 (50), 330 (100), 121 
(67), 91(100); HRMS (FAB) (Found: [M + H], 577.3455. C34H49N204Si requires 
m/z 577.3462). 
(4RS,5RS)-4-tert -Butyldimethylsilyloxy -5-N,N -dibenzylamino -6-(4-
methoxyphenyl)hexan-2-one 191 
OTBS 0 
To a solution of Weinreb amide 189 (0.0750 g, 0.13 mmol) in THF (5 cm') at -45 °C 
was added (trimethylsilyl)methyllithium (0.45 cm 3 , 1 .0 M in pentane, 045 mmol), 
The mixture produced was stirred for 2 hours before being quenched by the addition 
of 2 M anhydrous acetic acid (1 cm 3) and pH 7 phosphate buffer (10 cm 3). The 
organic phase was separated and the aqueous phase was extracted with EtOAc (3 x 
20 cm3). The combined organics were dried, and concentrated under reduced 
pressure. The remaining residue was chromatographed on silica gel [hexane:EtOAc 
(9:1)] to give 191 (0.0623 g, 90%) as an oil, Rf [hexane:EtOAc (7:3)] 0.61; Vm 
(neat)/cm 3061, 2929, 1716, 1613, 1583, 1512; 6H  (250 MHz; CDC13) 7.38-7.23 
(I OH, m, Arff), 7.26 (21-I, d, 1 8.7, ArR), 6.95 (2H, d, J 8.7, ArJI), 4.20 (11-1, ddd, J 
7.5, 4.1, 1.8, C4H), 4.16 (2H, d, J 13.4, NCH,T-IPh x 2), 3.88 (3H, s, OMe), 3.42 
(2H, d, 113.4, NCHAHBPh x 2), 3.20 (1 H, br t, 18.2, C41), 3.11 (1H, dd, 118.2,7.4, 
C3HSHT), 3.01-2.91 (2H, m, C6HHy + C6HxHy), 2.53 (1 H, dd, J 18.2, 4. 1, C3HH, 
1.78 (311, s, COCH3), 0.88 (9H, s, 'Bu), 0.02 (3H, s, SiCH3), -0.01 (3H, s, SiCH3); 
8, (62.9 MHz; CDC1 3) 207.3 (1C, Q), 158.3 (1C, Q), 141.3 (2C, Q), 132.8 (1C, Q), 
130.6 (2C, CH), 129.7 (4C, CH), 128.6 (4C, CH), 127.2 (2C, CH), 114.3 (2C, CH), 
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70.6 (1C, CH), 61.3 (1C, CH), 56.4 (2C, CH 2), 55.7 (IC, CH 3 ), 48.8 (1C, CH2), 31.0 
(IC, CH2), 30.8 (1C, CH3), 26.3 (3C, CH 3), 18.5 (1C, Q), -4.0 (1C, CH 3), -4.4 (IC, 
CH3); rn/z (FAB) 532 ([M + H], 23%), 530 (25), 410 (81), 330 (100), 121 (76), 91 






To a solution of Weinreb amide 189 (0.0656 g, 0.113 mmol) in THF (5 cm 3) at -45 
°C was added (trimethylsilyl)methyllithium (0.41 cm 3, 1.0 M in pentane, 0.41 
mmol). The mixture produced was stirred for 2 hours before being quenched by the 
addition of pH 7 phosphate buffer (10 cm 3 ). The organic phase was separated and the 
aqueous phase was extracted with EtOAc (3 x 20 cm3). The combined organics were 
dried, and concentrated under reduced pressure to give 188 (0.0690 g, 100%) as an 
oil, which was not purified further. Rf [hexane:EtOAc (4:1)] 0.78; 5H (200 MHz; 
CDC13) 7.30-7.23 (12H, m, Ar!]), 6.94 (2H, d, J8.6, Ar!]), 4.27-4.18 (1 H, m, C411), 
4.15 (2H, d, J 13.3, NCHHPh x 2), 3.87 (3H, s, OMe), 3.45 (2H, d, J 13.3, 
NCHxHyPh), 3.16-2.83 (4H, C 6HA HB + C6HAH8 + C51-I + C3HlFIN), 2.59 (1H, dd, .J 
17.3, 5.3, C3HMHN), 1.99 (111, d, J 10.5, C 1 HsH1), 1.87 (1 H, d, .110.5, CJHSHT), 0.88 
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Table 1: Crystal data and structure rejI nement for 110 
Part A: CRYSTAL DATA 
Empirical formula C26 . 50H32F6N0250P 
Formula weight 549.50 
Wavelength 0.71073 A 
Temperature 150(2) K 
Crystal system Monoclinic 
Space group C2 
Unit cell dimensions a = 19.9 14(2) A 	alpha = 90 deg. 
b=9.8326(11)A 	beta= 111.621(2) deg. 
c = 13.9100(16) A 	gamma = 90 deg. 
Volume 25 32.0(5) A 3 
Number of reflections for cell 4534 (2 <theta <27 deg.) 
Z 4 
Density (calculated) 1.441 Mg/rn3 
Absorption coefficient 0.181 mm- ' 
F(000) 1148 
Part B: DATA COLLECTION 
Crystal description Colourless block 
Crystal size 0.54 x 0.18 x 0.18 mm 
Instrument CCD area detector 
Theta range for data collection 1.57 to 29.04 deg. 
Index ranges -26<=h<=25,-13<=k<=13,-18<=I<=18 
Reflections collected 11621 
Independent reflections 6012 [R(int) = 0.02431 
Scan type Phi and omega scans 
Absorption correction Multiscan (Tmin= 0.907, Tmax=1) 
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Part C: SOLUTION AND 
REFINEMENT 
Solution Direct (SHELXS-97 (Sheldrick, 1990)) 
Refinement type Full-matrix least-squares on F 2 
Program used for refinement SHELXL-97 
Hydrogen atom placement Geom 
Hydrogen atom treatment Riding, rotating rigid group or restrained 
refall 
Data / restraints / parameters 6012/3/351 
Goodness-of-fit on FA2 1.044 
Conventional R [F>4sigma(F)] RI = 0.0404 [5211 data] 
Weighted R (F"2 and all data) wR2 = 0.0972 
Absolute structure parameter -0.05(8) -Strong enantiodistinguishing 
power 
Final maximum delta/sigma 0.003 
Weighting scheme caic 
w 1 /[\s1211(Fo"21)+(0 .0529P)"2"+0.0000 
PJ where P(Fo 12 1+2Fc"2'')/3 
Largest duff. peak and hole 0.267 and -0.244 e. A 3 
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Table 2: Atomic coordinates ( x 10), equivalent isotropic displacement parameters 
(A2 x 10) and site occupancies for 110. U(eq)is defined as one third of the trace of 
the orthogonalized Uf tensor. 
x  z U(eg) 0cc 
N(1) 491(1) 1710(2) -2179(1) 24(1) 1 
 884(1) 546(2) -1455(1) 24(1) 1 
0(3) 976(1) 1340(2) 258(1) 36(1) 1 
 1345(1) 1269(2) -448(1) 27(1) 1 
 1483(1) 2699(2) -791(2) 30(1) 1 
 1094(1) 2737(2) -1963(1) 28(1) 1 
 174(1) 1316(2) -3324(1) 29(1) 1 
 680(1) 581(2) -3725(1) 31(1) 1 
 666(1) -827(2) -3796(2) 36(1) 1 
 1117(1) -1511(3) -4195(2) 45(1) 1 
 1573(1) -781(3) -4545(2) 45(1) 1 
 1588(1) 609(3) -4489(2) 44(1) 1 
 1139(1) 1300(2) -4091(2) 36(1) 1 
 -129(1) 2248(2) -1868(1) 27(1) 1 
 -482(1) 3526(2) -2416(1) 27(1) 1 
 -1088(1) 3454(2) -3324(2) 33(1) 1 
 -1421(1) 4635(2) -3822(2) 40(1) 1 
 -1163(1) 5885(2) -3412(2) 42(1) 1 
 -568(1) 5968(2) -2497(2) 40(1) 1 
 -233(1) 4797(2) -2005(2) 33(1) 1 
 408(1) -598(2) -1343(2) 30(1) 1 
 874(1) -1789(2) -782(2) 28(1) 1 
 974(1) -2066(2) 235(2) 34(1) 1 
 1417(1) -3113(2) 781(2) 32(1) 1 
 1777(1) -3908(2) 304(1) 26(1) 1 
 1681(1) -3657(2) -725(1) 28(1) 1 
 1237(1) -2604(2) -1248(1) 28(1) 1 
0(37) 2248(1) -4924(2) 788(1) 31(l) 1 
C(38) 2269(1) -5342(2) 1782(2) 39(1) 1 
P(1) 2397(1) 29(1) 2940(1) 36(1) 1 
 2218(1) 1360(2) 2237(1) 83(1) 1 
 2557(1) -1293(2) 3633(1) 77(1) 1 
 3234(1) 285(2) 3251(1) 81(1) 1 
 1556(1) -236(2) 2610(1) 81(1) 1 
 2411(1) 924(2) 3899(1) 60(1) 1 
 2404(1) -821(2) 1980(1) 70(1) 1 
C(1 M) 5000 199(5) 5000 74(1) 1 
0(i M) 4650(2) -870(5) 4624(5) 100(2) 0.50 
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Table 3: Bond lengths for 110 










C(10)-C(1 1) 1.505(3) 













C(30)-C(3 1) 1.519(3) 













P(1) -F(1) 1.5943(16) 
C(1 M)-O(1 M) 1.264(5) 
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Table 4: Bond angles for 110. 














N( 1)-C(5)-C(4) 104.43(14) 
C(1 1)-C(10)-N(1) 115.59(14) 
C(12)-C(1 1)-C(16) 118.7(2) 
C(12)-C(1 1)-C(10) 120.5(2) 
C(16)-C(1 1)-C(10) 120.72(19) 
C(1 1)-C(12)-C(13) 120.8(2) 
C(14)-C(13)-C(12) 119.7(2) 
C(15)-C(14)-C(13) 120.2(2) 
C(14)-C(1 5)-C(1 6) 120.4(2) 
C(1 1)-C(16)-C(15) 120.2(2) 
C(21)-C(20)-N(1) 114.63(14) 
C(26)-C(21)-C(22) 118.65(18) 
C(26)-C(2 I)-C(20) 120.93(16) 
C(22)-C(21)-C(20) 120.35(18) 







C(32)-C(3 1)-C(30) 120.50(17) 
C(36)-C(3 1)-C(30) 122.00(16) 












F(3)-P(1 )-F(6) 88.74(9) 
F(2)-P(1)-F(4) 89.75(11) 
F(3)-P(1 )-F(4) 178.99(10) 
F(6)-P( 1 )-F(4) 90.29(10) 











Symmetry transformations used to generate equivalent atoms: 
Table 5: Anisotropic displacement parameters (12 x 10) for 110. The anisotropic 
displacement factor exponent takes the form: -2 p1 2 [h2 a *A  Ui] +... + 2 h k a * b* 
Ui 2] 
U!! U22 U33 U23 U13 U12 
N(1) 19(1) 26(1) 24(1) 1(1) 8(1) -1(1) 
 21(1) 25(1) 26(1) 1(1) 7(1) 2(1) 
 22(1) 35(1) 25(1) 1(1) 8(1) 4(1) 
 24(1) 31(1) 32(1) -4(1) 8(1) -3(1) 
 24(1) 26(1) 34(1) 1(1) 11(1) -3(1) 
 25(1) 35(1) 23(1) 2(1) 6(1) 0(1) 
 26(1) 40(1) 20(1) -4(1) 2(1) 2(1) 
 33(1) 42(1) 28(1) -7(1) 7(1) -1(1) 
 43(1) 47(1) 36(1) -15(1) 2(1) 7(1) 
 34(1) 66(2) 33(1) -13(1) 9(1) 10(1) 
 38(1) 65(2) 33(1) -2(1) 16(1) 4(1) 
 36(1) 43(1) 29(1) 1(1) 14(1) 2(1) 
 22(1) 30(1) 31(1) 4(1) 13(1) 4(1) 
 23(1) 31(1) 28(1) 2(1) 11(1) 3(1) 
 26(1) 38(1) 32(1) -3(1) 8(1) 1(1) 
 29(1) 56(1) 32(1) 8(1) 7(1) 11(1) 
 39(1) 41(1) 51(1) 20(1) 23(1) 16(1) 
 36(1) 30(1) 59(1) 0(1) 22(1) 1(1) 
 23(l) 37(1) 37(1) -4(1) 9(1) 1(1) 
 23(1) 29(1) 37(1) 4(1) 13(1) 2(1) 
 22(1) 26(1) 36(1) 5(1) 11(1) -2(1) 
 36(1) 34(1) 39(1) 2(1) 23(1) 6(1) 
 35(1) 34(1) 31(1) 4(1) 17(1) 3(1) 
 19(1) 28(1) 28(1) 0(1) 5(1) -3(1) 
 26(1) 28(1) 30(1) -3(1) 12(1) -1(1) 
 25(1) 31(1) 28(1) 3(1) 9(1) -3(1) 
0(37) 29(1) 32(1) 30(1) 4(1) 10(1) 5(1) 
C(38) 36(1) 44(1) 35(1) 13(1) 12(1) 7(1) 
P(1) 35(1) 44(1) 29(1) 3(1) 12(1) 6(1) 
 135(2) 63(1) 48(1) 21(1) 28(1) 3(1) 
 104(1) 49(1) 77(1) 20(1) 32(1) 21(1) 
 42(1) 110(2) 91(1) -42(1) 25(1) -18(1) 
 36(1) 107(2) 97(1) 1(1) 22(1) 5(1) 
 81(1) 66(1) 39(1) 1(1) 28(1) 23(1) 
 74(1) 83(1) 61(1) -33(1) 33(1) -16(1) 
C(1 M) 95(3) 49(2) 105(3) 0 70(3) 0 
0(1 M) 63(3) 61(3) 185(6) -47(3) 59(4) -15(2) 
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Table 6: Hydrogen coordinates (x  1O) and isotropic displacement parameters (A 2 
x 103)forllO. 
x ____ z 	' U(eg) 
 1226 137 -1750 29 
 680(40) 710(70) 250(70) 33(8) 
H(3') 1269(13) 1270(30) 864(15) 33(8) 
H(3A) 1815 779 -118 33 
H(4A) 1288 3406 -458 36 
H(4B) 2007 2858 -601 36 
H(5A) 898 3656 -2196 33 
H(5B) 1425 2480 -2317 33 
H(1 OA) -254 733 -3440 34 
H(IOB) 5 2154 -3737 34 
 345 -1329 -3569 43 
 1110 -2476 -4227 55 
 1878 -1244 -4825 54 
 1908 1105 -4724 53 
 1145 2266 -4068 43 
H(20A) -502 1531 -2009 32 
H(20B) 63 2423 -1114 32 
H(22) -1275 2592 -3606 39 
H(23) -1830 4577 -4448 48 
H(24) -1391 6691 -3755 50 
H(25) -391 6832 -2208 48 
H(26) 174 4862 -1376 40 
H(30A) 75 -893 -2035 35 
H(30B) 115 -275 -948 35 
 732 -1522 571 40 
 1474 -3284 1479 38 
H(35) 1919 -4207 -1063 33 
H(36) 1178 -2432 -1947 34 
H(38A) 2451 -4594 2276 58 
H(38B) 2589 -6131 2016 58 
H(38C) 1781 -5588 1736 58 
H(1M1) 4870 519 5576 110 
H(1 M2) 4883 904 4465 110 
H(1 M3) 5519 4 1 	5251 110 
H(1 M) 4205 -702 1 4408 149 
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Table 1: Crystal data and structure refinement Jon 52 
Part A: CRYSTAL DATA 
Empirical formula C 1 2H20C1N04 
Formula weight 277.74 
Wavelength 0.71073 A 
Temperature 150(2) K 
Crystal system Orthorhombic 
Space group P2(1)2(1)2(1) 
Unit cell dimensions a = 5.5704(17) A 	alpha = 90 deg. 
b= 8.711(3) A 	beta =90deg. 
c = 28.470(9) A gamma = 90 deg. 
Volume 1381.5 (7)  A 3 
Number of reflections for cell 4146 (2 <theta < 28.5 deg.) 
Z 4 
Density (calculated) 1.335 Mg/M3 
Absorption coefficient 0.283 mm' 
F(000) 592 
Part B: DATA COLLECTION 
Crystal description Colourless block 
Crystal size 0.36 x 0.32 x 0.27 mm 
Instrument CCD area detector 
Theta range for data collection 1.43 to 28.85 deg. 
Index ranges -7<=h<=7, -11<k<1 1, -38<l<37 
Reflections collected 12119 
Independent reflections 3385 [R(int) = 0.0359] 
Scan type Phi and omega scans 
Absorption correction Sadabs(Tmin= 0.849, Tmax= 1) 
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Part C: SOLUTION AND 
REFINEMENT 
Solution Patterson (DIRDIF) 
Refinement type Full-matrix least-squares on F 2 
Program used for refinement SHELXL-97 
Hydrogen atom placement Geometric/difmap (OH,Me,NH 3 ) 
Hydrogen atom treatment Riding/rotating group 
Data I restraints / parameters 3385/0/169 
Goodness-of-fit on F 2 1.154 
Conventional R [F>4sigma(F)] Ri = 0.0414 [3305 data] 
Weighted R (F 2 and all data) wR2 = 0.1043 
Absolute structure parameter -0.02(6) 
Final maximum delta/sigma 0.036 
Weighting scheme caic 
w=1/[\s'2'(Fo''2')+(0.0559P)"2"+0.3 I 69P] 
where P=(Fo'2'+2Fc"2")/3 
Largest diff. peak and hole 0.337 and -0.274 e. A 3 
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Table 2: Atomic coordinates (x  1O) and equivalent isotropic displacement 
parameters (jf2 x 10') for152. U(eqj is defined as one third of the trace of the 
orthogonalized UzJ tensor. 
x  z U(eg) 
C1(1) 8405(1) 8130(1) 7902(1) 29(1) 
0(1) 3490(3) 9842(2) 7118(1) 32(1) 
 5158(4) 9969(2) 6737(1) 28(1) 
0(2) 2880(3) 8126(2) 6274(1) 28(1) 
 5179(4) 8471(2) 6466(1) 22(1) 
0(3) 8637(3) 7375(2) 6858(1) 27(1) 
 6140(3) 7156(2) 6772(1) 20(1) 
N(4) 6608(3) 4399(2) 6884(1) 21(1) 
 5790(3) 5592(2) 6541(1) 18(1) 
 7188(4) 5411(2) 6080(1) 24(1) 
 7036(3) 3814(2) 5872(1) 21(1) 
 5092(4) 3365(2) 5599(1) 23(1) 
 491 1(3) 1898(2) 5411(l) 22(1) 
 6740(4) 849(2) 5494(1) 20(1) 
 8724(3) 1266(2) 5765(1) 23(1) 
 8850(3) 2740(2) 5948(1) 22(1) 
0(12) 6778(3) -632(1) 5327(1) 26(1) 
C(13) 4624(4) -1184(2) 5117(1) 34(1) 
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Table 3: Bond lengths for 152 
















C(10)-C(1 1) 1.388(2) 
0(1 2)-C( 13) 1.424(3) 
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Table 4: Bond angles for 152 












C(7)-C(6)-C(1 1) 117.68(16) 
C(7)-C(6)-C(5) 121.39(17) 
C(1 1)-C(6)-C(5) 120.92(16) 
C(6)-C(7)-C(8) 122.09(17) 
C(9)-C(8)-C(7) 119.04(17) 
0(1 2)-C(9)-C(8) 124.66(18) 
0(12)-C(9)-C(10) 115.07(17) 
C(8)-C(9)-C( 10) 120.27(16) 





Symmetry transformations used to generate equivalent atoms: 
Table 5: Anisotropic displacement parameters ('A2 x 1O )for 152. The anisotropic 
displacement factor exponent takes the form: -2 pi 2 [h2 a U]] + ... + 2 h k a * b * 
U12] 
Ull U22 U33 U23 U13 U12 
C1(1) 25(1) 39(1) 24(1) -7(1) 1(1) -10(1) 
0(1) 44(1) 28(1) 23(1) -1(1) 10(1) 8(1) 
 40(1) 21(1) 23(1) 0(1) 7(1) 2(1) 
0(2) 31(1) 32(1) 21(1) 2(1) -2(1) 4(1) 
 30(1) 20(1) 17(1) 1(1) 4(1) 1(1) 
0(3) 26(1) 33(1) 22(1) -7(1) 0(1) -4(1) 
 22(1) 20(1) 17(1) -1(1) 2(1) 1(1) 
N(4) 25(1) 21(1) 19(1) 1(1) 0(1) 2(1) 
 22(1) 18(1) 15(1) 3(1) -1(1) 0(1) 
C(S) 31(1) 23(1) 17(1) -3(1) 5(1) -4(1) 
 24(1) 22(1) 16(1) -1(1) 3(1) -3(1) 
 23(1) 22(1) 24(1) 1(1) 0(1) 4(1) 
 23(1) 25(1) 20(1) 1(1) -3(1) -2(1) 
 26(1) 21(1) 15(1) 0(1) 3(1) -1(1) 
 20(1) 27(1) 20(1) 1(1) 1(1) 3(1) 
 21(1) 29(1) 17(1) -3(1) 0(1) -1(1) 
0(12) 30(1) 21(1) 27(1) -5(1) -2(1) 2(1) 
C(13) 40(1) 1 	26(1) 35(1) -7(1) -7(1) -4(1) 
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Table 6: Hydrogen coordinates (x104) and isotropic displacement parameters 
(A2 x]O) for 152. 
x ____ z U(eg) 
H(1) 2708 10662 7143 48 
H(1 A) 6784 10190 6860 34 
H(1 B) 4680 10822 6527 34 
11(2) 1867 8068 6492 41 
H(2A) 6314 8600 6197 27 
 8834 7697 7133 40 
H(3A) 5270 7164 7079 23 
H(4A) 8240 4399 6899 32 
H(4B) 6083 3459 6790 32 
H(4C) 5997 4615 7173 32 
 4042 5438 6476 22 
H(5A) 6559 6157 5848 28 
H(5B) 8895 5664 6137 28 
 3846 4084 5539 28 
 3556 1617 5227 27 
H(10) 9973 549 5823 27 
11(1 1) 10207 3025 6131 27 
H(13A) 3301 -1102 5342 51 
H(13B) 4834 -2260 5026 51 

















DNA deoxyribonucleic acid 
de diastereomeric excess 
ee enatiomeric excess 
Et ethyl 
Ether diethyl ether 
FAB fast atom bombardment 
HMDS hexamethyldisilazide 
1-IPLC high performance liquid chromatography 





M mol dm-3 
MAP mitogen-activated protein 
Me methyl 
mRNA messenger ribonucleic acid 
Ms methanesulfonyl 
MOM methoxymethyl 




ppm parts per million 
Rt retention time for HPLC 
SAR structure activity relationship 
TBAF tetrabutylammonium fluoride 
TBS tert-butyldimethylsilyl 
TBDPS tert-butyldiphenylsilyl 
Tf trifluoromethane sulfonyl 
TFA trifluoroacetic acid 
THF tetrahydrofuran 
TIBS triisopropyl benzene sulfonyl 
t.l .c. thin layer chromatography 
TMS trimethylsilyl 
tRNA transfer ribonucleic acid 
Ts para-toluene sulfonyl 
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A new approach to the synthesis of the antibiotic anisomycin is reported that relies upon a key aldol disconnection. The glycolate aldol 
coupling proceeds in 75% yield and with >95% diastereoselectivity, which allows the 13-step synthesis to proceed in 35% overall yield. 
Anisomycin 1 was first isolated from the fermentation broths 
of Streptomyces griseolus and Streptomyces roseochromo-
genes by Sobin and Tanner in 1954.1  Renewed interest in 
this antibiotic' has arisen from reports of high antitumor 
activity in vitro, with IC50 values in the nanomolar range, 3 
and recent studies that have shown that anisomycin may be 
used in a synergistic fashion with a cyclin-dependent protein 
kinase inhibitor to kill carcinoma cells.' Anisomycin has 
found widespread use as a tool in molecular biology, where 
it has been shown to inhibit protein synthesis 5 and to activate 
JNK and p38 kinases. 6 
Anisomycin has attracted much synthetic interest over the 
past 30 years, with over 20 syntheses of the antibiotic or its 
biosynthetic precursor deacetylanisomycin being reported in 
the literature. 7 However, many of these syntheses have 
suffered from a series of protection and deprotection steps 
Sobin, B. A.; Tanner, F. W., Jr. J. Am Chem. Soc. 1954, 76, 4053. 
The Merck Index, 12th ed.; Wmdholz, M., Ed.; Merck: Whitehouse 
Station, NJ, 1996: p  710. 
Hosoya, Y.; Kamcyama, 1.; Naganawa, H.; Okami, Y.; Takeuchi, 
T. J. Antibiot. 1993, 46, 1300. 
(a) Van der Bosch, J.; Rueller, S.; Schlaak, M. German Patent DE 
19,744,676, 1999; Chem. Abstr. 1999, 130, 291581. (b) Rueller, S.; Stahl, 
C.; Kohler, G.; Eickhoff, B.; Breder, J.; Schlaak, M.; van der Bosch, J. 
Gun. Cancer Rex. 1999, 5, 2714. 
For a recent example of its use, see: (a) Dudai, Y. Nature 2000, 
406, 686. (b) Nader, K.; Schafe, G. E.; Le Doux, J. E. Nature 2000, 406, 
722. 
Tbrocsik, B.; Szeberényi, J. Eur. J. Neurosci. 2000, 12, 527 and 
references therein. 
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in the later stages, and the need for an efficient synthesis 
still remains. 
We were attracted to the synthesis of anisomycin I 
following our successful synthesis of the iminosugar DAB-
1 8  utilizing a highly diastereoselective syn glycolate aldol 
reaction with a serine-derived a-dibenzylamino aldehyde.' 
We envisaged that a similar approach (Figure 1), using a 
(a) Wong, C. M.; Bucchini, J.; Chang, I.; Ic Raa, J.; Schenk, R. 
Can. J. Chem. 1969, 47, 2421. (b) Oida, S.; Ohki, E. Chem. Pharm Bull. 
1969, 17, 1405. (c) Feiner, I.; Schenker, E. Helu. Chi,n. Ada 1970, 53, 
754. (d) Verheyden, J. P. H.; Richardson, A. C.; Bhatt, R. S.; Grant, B. D.; 
Flitch, W. L.; Moffat, J. G. Pare App!. Chem. 1978, 50, 1363. (e) 
Schumacher, D. P.; Hall, S. S. J. Am. Chem. Soc. 1982, 104, 6076. (t) 
Buchanan, J. G.; MacLean, K. A.; Wightman, R. H.; Paulsen, H. J. Chem. 
Soc.. Perkin Trans. 11985, 486. (g) lids, H.; Yama.zaki, N.; Kibayashi, C. 
I. Org. Chem. 1986, 51, 1069. (h) Meyers, A. I.; Dupre, B. Heterocycles 
1987, 25, 113. (i) Shono, T.; Kise, N. Chem. Left. 1987, 697. (j) Baer, H. 
H.; Zamkanei, M. J. Org. Chem. 1988, 53. 4786. (k) Jegham, S.; Das, B. 
C. Tetrahedron Lett. 1988, 29, 4419. (1) Takano, S.; Iwabuchi, Y.; 
Ogasawara, K. Heterocycles 1989, 29, 1861. (m) Takahata, H.; Banba, Y.; 
Tajima, M.; Momose, I. J. Org. Chem. 1991, 56, 240. (n) Ballini, R.; 
Marcantoni, E.; Petrini, M. J. Org. Chem. 1992, 57, 1316. (o) lkota, N. 
Heterocycles 1995, 41, 983. (p) Yoda, H.; Nakajima, T.; Yamazaki, H.; 
Takabe, K. Heterocycles 8995, 41. 2423. (q) Kang. S. H.; Choi, H.-W. 
Chem. Commun. 1996, 1521. (r) Han, G.; LaPorte, M. G.; McIntosh, M. 
C.: Weinreb, S. M.; Parvez, M. J. Org. Chem. 1996, 61, 9483. (s) Veith, 
U.; Schwardt, 0.; Jaget, V. Synlctt 1996, 1181. (t) Huang, P. Q.; Wang, S. 
L.; Ruan, Y. P.; Gao, J. X. Nat. Prod. Lee. 1998, 11, 101. (u) Shi, Z.-C.; 
Lin, G.-Q. Tetrahedron: Asymmetry 1995, 6, 2907. (v) Delair, P.; Brot, 
E.; Kanazawa, A.; Greene, A. E. J. Org. C/tam. 1999, 64, 1383. (w) 
Schwartdt, 0.; Veith, U.: Gaspard, C.; Jager, V. Synthesis 1999, 1473. (x) 
Hutin, P.; Haddad, M.; Larcheveque, M. Tetrahedron: Asymmetry 2000, 
Il, 2547. 
Hulrne, A. N.; Montgomery, C. H.; Henderson, D. K. J. Chem. Soc., 
Perkin Trans. 1 2000, 1837. 
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Figure 1. Retrosynthetic analysis of anisornycin (1). 
tyrosine derived aldehyde 2 and the glycolate derivative of 
Evans oxazolidinone 3, would allow a highly efficient 
synthesis of anisomycin. 
D-Tyrosine was readily converted to its methyl ester 
hydrochloride salt, using in situ generation of the required 
acid (Scheme I). Direct benzylation of the amino functional- 
Scheme 1. Synthesis of Tyrosine-Derived Aldehyde 2 




















Conditions: (a) AcCI, MeOH (100%); (b) Boc 20, NaHCO 3 , 
EtOH (99%); (c) Mel, K2CO3, DMF (97%); (d) TFA, CH202 
(100%); (e) BnBr, K 2CO3, MeCN (95%); (t) LiBH4, MeOH (87%); 
(g) Swem (100%); (h) DIBAL-H, toluene (90%). 
ity was found to be impossible in the presence of the phenol; 
however, the amino functionality could be selectively 
protected to give the Boc-protected methyl ester 4 in 
excellent yield. The free phenol was then alkylated with 
methyl iodide in the presence of potassium carbonate,'° and 
treatment with trifluoroacetic acid gave the primary amine 
5. Subsequent NN-dibenzylation (BnBr, K2CO3)  and reduc-
tion of the ester with lithium borohydride also proceeded in 
excellent yield to give the key precursor, amino alcohol 6. 
For a recent review on the role of a-dibenzylarnino aldehydes in 
synthesis, see: Recta, M. T. Chem. Rev. 1999, 99, 1121. 
The use of K2CO3 was shown to be of crucial importance in 
maintaining the stereochemical integrity of the a-amino ester. 
The desired tyrosine-derived aldehyde 2 was obtained via 
Swern oxidation. We and others 9 have found this two-step 
reduction/oxidation protocol to be the most efficient for the 
generation of aldehydes of this type. 
The optical purity of alcohol 6 was confirmed by chiral 
HPLC using a Chiracel OD-H column (solvent; 10% propan-
2-ol in hexane). Reassuringly, when compared with traces 
for the racemic alcohol, this showed that there was no 
appreciable racemization of alcohol 6 (material >98% ee). 
Alcohol 6 was found to be a convenient point in the synthesis 
to store gram quantities of material as a result of its observed 
stability. Samples of aldehyde 2 (synthesized and isolated 
using standard Swem procedures) were treated with DIBAL-H 
to regenerate alcohol 6. Again the alcohol was confirmed 
by chiral HPLC to be >98% ee, suggesting that minimal 
racemization had occurred during the oxidation of 6 to 2. 
Thus aldehyde 2 could be produced with high optical purity 
in seven steps and 80% overall yield from D-tyrosine. 
The syn glycolate aldol reaction employed in the synthesis 
of DAB-I 8 was found to be the result of "matched" 
stereoselectivity of the two components. On the basis of this 
precedent, it was anticipated that formation of the C(3)—
C(4) stereochemistry observed in 1 would require a "mis-
matched" aldol reaction. In this reaction the stereochemical 
induction from the oxazolidinone component would be 
required to outweigh that imposed by the ct-chiral aldehyde. tt 
The glycolate derivative of Evans oxazolidinone 3 was 
prepared as described in the literature from benzyloxyacetyl 
chloride and (4R)-benzyloxazolidin-2-one. 12 Formation of the 
Z-boron enolate (Bu2BOTf, Et3N, CH202) and reaction with 
aldehyde 2 gave the desired svn aldol adduct 7 in good yield 
(75%) and as the major diastereomer (>95% de, Scheme 
2)) 
Scheme 2. Glycolate Aldo] Coupling" 
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Conditions: (a) (i) Et 3N, Bu2BOTf, CH2Cl 2 ; ( ii) 2 (75%); (b) 
LiBH4, MeOH (80%); (c) (i) TsCl, DMAP, CH2Cl 2 ; ( ii) Dowex 
Cl - (85%). 
Aldol adduct 7 was readily reduced to the diol 8 using 
L1BH 4 . 14 Selective tosylation of the primary alcohol in the 
presence of TsCl/DMAP resulted in the formation of the 
(II) A full analysis of the results of this and other related glycolate aldol 
reactions will be reported in a separate communication. 
(12) Fuhry, M. A. M.; Holmes, A. B.; Marshall, D. R. J. Chem Soc.. 
Perkin Trans. 11993, 2743. 
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pyrrolidinium tosylate salt,' 5 with no evidence of ditosylated 
material being formed. Conversion to the chloride salt 9 was 
achieved using Dowex resin treated with 1% HCI. Counterion 
exchange was confirmed by the absence of the diagnostic 
tosylate peaks [observed at 6 = 2.29 (s), 7.83 (d, J 8.2 Hz) 
and 7.10 (d, J 8.2 Hz)] in the H NMR spectrum. 
Completion of the synthesis of anisomycin 1 was achieved 
most efficiently via partial deprotection of the quaternary 
salt (Scheme 3). When the salt 9 was subjected to hydro- 
Scheme 3. Synthesis of Anisomycin (1)" 
BnBn 	 Bn 
N" Cl- 	a 
MeOC bBn 	MeOXJ HO OBn 
9 	 10 
Bn 
H.HCI 	 I 
Me0 34 	 MeO'IObBn AcO OH 
1 	 11 
"Conditions: (a) Pd/C (cat.), K2CO3,  H2, MeOH, 10 mm (94%); 
(b) Ac 20, Et 3N, DMAP, CH2 Cl 2 (92%); (c) Pd(OH) 2 (Cat.), H 2 , 
HCl, MeOH (100%). 
gelialion under basic conditions for 10 min or less, the 
benzyl -protected pyrrolidine 10 could be isolated in high 
yield (94%). Acetylation of this benzylated material was 
found to be more efficient than direct acylation of the 
chloride salt. This is presumed to be due to the increased 
solubility of the substrate, which also greatly enhances the 
ease of isolation of the product material. Final debenzylation 
was found to require "fresh" palladium hydroxide for 
complete deprotection to take place. Difficulties associated 
with partial salt formation during Celite filtration of the 
deprotected pyrrolidine were obviated by using acidic 
conditions provided by the addition of 2 equiv of a I M 
solution of HCI in ether to the reaction mixture to generate 
the pyrrolidine hydrochloride salt. This allowed analytically 
pure anisomycin I to be isolated as its hydrochloride salt in 
quantitative yield. 
In summary, an extremely rapid synthesis of anisomycin 
1 has been achieved in 13 steps with a 35% overall yield. 
The synthesis relies upon a key glycolate aldol coupling, 
which has been shown to proceed in high yield and with 
excellent diastereoselectivity. Of note, this synthesis does 
not require extensive protecting group swaps in the final 
steps. Rather, the synthesis relies upon a stepwise deprotec-
tion of the benzyl protecting groups that were introduced at 
an early stage in the synthesis. The efficiency of the synthesis 
of the differentially protected aldehyde 2 (prepared in 80% 
overall yield from 0-tyrosine) will allow future access to a 
wide range of analogues using this synthetic route. 
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A synthetic route involving selective mono-N-debenzylation of the 
aldol adduct 7, cyclization to a protected pyrrolidin-2-one, and then reduction 
to the protected pyrrolidine 10 was not pursued, as in practice it was found 
to be most convenient to carry out the aldol coupling and reduction to 
alcohol 8 without purification of the intermediate aldol adduct 7. 
The Evans oxazolidinone was also recovered in reasonable yield 
(60%). 
Similar mesylate-induced cyclizations have been observed in the 
synthesis of N-(3-pyrrolodinylmethyl)benzamides: Thomas, C.; Hubner, 
H.; Gmeiner, P. Bioorg. Med. Chem. Len. 1999, 9, 841. 
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